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           Abstract 
 
Reversible modification of protein function by PKA phosphorylation is critical to a variety 
of processes in the heart, including the modulation of cardiac output in response to 
stress, and the transduction of cardioprotective signals. As a result, PKA phosphorylation 
events must be tightly regulated. This regulation is achieved by compartmentalisation of 
cAMP/PKA signal transduction cascades, which is mediated by phosphodiesterase 
enzymes (PDEs) and A-kinase anchoring proteins (AKAPs). PDEs provide the only means of 
hydroysing cAMP in cells, and in recent years, the use of genetically encoded FRET-based 
cAMP sensors has allowed direct visualisation of discrete cAMP microdomains created by 
subcellular tethering of PDEs in cardiac cells. The physical compartmentalisation of PKA 
by AKAPs ensures that only a small subpopulation of PKA is activated by these cAMP 
microdomains. Macromolecular complexes nucleated by AKAPs bring together cAMP 
effectors, signal terminating enzymes and other scaffold proteins, to facilitate PKA 
signaling events.  The aim of this thesis was to investigate the signaling elements which 
participate in these complexes to modulate PKA phosphorylation of the myofilament 
protein troponin I and the small heat shock protein Hsp20 in the heart. Both of these 
proteins are phosphorylated by PKA at their N termini in response to β-adrenergic 
stimulation, resulting in increased cardiac output and enhanced cardioprotection.  
 
PKA phosphorylation of TnI mediates the fight or flight response, by reducing the Ca
2+ 
sensitivity of the myofilament and altering the strength of contraction and rate of 
relaxation of the heart to increase cardiac output. In the first part of this thesis, I 
investigated the specific PDE isoforms which regulate cAMP/PKA signaling at the 
myofilament. A novel FRET-based cAMP sensor which is targeted to troponin I at the 
myofilament demonstrated that PDE4 is the main phosphodiesterase family which 
modulates cAMP levels in the subcellular compartment around troponin I. Biochemical 
studies identified a specific association between troponin I and the long 
phosphodiesterase isoform PDE4D9. The binding site for PDE4D9 on troponin I was 
mapped using peptide array technology to a region on the flexible C terminus of the II 
 
myofilament protein, and the sequence information used to design a cell permeable 
peptide disruptor of this interaction. Disruption of the troponin I-PDE4D9 complex in cells 
using this peptide was sufficient to promote PKA phosphorylation of troponin I in the 
absence of other stimuli. This approach may be of benefit in the treatment of diseases 
such as heart failure, where PKA phosphorylation of myofilament proteins is known to be 
reduced. Control of post-translational modifications at the level of the myofilament by 
specific PDE isoform inhibitors represents a promising therapeutic avenue which has not 
yet been explored.  
 
 In the second part of the thesis I investigated the signaling components which regulate 
PKA phosphorylation of Hsp20. Hsp20 is known to protect against ischaemic injury and 
cardiac hypertrophy, and its cardioprotective actions are enhanced by PKA 
phosphorylation on Ser16. Biochemical studies identified an interaction between Hsp20 
and AKAP-Lbc in cardiac cells, and selective knockdown of AKAP-Lbc confirmed that this 
interaction is required for β-adrenergic-induced PKA phosphorylation of Hsp20 and the 
anti-apoptotic  effects of Hsp20 in cardiac myocytes. FRET-based studies using a cAMP 
sensor targeted to Hsp20 demonstrated the role of PDE4 isoforms in modulating cAMP 
levels around Hsp20, and biochemical techniques identified PDE4D isoforms in the 
macromolecular complex formed by Hsp20 and AKAP-Lbc. The AKAP-
Lbc/PKA/Hsp20/PDE4D complex appears to play a key role in cardioprotection via the 
modulation of Hsp20 Ser16 phosphorylation, and selective targeting of signaling elements 
that enhance this modification represents a new therapeutic avenue for the prevention 
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1.1 Signal transduction and the second 
messenger concept 
Signal transduction is the process by which an extracellular ligand binds to and activates a 
cell surface receptor, eliciting a specific intracellular response. This concept is now a 
central tenet in biology. Extracellular ligands may be thought of as the ‘first messengers’ 
in signal transduction cascades, and are usually hormones or neurotransmitters which 
cannot cross the plasma membrane. Instead, their signals are transduced into an 
alteration in the concentration of intracellular ‘second messengers’ in order to achieve an 
appropriate response (Sutherland 1972). The first of these to be discovered, and one of 
the most studied second messengers, is the cyclic nucleotide 3’5’-adenosine 
monophosphate, or cAMP (Figure 1-1) (Beavo & Brunton 2002). Other second 
messengers include cyclic 3’5’-guanosine monophosphate (cGMP), calcium, and the 
phosphatidylinositol derivatives inositol triphosphate (IP3) and diacylglycerol (DAG) 
(Berridge 1984).  
 
cAMP was identified as a second messenger as early as 1958 by Earl Sutherland 
(Sutherland & Rall 1958). Sutherland was investigating how the hormone adrenaline led 
to activation of glycogen phosphorylase and subsequent glycogenolysis in dog liver, and 
observed that a heat stable factor was required to activate the phosphorylase enzyme. 
Chemical analysis showed that this factor contained 1:1:1 ratios of adenine, ribose and 
phosphate, and could be enzymatically inactivated to 5’AMP. The discovery of cAMP and     Chapter 1  Introduction   
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its relation to the mechanisms of hormone action led to Sutherland winning a Nobel Prize 
in 1971. Indeed, between 1971 and 2000, discoveries about cyclic nucleotides and signal 
transduction garnered 5 separate Nobel Prizes, indicating the fundamental nature of this 
field (Beavo & Brunton 2002). cAMP signal transduction cascades have now been 
implicated in the control of a vast array of intracellular processes, including glucose 
metabolism, muscle contraction, regulation of gene transcription and cell survival 




Figure 1-1 Structure of the second messenger cyclic adenosine 3’5’-monophosphate (cAMP). 
The 3’ bond hydrolysed by phosphodiesterase (PDE) enzymes is indicated by a red arrow. 
Adapted from (Bender & Beavo 2006). 
 
 
1.2 cAMP generation 
1.2.1 G protein-coupled receptors 
The first step in cAMP signal transduction is the binding of a ligand to a cell surface 
receptor. G protein-coupled receptors (GPCRs) represent the largest family of 
transmembrane receptors; in fact, around 2% of the genes in the mammalian genome are 
thought to code for GPCRs (Hollmann et al 2005). All GPCRs are composed of 7 α-helices     Chapter 1  Introduction   
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that span the plasma membrane, connected by 4 intracellular and 3 extracellular loops, 
and N terminal and C terminal tails which may be subject to post-translational 
modifications (Ji et al 1998) (Figure 1-2). Ligand specificity is determined by different 





Figure 1-2 Structure of a typical G protein-coupled receptor. Adapted from (Ji et al 1998).  
Though regulated by many different agonists, GPCRs share a common heptahelical structure.  
The 7 transmembrane α-helices (TM1-7) are linked by 3 extracellular loops (exoloops) and 4 




Despite their structural similarities, ligand binding to GPCRs can bring about very different 
physiological effects. Two of the best studied GPCRs are the β1- and β2-adrenergic 
receptors (ARs) in the heart. During conditions of stress, the heart must increase its rate 
and strength of contraction in order to meet the additional physiological demands of the 
body. The sympathetic nervous system stimulates cardiac function through the release of 
the hormonal neurotransmitters adrenaline and noradrenaline, which bind to β1- and β2-
ARs on the plasma membrane of cardiac myocytes (Xiang & Kobilka 2003). Despite high 
receptor homology, ligand binding to different β-AR subtypes leads to distinct 
intracellular effects. Both β1 and β2-ARs couple to the stimulatory G protein Gs; however,     Chapter 1  Introduction   
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β2-AR also couple to the inhibitory G protein Gi (Xiao 2000). The dominant effects of β1 
stimulation are an increase in heart rate (chronotropy), force of contraction (inotropy) 
and rate of relaxation (lusitropy), while β2 stimulation has only modest effects on heart 
rate. Chronic β1 stimulation is associated with a detrimental cardiac phenotype, with 
increased cardiac myocyte hypertrophy and apoptosis, whereas β2 stimulation promotes 
cell survival (Zhu et al 2003, Zhu et al 2001) (Figure 1-3). Thus, activation of very similar 





Figure 1-3 Adrenergic stimulation of different β-receptor subtypes mediates distinct 
intracellular effects.  
Chronic stimulation of β1-AR leads to pathological cardiac remodelling, cardiac hypertrophy and 
apoptosis, whereas chronic β2-AR stimulation promotes cell survival. AR, adrenergic receptor; 
AC, adenylyl cyclase enzyme; Gs, stimulatory G protein; Gi, inhibitory G protein.   
 
1.2.2 G proteins 
 
G proteins are guanine nucleotide-binding proteins, which associate with the intracellular 
loops and C terminal tail of GPCRs. G proteins act as molecular switches, cycling between     Chapter 1  Introduction   
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inactive, GDP-bound and active, GTP-bound states. G proteins are heterotrimeric, 
consisting of α, β and γ subunits (Hollmann et al 2005). They may be classified into 4 
families according to the presence of different α subunits as: Gs, Gi, Gq/11 and G12/13. 
Ligand binding to a GPCR induces a conformational change in the receptor which leads to 
coupling to and activation of one or more G proteins, via exchange of GDP for GTP. 
Activated G proteins dissociate into α-GTP and βγ subunits, which can interact with 
specific effector proteins. α and βγ subunits may bind to the same effector to mediate 
opposing or synergistic effects (Table 1-1) (Hollmann et al 2005). The major effectors of G 
protein subunits are the adenylyl cyclase enzymes described below. 
 
 
1.2.3 Adenylyl cyclases 
 
Adenylyl cyclases (ACs) are enzymes which catalyse the conversion of adenosine 
triphosphate (ATP) into cAMP (Figure 1-4). Nine isoforms of ACs have been identified to 
date, which are summarised in Table 1-1 (Willoughby & Cooper 2007).  
 
 
Figure 1-4 Conversion of ATP to cyclic adenosine 3’5’-monophosphate (cAMP) by adenylyl 
cyclase enzymes.  
Adenylyl cyclases catalyse the conversion of ATP to pyrophosphate (PPi) and 3’5’-cAMP, which 
acts as a second messenger in cells. PDEs catalyse the hydrolytic cleavage of cAMP to 5’AMP, 
terminating the cAMP signal (Section 1.4, Figure 1-1).  
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ACs are large proteins with a common secondary structure, consisting of cytoplasmic N 
and C termini flanking two distinct transmembrane domains, which are joined by a 
cytoplasmic loop. This loop, together with the C terminus, functions as the ATP binding 
site and forms the catalytic core of the cyclase (Cooper & Crossthwaite 2006). Despite 
their structural similarities, ACs share little sequence homology, other than in the 
catalytic unit, and show different tissue distributions and modes of regulation 
(summarised in Table 1-1). All ACs are activated to some extent by the stimulatory G 
protein Gs, while the majority of isoforms are inhibited by Gi. AC activators such as Gs 
promote a conformational change in the cytosolic domains which form the catalytic unit 
that facilitates catalysis, while Gi maintains the catalytic unit in an open conformation, 
preventing formation of the catalytic site and inhibiting ATP binding (Cooper & 
Crossthwaite 2006, Tesmer et al 1997). ACs may also be regulated by intracellular Ca
2+ 















AC1  Brain  +  -  -  Ca
2+/Calmodulin (CaM) 
 
AC2  Lung, brain  +  No effect  +  PKC 
 
AC3  Pancreas, olfactory 
epithelium 
+  -  No effect  Ca
2+/CaM 
 
AC4  Widespread  +  No effect  +  PKC 
 
AC5  Heart  +  -  No effect  PKA, PKC; Ca
2+ 
 
AC6  Heart, kidney  +  -  No effect  PKA, PKC; Ca
2+ 
 
AC7  Widespread  +  No effect  No effect  PKC 
 
AC8  Brain, pancreas  +  -  -  PKC; Ca
2+ 
 




Table 1-1 Summary of expression and regulatory properties of the 9 adenylyl cyclase isoforms. 
Adapted from (Willoughby & Cooper 2007).      Chapter 1  Introduction   
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1.3 cAMP effectors 
 
So far, cAMP signal transduction has been described from agonist binding to a GPCR and 
stimulation of Gαs through to AC production of cAMP. This section will discuss the 3 







Figure 1-5  An overview of cAMP signaling in cells. cAMP is produced following stimulation of 7 
transmembrane domain receptors at the plasma membrane. These receptors couple to G-
proteins, which activate adenylyl cyclases leading to the conversion of ATP into cAMP. The 
effects of cAMP within the cell are mediated by three distinct effector proteins: PKA, Epac and 
cyclic nucleotide-gated channels. cAMP is degraded by phosphodiesterase enzymes. 7-TM, 7 
transmembrane domain receptor; G, G-protein; AC, adenylyl cyclase; PKA, cAMP-dependent 
protein kinase A; PDE, phosphodiesterase.  




Protein kinase A (PKA) was the first effector of cAMP to be identified. It was originally 
isolated in the laboratory of Ed Krebs in 1968, and is considered to be the principal 
cellular receptor for cAMP (Walsh et al 1968). The PKA holoenzyme is a heterotetramer 
consisting of two regulatory (R) subunits and two catalytic (C) subunits. PKA regulatory 
subunits are encoded by four genes, which are subdivided into two classes: RI (RIα and 
RIβ) and RII (RIIα and RIIβ). PKA catalytic subunits are encoded by three genes: Cα, Cβ and 
Cγ. The subunits possess distinct biochemical and physical properties, and are 
differentially expressed in different cell types (Tasken & Aandahl 2004). Under resting 
conditions i.e. conditions of low intracellular cAMP, the regulatory subunits maintain the 
catalytic subunits in an inactive conformation (Taylor et al 1990). When cAMP levels rise 
within the cell, two molecules of cAMP bind to each R subunit. This leads to dissociation 
and activation of the C subunits (Figure 1-6). PKA C subunits phosphorylate their target 
proteins on serine-threonine residues, which are typically found in a consensus sequence 
of R-R-X-S/T-X- (Kemp et al 1977).
 
Figure 1-6  Activation of the cAMP-dependent protein kinase (PKA) in response to increased 
cAMP levels. In resting conditions when cAMP is low, PKA exists as an inactive heterotetramer 
with an R2C2 conformation. The two catalytic subunits are maintained in an inhibited state by 
the two regulatory subunits. When cAMP levels are elevated, cAMP binds to the R subunits 
with 2:1 stoichiometry. Active C subunits are released and go on to phosphorylate downstream 
targets involved in a diverse range of biological processes, such as transcription (Delghandi et al 
2005), ion exchange (Marx et al 2002) and muscle contraction (Solaro 2008).     Chapter 1  Introduction   
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The actions of PKA are opposed by specific protein phosphatases (PPs), which 
dephosphorylate PKA substrates. PP1 and PP2A are the most abundant of the 
serine/threonine protein phosphatase families (Virshup & Shenolikar 2009), and are 
themselves composed of a number of regulatory and catalytic subunits which direct their 
substrate recognition and specificity (Hubbard & Cohen 1993). PKA is also 
counterbalanced by the actions of protein kinase inhibitor (PKI), a small naturally 
occurring polypeptide that exists in the cytoplasm. Three isoforms of PKI have been 
identified, α, β and γ, which also show cell type-specific expression. PKI binds to free 
catalytic subunits of PKA and inhibits them in a similar way to PKA regulatory subunits 
(Taylor et al 2005), and synthetic forms of PKI have been developed as a means of 
studying the roles of PKA in cellular signaling processes (Murray 2008).  
 
1.3.2 Epac 
The exchange proteins activated by cAMP (Epacs) were first discovered in 1998, when de 
Rooij and co-workers showed that the small GTPase Rap1 could be activated by cAMP 
independently of PKA (de Rooij et al 1998). Epacs are the most recent effectors of cAMP 
to be identified. Two isoforms of Epac are known, Epac1 and Epac2, which show differing 
tissue distributions. Epac1 is abundant in blood vessels, kidney and adipose tissue, 
whereas Epac2 is highly expressed in the central nervous system and some hormonal 
tissues (Kawasaki et al 1998, Kilpinen et al 2008). Structurally, the two isoforms are 
closely related; however, Epac2 has a second cAMP binding domain at its N terminus (de 
Rooij et al 2000). 
 
Functionally, Epacs act as guanine nucleotide exchange factors (GEFs) for the Rap family 
of small GTPases. Binding of cAMP to Epac promotes its GEF function, leading to 
activation of Rap1 and Rap2 via an exchange of GDP for GTP (de Rooij et al 2000). The lack 
of specific pharmacological inhibitors of Epac initially complicated investigations into the 
functions of Epac; however, the development of the Epac-selective cAMP analogue 8-
pCPT-2’-O-Me-cAMP, also known as 007, has helped identify roles for Epac in a diverse 
range of biological processes (Enserink et al 2002). These include: effects on synaptic 
plasticity and memory retrieval (Ouyang et al 2008), potentiation of insulin secretion     Chapter 1  Introduction   
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(Shibasaki et al 2007), and effects on cardiac contractility via modulation of calcium 
handling at the sarcoplasmic reticulum (Dodge-Kafka et al 2005) (discussed further in 
Section 1.6.4.1). Many of these functions are also regulated by PKA, indicating that there 
is significant crosstalk between PKA and Epac signaling pathways (Bos 2003).  
 
1.3.3 Cyclic nucleotide-gated channels 
Cyclic nucleotide-gated channels (CNG) are ion channels, belonging to the superfamily of 
voltage-gated ion channels, and are activated by cAMP or cGMP binding. Cyclic 
nucleotides regulate the opening of these channels by binding directly to a conserved 
cyclic nucleotide-binding domain (CNBD) on the channel (Yu et al 2005). Binding induces a 
conformational change that serves to open the channel pore. CNG channels are cation 
channels, and allow the flow of Na
+, K
+ and Ca
2+ ions across membranes, thus converting 
cyclic nucleotide signals into changes in membrane potential and intracellular calcium 
levels. CNG channels were originally identified in retinal photoreceptors and olfactory 
neurons, and play a vital role in transducing sensory signals (Kaupp & Seifert 2002). CNG 
channels are also present at high levels in the sino-atrial node and conduction system of 
the heart, where they are involved in the control of cardiac automaticity (Baruscotti et al 
2010).  
 
1.4 cAMP degradation by phosphodiesterases 
cAMP is vital to many  cellular signal transduction cascades. Cyclic nucleotide 
phosphodiesterases (PDEs) represent the only means of degrading cAMP within cells, and 
are therefore crucial regulators of all aspects of cAMP signaling (Conti & Beavo 2007, 
Houslay 2010). PDEs hydrolyse cAMP and cGMP to 5’AMP and 5’GMP respectively, with 
varying degrees of specificity. Twenty one genes encoding PDEs have been identified in 
the human genome, and these have been grouped into 11 PDE families, based on their 
amino acid sequences, structures, enzyme kinetics, modes of regulation and tissue 
distributions (Conti & Beavo 2007, Houslay 2010) (Figure 1-8 and Table 1-2). Of the 11 
families identified, PDEs 3, 4, 7 and 8 selectively hydrolyse cAMP, while PDEs 5, 6 and 9     Chapter 1  Introduction   
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are selective for cGMP, and PDEs 1, 2, 10 and 11 hydrolyse both cyclic nucleotides with 
varying efficiencies (Conti & Beavo 2007). To date, over 50 PDE isoforms are known. 
These are generated via alternative mRNA splicing and the use of multiple promoter sites 
(Houslay et al 2007).  
 
1.4.1 The 11 PDE families: structures and specificities 
1.4.1.1. Catalytic and regulatory domains 
PDEs have a modular structure, consisting of catalytic and regulatory domains. Although 
they do not share a high sequence identity, the structural information available indicates 
that the catalytic domain is highly conserved across the 11 families (Xu et al 2000, Zhang 
et al 2004). The catalytic domain of PDEs consists of 16 α-helices grouped into 3 
subdomains, which form a deep binding pocket for either cAMP, cGMP or inhibitors. 
Many of the amino acid residues which are conserved across all PDEs are found in this 
active site pocket (Zhang et al 2004). The catalytic domain also co-ordinates one Zn
2+ ion 
and one Mg
2+ ion (Xu et al 2000), which are essential for catalysis. Substrate selectivity is 
thought to be determined by the position of an invariant glutamine residue which 
stabilises the purine ring of the cyclic nucleotide in the binding pocket. Depending on the 
orientation of this residue in the pocket, the enzyme will have specificity for either cAMP, 
cGMP, or both (Zhang et al 2004). This is referred to as a “glutamine switch mechanism”.  
Other amino acids conserved across PDE families are also thought to contribute to 
substrate and inhibitor specificities by altering the shape and size of the binding pocket 
(Wang et al 2005). 
 
PDEs differ markedly at their N and C termini, and may possess a number of different 
regulatory domains. These include regions for ligand binding, inhibition of the catalytic 
domain, kinase phosphorylation sites and domains which mediate oligomerisation (Conti 
& Beavo 2007). These will be discussed further in the following sections on individual PDE 
families. The characteristics of the 11 PDE families are summarised in Table 1-2 below, 
and their domain structure is illustrated in Figure 1-8.  








Genes  Substrate 
(cAMP, cGMP) 
Regulation  Tissue 
distribution 
Inhibitors 
PDE1  A, B, C  Both; cGMP 

















EHNA,           
BAY 60-7550 
PDE3  A, B 
 













A, B, C, D  cAMP  UCR1 and UCR2; 
phosphorylation by 
PKA and ERK1/2 




A  cGMP  cGMP via GAF 











A, B, C  cGMP  Rhodopsin, 
transducin; 
cGMP via GAFs 









PDE8  A, B 
 





PDE9  A 
 
cGMP    Brain  Zaprinast,    
BAY 73-6691 




GAF domains; PKA  Brain  Novel agents 
(see text), 
IBMX, Zaprinast 
PDE11  A  Both; similar 
Km and Vmax 
values 







Table 1-2  Summary of the characteristics of the 11 PDE families. 




PDE1 enzymes are encoded by 3 genes, A-C, all of which have multiple promoter 
sequences and splice variants (Zhao et al 1997). PDE1 enzymes have two Ca
2+/calmodulin 
(CaM) binding domains in their N termini (Lynch et al 2006). Binding of 4 Ca
2+ ions to 
these domains results in PDE activation, and increased cyclic nucleotide hydrolysis. PDE1 
isoforms can hydrolyse both cAMP and cGMP, but have around a 20 fold lower kM for 
cGMP and therefore preferentially hydrolyse cGMP over cAMP (Francis et al 2001).  The N 
terminus of PDE1 also contains a PKA phosphorylation site, and PKA phosphorylation of 
PDE1 has been shown to reduce its affinity for Ca
2+/CaM (Yan et al 1996).  
 
PDE1 isoforms are particularly highly expressed in the cardiovascular and central nervous 
systems, where they have been linked with vascular smooth muscle proliferation 
(Rybalkin et al 1997) and the pathogenesis of Parkinson’s disease (Laddha & Bhatnagar 




Three splice variants of PDE2 are encoded by a single gene, PDE2A (Rosman et al 1997).  
PDE2, PDE5, PDE6, PDE10 and PDE11 enzymes all contain two GAF domains within their N 
terminus (Ho et al 2000, Lynch et al 2006). GAF domains are cGMP binding domains, and 
the acronym ‘GAF’ derives from the first proteins these domains were identified in 
(cGMP-specific PDEs, Anabena adenylyl cyclases and the E. coli transcription factor Fh1a) 
(Aravind & Ponting 1997). Binding of cGMP to the GAF domains stimulates the hydrolytic 
activity of the enzyme. PDE2 enzymes hydrolyse both cAMP and cGMP with roughly equal 
kMs (Erneux et al 1981). The GAF domains promote cAMP hydrolysis; thus, a small rise in 
intracellular cGMP will lead to a fall in cAMP levels. However, higher levels of cGMP will 
then compete out cAMP at the active site of the enzyme, leading to cGMP hydrolysis with 
inhibition of cAMP hydrolysis (Martinez et al 2002). 
PDE2 is mainly expressed in the cytosol of the adrenal gland, heart, liver and brain 
(Yanaka et al 2003, Yang et al 1994). In the brain, it is thought to regulate hippocampal 
cGMP signaling and NMDA receptor-linked signaling pathways involved in the     Chapter 1  Introduction   
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development of memory (Suvarna & O'Donnell 2002). PDE2 is inhibited by erythro-9-(2-
hydroxy-3-nonyl)adenine (EHNA) (Podzuweit et al 1995), which binds to both the catalytic 
and regulatory regions of the PDE (Michie et al 1996), and by BAY 60-7550, an EHNA 
analogue with greater potency (Boess et al 2004). 
 
1.4.1.4. PDE3 
PDE3 enzymes are encoded by 2 genes (Reinhardt et al 1995). PDE3 isoforms show high 
specificity for cAMP, and, although cGMP can also bind the active site of the enzyme with 
a similar affinity, it is only weakly hydrolysed (Manganiello et al 1995). cGMP can, 
therefore, inhibit cAMP hydrolysis by PDE3 (Francis et al 2001). PDE3 isoforms can be 
phosphorylated and activated by both PKA and Akt (PKB) (Manganiello & Degerman 
1999).  
PDE3A and PDE3B show quite distinct tissue distributions. PDE3A is highly expressed in 
the cardiovascular system and lung while PDE3B mRNA is abundant in adipose tissue and 
hepatocytes (Reinhardt et al 1995). In fact, PDE3B plays a crucial role in regulating the 
effects of cAMP on insulin signaling in insulin responsive-tissue (Zhao et al 2002). PDE3B is 
phosphorylated and activated by Akt in response to insulin stimulation of sensitive cells, 
leading to increased cAMP hydrolysis, and effects on lipolysis, gluconeogenesis and 
glycogenolysis (Geoffroy et al 2001). The role of PDE3 in the cardiovascular system is 
discussed further in Section 1.4.3. PDE3 is inhibited by cilostamide, milrinone and 
cilostazol, which is used clinically in the treatment of intermittent claudication 
(Strandness et al 2002).  
 
1.4.1.5. PDE4 
Members of the PDE4 family are of particular importance in the cardiovascular system 
(Houslay et al 2007). This family will be discussed in detail in Section 1.4.2 below. 
 
1.4.1.6. PDE5 
Three splice variants of the PDE5A gene have been identified, which differ at their N 
termini (Kotera et al 1999, Rybalkin et al 2003). PDE5A is cGMP-specific, and contains 
GAF-A and GAF-B domains (McAllister-Lucas et al 1995). Binding of cGMP to the GAF     Chapter 1  Introduction   
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domains facilitates N terminal phosphorylation of the PDE by PKA and PKG, which 
activates cGMP hydrolysis (Francis et al 2001, Smith et al 2000). PDE5 is most highly 
expressed in the lung, heart, cerebellum, kidney and smooth muscle (Giordano et al 
2001). cGMP is an important regulator of smooth muscle function (Figure 1-7) (Rybalkin 
et al 2003), and a number of commercially successful clinical inhibitors of PDE5 have been 
developed which regulate smooth muscle tone. These include sildenafil (Viagra, Pfizer 
Pharmaceuticals) and tadalafil (Cialis, ICOS/GlaxoSmithKline) which are both licensed for 
the treatment of erectile dysfunction (Boolell et al 1996, Padma-Nathan et al 2001). PDE5 
inhibitors are also used in the treatment of pulmonary artery hypertension (Singh 2010). 
 
Figure 1-7  Regulation of vascular smooth muscle tone by cGMP and PDE5.  
Adapted from (Rybalkin et al 2003). Nitric oxide (NO) is a well known mediator of vasodilation. 
NO activates guanylyl cyclase (GC) in smooth muscle cells, leading to increased cGMP levels and 
activation of the cGMP-dependent protein kinase (PKG). PKG phosphorylates several 
downstream targets, including myosin phosphatase (Surks et al 1999) and smooth muscle 
calcium channels (Fukao et al 1999). This leads to reduced intracellular Ca
2+ concentration and 
sensitivity to Ca
2+, and decreased smooth muscle tone (Schlossmann et al 2003). PDE5 
hydrolyses cGMP and is found in all types of smooth muscle, where it plays a pivotal role in 
regulating this pathway (Rybalkin et al 2003). Inhibitors of PDE5 increase cGMP levels and 




Three genes (A-C) encode phosphodiesterase 6 isoforms. PDE6 is cGMP-specific, and is 
highly expressed in the retina, on the internal membrane of photoreceptors (Gillespie & 
Beavo 1988). These specialised cells contain light sensitive pigments (opsins) which 
become activated upon exposure to light. Changes in cGMP levels help to transmit this 
signal to the plasma membrane. In the dark, PDE6 adopts an inactive conformation, with 
an inhibitory γ subunit occupying the catalytic site (Mou et al 1999). Excitation of the 
visual pigment rhodopsin by light activates the coupled G protein transducin (Arshavsky 
et al 2002). Transducin then binds to PDE6, displacing this inhibitory subunit and leading 
to enhanced cGMP hydrolysis (Mou & Cote 2001). The resulting fall in cGMP levels leads 
to closure of cGMP-gated ion channels, membrane hyperpolarisation and generation of a 
membrane potential at photoreceptor synapses (Cote 2004). PDE6 also possesses 2 
regulatory GAF domains, and binding of cGMP to these domains increases the affinity of 
the PDE for the inhibitory subunit (Mou et al 1999). There are no specific inhibitors of 
PDE6; however, most PDE5 inhibitors also show some inhibition of PDE6 due to their 
similar catalytic sites. In fact, some retinal effects have been observed with sildenafil (Luu 
et al 2001), although the clinical relevance of this is unclear. 
 
1.4.1.8. PDE7 
The PDE7-11 families are the least well studied phosphodiesterases. PDE7 enzymes are 
specific for cAMP and are coded for by two genes (Beavo 1995). PDE7B is principally 
expressed in the pancreas, brain and heart (Hetman et al 2000). PDE7A is expressed at 
high levels in cells of the immune system, particularly in T lymphocytes, where it is 
upregulated in response to T-cell activation (Smith et al 2003). Thus, inhibition of PDE7 by 
compounds such as the novel PDE7A inhibitor ASB16165 may have important anti-
inflammatory effects (Kadoshima-Yamaoka et al 2009).  
 
1.4.1.9. PDE8 
PDE8A and PDE8B comprise the PDE8 family (Fisher et al 1998, Hayashi et al 1998). 
Members of this family are highly specific for cAMP (Francis et al 2001), and contain a PAS 
domain (named after 3 proteins which express this domain: Period circadian protein, Aryl     Chapter 1  Introduction   
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hydrocarbon receptor nuclear translocator protein and Single minded protein) (Tei et al 
1997). Recent structural studies suggest that this domain may allosterically regulate 
cAMP binding to the PDE (Wang et al 2008).  
 
PDE8A is highly expressed in the testis, ovary and bowel (Fisher et al 1998), while PDE8B 
expression appears to be thyroid-specific (Hayashi et al 1998). PDE8 is insensitive to most 
PDE inhibitors, including the broad spectrum PDE inhibitor isobutyl-methylxanthine 
(IBMX) (Wang et al 2008). IBMX binds to a common region of the catalytic domain of 
many PDE families, acting as a non-specific, competitive inhibitor of cyclic nucleotide 
binding (Huai et al 2004). Structural studies of the catalytic domain of PDE8A1 have 
identified 2 additional helices in this region, and defined an important role for Tyr748 in 
the prevention of IBMX binding. Mutation of this residue to phenylalanine increased the 
sensitivity of the PDE to non-specific PDE inhibitors (Wang et al 2008). PDE8 activity is 
blocked by the inhibitor of platelet aggregation dipyridamole with an IC50 of 5-9µM 
(Fisher et al 1998).  
 
Recently, PDE8A has been linked to calcium handling in the heart by a study employing 
PDE8A knockout mice. PDE8A transcripts and protein were detected in the ventricles of 
wildtype mice hearts, and altered calcium transients were observed in PDE8A-/- mice 
compared with wildtype mice, following stimulation with the synthetic β-agonist 
isoproterenol (Patrucco et al 2010). Thus, PDE8A may play a role in the regulation of 
cardiac contraction. PDE8B expression has also been found to be upregulated in the 
hippocampus of Alzheimer’s disease brains, therefore both PDE8 subfamilies may 
represent important therapeutic targets (Perez-Torres et al 2003). 
 
1.4.1.10. PDE9 
PDE9 is encoded by a single gene with a large number of splice variants (Guipponi et al 
1998). The mRNA of certain PDE9 isoforms is highly expressed in the cortex and 
hippocampus of the brain (Reyes-Irisarri et al 2007). Interestingly, the locus for PDE9A 
maps to a region of chromosome 21 which is known to be associated with several genetic 
disorders, including bipolar affective disorder (Guipponi et al 1998). PDE9A is also     Chapter 1  Introduction   
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inhibited by the PDE5 inhibitor zaprinast, but not by the non-selective inhibitor IBMX 
(Soderling et al 1998). Recently, a novel selective inhibitor of PDE9, BAY 73-6691, has 
been developed which enhanced formation and retention of long term memory in rats 
(van der Staay et al 2008), indicating the possibility of an important neuropsychiatric role 
for enzymes of this family.   
 
1.4.1.11. PDE10 
Members of the PDE10A family show dual specificity for cAMP and cGMP, with kMs of 
0.05 and 3µM respectively. The Vmax for cAMP is 4.7 times higher and therefore this 
substrate is preferentially hydrolysed. In common with PDE2, 5, 6 and 11, they contain 2 
GAF domains at their N termini, which may have a regulatory function (Soderling et al 
1999). The PDE10A2 isoform is PKA phosphorylated on its N terminus at Thr16, and this 
modification appears to regulate its subcellular distribution between the cytosol and 
Golgi in rat neurons (Kotera et al 2004).  
 
PDE10A is highly expressed in the brain, particularly the caudate nucleus and putamen, 
and is also abundant in the thyroid and testis (Fujishige et al 1999). PDE10A knockout 
mice display decreased behavioural responses to stimuli, and altered striatal 
dopaminergic signaling consistent with rodent models of schizophrenia (Siuciak et al 
2006, Siuciak et al 2008). Novel selective PDE10A inhibitors are currently being developed 
and are of great interest as potential therapeutic agents for this complex disorder (Hage 
et al 2009, Malamas et al 2011a, Malamas et al 2011b). 
 
1.4.1.12. PDE11 
The single PDE11 gene has 4 splice variants (Fawcett et al 2000). PDE11A has GAF 
domains at its N terminus, and PDE11A mRNA is seen predominantly in skeletal muscle, 
kidney, liver, prostate and testis. PDE11 hydrolyses cAMP and cGMP with similar kM and 
Vmax values, and is likely to regulate levels of both cyclic nucleotides in vivo (Fawcett et al 
2000). Structurally, PDE11 shares most similarity with PDE5, and is modestly inhibited by 
tadalafil (Francis 2005); however, it is also inhibited by IBMX and dipyridamole (Fawcett 
et al 2000).  Studies of PDE11-/- mice have suggested a role in the generation of     Chapter 1  Introduction   
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spermatozoa. This has raised concerns because of the increasing use of tadalafil (Wayman 
et al 2005), though evidence linking PDE11A to spermatogenesis in humans is lacking 
(Francis 2005).  
 
 
Figure 1-8  Domain structures of PDE families 1-11. Adapted from (Conti & Beavo 2007). 
The 11 PDE families shown are grouped according to their differing structures, kinetics, tissue 
distributions and modes of regulation. The domain structures of PDE1-11 and the associated 
regulatory mechanisms for each family are described in Sections 1.4.1.2. to 1.4.1.12., and 
summarised in Table 1-2. 





PDE4 enzymes are cAMP-specific phosphodiesterases. The PDE4 family is encoded by 4 
genes: PDE4A, PDE4B, PDE4C and PDE4D. These are located on chromosomes 1, 5 and 19 
in humans, and encode over 20 different isoforms, by means of alternate mRNA splicing 
and the use of multiple promoter sites (Houslay & Adams 2003, Houslay et al 2007). PDE4 
isoforms have a modular structure, consisting of an isoform-specific N terminus, 
regulatory domains termed upstream conserved regions (UCRs), the conserved catalytic 
domain common to all PDE families, and a subfamily-specific C terminal region (Lynch et 
al 2007).  
 
1.4.2.1. N terminal region 
The N terminal region of PDE4 is unique to each isoform, and plays an important role in 
protein-protein interactions and intracellular targeting of the enzyme (Houslay 2010). For 
example, PDE4D5 isoforms are targeted to the signaling scaffold protein β-arrestin at the 
plasma membrane to modulate β-adrenergic signaling (Bolger et al 2006, Bolger et al 
2003).  
 
1.4.2.2. Upstream conserved regions (UCRs) 
PDE4 isoforms can be sub-classified based on the presence of two regulatory domains, 
UCR1 and UCR2 (Houslay & Adams 2003) (Figure 1-9 and Table 1-3). Long forms possess 
both UCR1 and UCR2, as well as two linker regions (LRs) which join them to the catalytic 
domain. Short forms lack UCR1 and the first linker region, and super short forms lack 
UCR1 and LR1, and also have an N terminal truncation of UCR2. Finally, dead short 
isoforms such as PDE4A7 lack UCR1 and UCR2, and have a truncated catalytic domain 
which renders them catalytically inactive (Houslay et al 2007). It is thought that UCR1 and 
UCR2 interact to form a regulatory module that co-ordinates phosphorylation of the PDE 
by PKA and ERK and regulates the catalytic domain (MacKenzie et al 2000, MacKenzie et 
al 2002).  
 




PDE4 Class  Truncations  Isoforms 
Long  None  4A4/5, 8, 10, 11 
4B1, 3, 4 
4C1, 2, 3 
4D3, 4, 5, 7, 8, 9 
Short  Lack UCR1  4B2 
4D1, 2 
Super short  Lack UCR1, LR1, N terminus of UCR2  4A1 
4B5 
4D6 




Table 1-3 Classification of PDE4 isoforms.  
 
 
1.4.2.3. Conserved catalytic domain 
The catalytic domain of PDE4 is common to all the PDE families, and has already been 
discussed (Section 1.4.1.1.).  
 
1.4.2.4. Unique C terminal region 
The final exon of PDE4 genes encodes a subfamily-specific C terminal region. The 
significance of this region is not fully understood, but may involve a regulatory function, 
as recent structural studies of PDE4 isoforms bound to inhibitors have revealed. The 
sequence differences in this region have been exploited by our laboratory to make the 
subfamily-specific antisera used in Chapters 4 and 5, and in the design of more specific 
PDE inhibitors (Burgin et al 2010, Houslay & Adams 2010).  
 
 




Figure 1-9 Domain structure of PDE4 isoforms. Adapted from (Houslay & Adams 2003).  
PDE4 isoforms are classified  by the presence or absence of two upstream conserved regions 
(UCR1 and UCR2). Long isoforms have both UCR1 and UCR2. Short isoforms lack UCR1, while 
super short isoforms lack UCR1 and have an N terminal truncation of UCR2. A fourth form of 
PDE4, ‘dead short’, exists, which lacks both UCR1 and UCR2, and is therefore catalytically 
inactive. 
 
1.4.2.5. Cellular functions of distinct PDE4 subfamilies 
Members of the PDE4B subfamily have been linked with schizophrenia. DISC1 and DISC2 
(Disrupted In Schizophrenia 1 and 2) were identified as novel genes spanning a 
translocation breakpoint strongly associated with schizophrenia in a large Scottish family 
(Blackwood et al 2001).  The DISC1 gene encodes a scaffolding protein which can interact 
with the UCR2 domain of PDE4B  (Millar et al 2005). The DISC1-PDE4B interaction is 
maximal in resting cells, and it appears that upon stimulation of cells leading to a rise in 
cAMP, DISC1 may activate and release this sequestered PDE4B to regulate local cAMP 
levels. Consistent with this, mutations in DISC1 which give rise to schizophrenia and 
depression phenotypes in mice are located within binding sites for PDE4B (Millar et al 
2007).      Chapter 1  Introduction   
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PDE4B also appears to play a role in the immune system. Much of this information has 
come from studies of PDE4B knockout mice. PDE4B -/- mouse macrophages display 
defective production of the inflammatory cytokine TNFα (Jin et al 2005), and neutrophils 
from these mice showed altered expression of surface adhesion molecules and defective 
chemotaxis (Ariga et al 2004). Thus, there is considerable interest in defining the role of 
this subfamily in the pathogenesis of chronic inflammatory diseases such as asthma and 
chronic obstructive pulmonary disease (COPD) (Houslay et al 2007).  
 
The PDE4D subfamily consists of 11 isoforms, PDE4D1-11. Several of these isoforms have 
only recently been discovered (PDE4D6-11), and so little is known about their respective 
functions (Chandrasekaran et al 2008, Gretarsdottir et al 2003, Lynex et al 2008, Wang et 
al 2003). PDE4D knockout mice exhibit behavioural effects consistent with an anti-
depressive phenotype, suggesting an important role for this subtype in the 
pathophysiology and pharmacotherapy of depression (Zhang et al 2002). 
 
PDE4D is also important in the cardiovascular system. PDE4D knockout mice develop 
progressive age-related cardiomyopathies and are susceptible to exercise-induced cardiac 
arrhythmias and sudden cardiac death, despite apparently normal global cAMP signaling 
(Lehnart et al 2005). The mechanisms behind these effects will be discussed in Section 
1.6.5.  
 
1.4.2.6. PDE4 inhibition and its clinical implications 
As PDE4 is the major cAMP-hydrolysing family in many cells types, it represents a 
promising therapeutic target. PDE4 subfamilies have been implicated in diseases of the 
central nervous system, immunological and respiratory systems. The increasing clinical 
use of PDE5 inhibitors such as sildenafil has spurred attempts to replicate this success 
with PDE4 inhibitors. Rolipram (4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) 
is the prototypical inhibitor of enzymes of the PDE4 family (Figure 1-10). This compound is 
directed against the active site of the PDE, binding competitively with cAMP, and 
therefore inhibits all PDE4 family members with similar efficacy (Spina 2008). Due to this 
blanket inhibition of PDE4, the development of PDE4 inhibitors for clinical use has 
unfortunately been hampered by unacceptable dose-related side-effects, in particular     Chapter 1  Introduction   
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emesis, diarrhoea and headache (Pages et al 2009). Pharmaceutical companies have, 
therefore, focused considerable efforts on designing compounds and methods of drug 
delivery with an improved therapeutic range (Pages et al 2009). In the past 12 months, 
one such PDE4 inhibitor, Roflumilast (DAXAS®, Bristol-Myers-Squibb) (Figure 1-10), has 
been licensed in the UK for the treatment of severe exacerbations of COPD, a highly 
prevalent, poorly reversible inflammatory disease of the airways.  In Phase III clinical 
trials, Roflumilast was found to reduce the requirement for steroid and antibiotic 
treatments, and reduce hospitalisation resulting from exacerbations of COPD (Calverley et 




Figure 1-10 Chemical structures of the PDE4 inhibitors Rolipram and Roflumilast. Adapted from 
(Pages et al 2009).  
Rolipram (chemical formula C16H21N03) is the prototypical inhibitor of PDE4 family members. 
Roflumilast is a long-acting PDE4 inhibitor which has been developed by the pharmaceutical 
industry for the treatment of severe exacerbations of chronic obstructive pulmonary disease 
(COPD) (Calverley et al 2009).  
 
Designing selective inhibitors of PDE4 subfamilies remains challenging, due to the high 
homology of PDE4 catalytic domains. A recent study, which determined the co-crystal 
structures of PDE4 bound to a number of inhibitors, revealed a novel mode of inhibitor 
binding to PDE4, involving UCR2 rather than the active site (Burgin et al 2010). This study 
may facilitate the design of small molecule PDE4 subtype-specific inhibitors which exhibit 
less class-related side-effects (Houslay & Adams 2010).      Chapter 1  Introduction   
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1.4.3 The roles of individual PDE isoforms in the heart 
PDE2, PDE3, PDE4 and PDE5 are the main phosphodiesterase families expressed in the 
heart; however, it has recently been appreciated that members of the PDE1 (Vandeput et 
al 2007) and PDE8 families (Patrucco et al 2010) also show cardiac expression. PDE3 and 
PDE4 provide the major cAMP-hydrolysing activity in rat cardiac myocytes, with PDE4 
having double the activity of PDE3 (Mongillo et al 2004, Richter et al 2005). Together 
these 2 families account for around 90% of cAMP hydrolysis (Richter et al 2005), with the 
PDE4D subfamily contributing around 60% of the cAMP hydrolysing activity of PDE4  
(Mongillo et al 2004).  
 
The non-redundant nature of individual PDE4 isoforms is well illustrated in the heart. 
Several recent studies have highlighted the importance of PDEs in normal cardiac 
signaling, and specific roles for individual PDE isoforms in key processes such as 
excitation-contraction coupling are now being defined. For example, the long 
phosphodiesterase isoform PDE4D3 has been shown to exist in a complex with the 
ryanodine receptor (RyR2) which mediates calcium release from the SR, and maintain it in 
a PKA-hypophosphorylated state (Dodge-Kafka et al 2005). This interaction is discussed 
further in Section 1.6.4.1.  
 
1.4.3.1. PDE4D5 and β-arrestin 
Specific PDE isoforms have also been shown to associate with -adrenergic receptors to 
mediate distinct effects. β-arrestins are cytosolic proteins which are recruited to activated 
β2-adrenergic receptors following phosphorylation of the C terminal tail of the receptor 
by G-protein receptor coupled kinase (GRK) (Kohout & Lefkowitz 2003, Perry & Lefkowitz 
2002). This prevents further interaction of the receptors with G-proteins, thereby 
desensitising the receptor and leading to uncoupling of the response. Our laboratory and 
others have shown that -arrestins recruit a subpopulation of PDE4D5 to activated β2-
adrenergic receptors to promote receptor desensitisation by hydrolysing the cAMP which 
has already been produced (Perry et al 2002) (Figure 1-11). Binding sites for β-arrestin on 
PDE4D5 have now been mapped to its unique N terminal region, and the C terminal of 
the conserved catalytic domain (Bolger et al 2006, Bolger et al 2003). Thus, PDE4D5 limits 




Figure 1-11  Interaction of β-arrestin and PDE4D5.  
Upper panel: Schematic representation of β-arrestin binding to the GRK-phosphorylated β2-
adrenergic receptor. This interaction sterically inhibits association of the receptor with 
stimulatory G proteins, and reduces adenylyl cyclase activation and cAMP production. β-
arrestin recruits the long PDE4 isoform PDE4D5 to the receptor, leading to hydrolysis of cAMP 
which has already been produced, and promoting receptor desensitisation. Lower panel: 
PDE4D5 possesses 2 distinct interaction sites for β-arrestin. The N terminal site overlaps an 
interaction site for the scaffold protein RACK1, so alterations in RACK1 levels may modulate β-
adrenergic signaling (Bolger et al 2006). 
 
1.4.3.2. PDE4D8 and β-adrenergic receptors 
The β1 and β2 adrenergic receptors are structurally very similar; however, they play very 
distinct physiological and pathological roles within the heart (Xiao et al 2004) (described 
in Section 1.2.1). For almost a decade, it has been known that PDE4D5 is recruited to the 
β2-adrenergic receptor complex, via its association with β-arrestin (Perry et al 2002), 
though no PDEs were known to associate with the β1 receptor. Recently, PDE4D8 has 
been shown to bind directly to the unoccupied β1-adrenergic receptor. Agonist 
occupancy of the receptor leads to dissociation of the PDE-receptor complex. PDE binding 
may induce a conformational change in the receptor, or recruit other proteins to the 
receptor (Richter et al 2008). Thus, β1 and β2-adrenergic receptors may be regulated in 
distinct manners by PDEs (Figure 1-12).  





Figure 1-12  Specific interactions of PDE4D isoforms with β-adrenergic receptor subtypes. 
Adapted from (Richter et al 2008). β1 and β2-adrenergic receptors form complexes with 
different PDE4D isoforms. The modes of interaction and the effects of agonist binding are 
distinct for the two receptor subtypes.  PDE4D8 is recruited to the unoccupied β1 receptor 
under basal conditions and associates directly to regulate cAMP levels, whereas PDE4D5 
translocates to the occupied β2 receptor and interacts with it via the signaling scaffold protein 
β-arrestin (Perry et al 2002, Richter et al 2008).  
 
 
1.5 Excitation-contraction coupling and cAMP       
signaling in the heart 
1.5.1 Cardiac contraction 
Cardiac excitation-contraction coupling (ECC) is the process by which electrical excitation 
of the heart is coupled to contraction and relaxation (Bers 2002). Under normal 
conditions, the heart acts as its own pacemaker. In the course of one heart beat, a  wave 
of depolarisation initiates in the sino-atrial node and propagates through the atria and 
atrio-ventricular node into the ventricles (Bers & Despa 2006). During this depolarisation, 
Ca
2+ enters the cells via L-type Ca
2+ channels, generating an inward calcium current (ICa) 
(Figure 1-13).  L-type Ca
2+ channels are located mainly at the junction of the cardiac     Chapter 1  Introduction   
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myocyte plasma membrane (sarcolemma) and the sarcoplasmic reticulum (SR), a 
specialised intracellular Ca
2+ store. Increasing ICa leads to a local increase in Ca
2+ at the SR, 
and triggers the release of large quantities of stored Ca
2+ ions from it via Ca
2+ release 
channels known as ryanodine receptors (RyR). This process is referred to as Ca
2+-induced 
Ca
2+ release (CICR). Free intracellular Ca
2+ ([Ca
2+]i) then binds to the myofilaments which 
comprise the muscle fibres, and triggers contraction (Bers & Despa 2006). This process 
must be reversed for relaxation to occur. Ca
2+ is transported back into the SR via the 
sarco(endo)plasmic reticulum Ca
2+ ATPase pump (SERCA), and into the extracellular space 
through the actions of the sarcolemmal Na
+/Ca
2+ exchanger (NCX). [Ca
2+]i falls, Ca
2+ 
dissociates from the myofilaments, and a single heartbeat is completed, ready for the 




Figure 1-13  Excitation-contraction coupling in the heart. Adapted from (Bers & Despa 2006). 
Ca
2+ enters cardiac myocytes via L-type calcium channels, leading to a local rise in [Ca
2+]i at the 
SR. This triggers Ca
2+ -induced release of Ca
2+ from SR ryanodine receptor channels. Free Ca
2+ 
associates with the myofilaments, leading to contraction of the heart (known as systole) and 
the propulsion of oxygenated blood around the body. Ca
2+ is then taken back up into the SR or 
expelled from the cytosol through Na
+/Ca
2+ exchangers at the sarcolemma, leading to a 
corresponding fall in [Ca
2+]i. Ca
2+ dissociates from the myofilaments, and relaxation (diastole) 
occurs. The relaxed heart is able to fill with blood, ready for the process to begin again.      Chapter 1  Introduction   
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Myofilaments are composed of protein-rich bundles of thick and thin filaments. Thick 
filaments are formed primarily from the protein myosin, while thin filaments are 
predominantly actin-based.  The basic contractile unit of the myofilament is the 
sarcomere (Figure 1-14). Contraction occurs when the head domain of myosin in the thick 
filament interacts with actin in the thin filament to form crossbridges, causing the 
filaments to slide past each other in an ATP-dependent process, and the sarcomeres to 
shorten (Hernandez et al 2001) (Figure 1-14). A number of proteins are associated with 
the thick and thin filaments to regulate this process. The best studied of these is the 
troponin complex associated with the thin filament.  
 
 
Figure 1-14 Contraction and relaxation of the sarcomere.  
The sarcomere is the smallest contractile unit of the myofilament, measuring about 2 µm in 
length. Up to 100 000 aligned sarcomeres may be present in one myofilament. Sarcomeres are 
composed of overlapping thick and thin filaments. Thin filaments are formed by actin, and are 
anchored to the Z lines (Z discs) which form the boundaries of one sarcomeric unit. Thick 
filaments are composed of myosin, and are cross-linked to the M line in the middle of the 
sarcomere, and linked to the Z line by the giant protein titin, which maintains the structure of 
the sarcomere (Engel et al 2004). The M and Z lines are named for their microscopic 
appearance, and the overlapping nature of the myofilament proteins gives rise to the 
characteristic striations of these cells. For contraction to occur, nerve impulses must be 
transmitted to the sarcolemma where they give rise to an action potential. This action potential 
triggers the influx of Ca
2+ions and Ca
2+release from the SR described above. Ca
2+ binds to the 
myofilament as described below,  and leads to conformational changes which allow actin and 
myosin to interact. The globular head of myosin forms crossbridges with actin, and the 
filaments slide over each other leading to shortening of the sarcomere. This movement is 
powered by the intrinsic ATP hydrolytic activity of the myosin head (Engel et al 2004).     Chapter 1  Introduction   
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1.5.2 The troponin complex and tropomyosin 
A number of proteins are associated with actin and myosin in the sarcomere, such as the 
myosin-associated proteins myosin-binding protein-C and titin, and the actin-associated 
proteins troponin and tropomyosin (summarised in Table 1-4). These proteins have 
multiple functions, including maintaining the structural integrity of the myofilament, 
organising the filaments during development, and modulation of contraction (Engel et al 
2004, Solaro 2010), and mutations in them have been linked to the development of 
various diseases, such as familial hypertrophic cardiomyopathy (Hernandez et al 2001). 
 
 In the heart and skeletal muscle, the principal regulators of contraction are the thin 
filament-associated proteins troponin (Tn) and tropomyosin (TM) (Engel et al 2004). 
Tropomyosin is a 65kDa coiled coil of 2 α-helices, measuring 41nm by 2nm. In the thin 
filament, actin monomers are polymerised to form long helical strands. TM lies in a 
groove on the surface of the actin helices, with each TM molecule spanning 7 actin 
monomers. 
 
Protein  MW , Structure  Location  Function 
Actin  42kDa, globular 
monomer 
Thin filament, as 
helical polymer 
Forms thin filament, interacts 
with myosin 
α-actinin  190kDa dimer  Z line  Integrates Z line, binds and ? 
links actin and titin 
Myosin  520kDa hexamer  Thick filament, as 
helical polymer 
Forms thick filament, ATP-
dependent filament sliding 
Myosin-binding 
protein C 




filament, modulates contraction 
Titin  3MDa  Extends from Z line to 
M line 
Sarcomeric development and 
stability 
Tropomyosin  65kDa coiled coil 
dimer 
Thin filament, one 
molecule stretches 
over 7 molecules of 
actin 
Filament stability and regulation 
of contraction 
Troponin  80kDa complex of 
3 subunits 
Thin filament; one 
per tropomyosin 
Regulation of contraction 
 
Table 1-4  Structure and function of major sarcomeric proteins. Adapted from (Engel et al 2004).     Chapter 1  Introduction   
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The 80kDa Tn complex consists of 3 proteins: troponin C (TnC), troponin T (TnT) and 
troponin I (TnI), which are named according to their first identified functions. TnC is a 
Ca
2+-binding protein, TnT binds to tropomyosin, and TnI forms the inhibitory subunit of 
the heterotrimeric complex (Engel et al 2004). The crystal structure of the core Tn 
complex in Ca
2+ saturated and unsaturated forms has now been solved, which has 
provided a wealth of information on how this complex regulates contraction (Takeda et al 
2003).  
 
1.5.2.1. Troponin C 
TnC is the Ca
2+-binding component of Tn, and functions as a Ca
2+ sensor. TnC is an 18kDa 
globular protein, with binding sites for TnT, TnI and tropomyosin (Engel et al 2004). TnC 
exists in a dumbbell shape, with 2 globular heads with helix-loop-helix conformations, 
linked by a central α-helix. These globular heads contain the Ca
2+ binding sites. In the Ca
2+ 
unbound form, the helices flanking the Ca
2+ binding sites of TnC are closely aligned, 
creating a ‘closed’ conformation. Upon Ca
2+ saturation, the protein undergoes a 
conformational change, with these helices rotating to create a more open conformation 
which exposes TnI binding sites on TnC. TnC and TnI are then able to interact (Takeda et al 
2003) (Figure 1-16).  
 
1.5.2.2. Troponin T 
TnT provides the main link between the Tn complex and tropomyosin. TnT has a 
molecular weight of approximately 34kDa, and possesses an extended N terminal region 
and a globular C terminal head. Interactions with TM occur via the N terminus, while the 
C terminus of the protein contains binding sites for TnC and TnI. One Tn complex binds to 
one TM molecule via TnT, thus Tn and TM are both equally spaced along the actin 
filament.  A helical region of TnT interacts with helix 2 of TnI to form a rigid structure 
know as the IT arm (Figure 1-16), which may be involved in TM positioning on actin 
(Takeda et al 2003). 
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1.5.2.3. Troponin I 
Cardiac troponin I (TnI) is a key mediator of cardiac contraction and relaxation, and forms 
the inhibitory component of the troponin complex (Layland et al 2005, Solaro 2010, 
Solaro et al 2008). TnI is a 210 amino acid protein with a molecular mass of 28kDa. A 32 
amino acid N terminal extension is present in cardiac isoforms of TnI, but lacking in 
skeletal muscle isoforms of the protein (Solaro et al 1976). This N terminal region contains 
two neighbouring consensus PKA phosphorylation sites, at Ser22 and Ser23. TnI consists 
of 4 α-helices, and contains sites for actin and TnC binding at its C terminus (Galinska-
Rakoczy et al 2008, Takeda et al 2003) (Figure 1-15). Helix 2 participates in the IT arm with 
TnT (Takeda et al 2003).  
 
 
Figure 1-15 Schematic representation of the domain structure of cardiac troponin I (cTnI).  
TnI is a 210 amino acid protein integral to the contraction of cardiac and skeletal muscle. TnI 
contains binding sites for TnT and TnC (as shown), and exists in a heterotrimeric complex with 
these proteins to regulate actin-myosin interactions. The C terminus of TnI is able to interact 
directly with actin (Galinska-Rakoczy et al 2008). The cardiac isoform of TnI, cTnI, possesses a 
unique 32 amino acid N terminal extension which contains 2 consensus PKA phosphorylation 
sites. cTnI is, therefore, subject to regulation by β-adrenergic/cAMP/PKA signaling pathways 
(Solaro et al 1976). The 4 α-helices of TnI are indicated in purple, and amino acids defining each 
helix are numbered. 
 
At low [Ca
2+]i, equivalent to a period of cardiac relaxation, TnT and TnI hold TM in a fixed 
position on actin. This conceals the myosin binding sites on actin, preventing actin-myosin 
interactions and inhibiting crossbridge formation. During contraction, release of Ca
2+ from 
SR stores leads to a transient rise in cytosolic Ca
2+ levels (Bers 2002). Ca
2+ binds to TnC, 
causing a conformational change that exposes binding sites for TnI on TnC (Engel et al 
2004, Galinska-Rakoczy et al 2008, Galinska et al 2010, Howarth et al 2007). Binding of TnI 
helix 3 to the N lobe of TnC in the presence of Ca
2+ acts as a molecular switch and induces 
release of the C terminal of TnI from interactions with actin-TM (Takeda et al 2003). This 
results in a shift in the position of TM on actin, and exposes myosin binding sites. 
Crossbridge formation can then occur, leading to force generation and contraction (Figure 





Figure 1-16  Structure of the core troponin complex. Adapted from (Takeda et al 2003). 
Troponin I is shown in blue, troponin C in red and troponin T in yellow. The three Ca
2+ ions co-
ordinated by TnC are shown as black spheres. A. Predicted secondary structure of the complex. 
The second α-helices of TnI and TnT form a rigid coiled coil known as the IT arm, which anchors 
the complex to tropomyosin on the thin filament. Ca
2+ binding to TnC leads to a conformational 
change which frees the C terminal  of TnI from interactions with actin. This alters the position of 
TM relative to the thin filament, and promotes actin-myosin interactions (Takeda et al 2003). B. 
Space-filling model of the complex. C. Movement of the flexible C terminus of TnI in response to 
Ca
2+ binding to TnC. Adapted from (Takeda et al 2003). In the absence of Ca
2+, TnI remains 
associated with actin (light blue conformation). When Ca
2+ binds to TnC, helix 3 of TnI acts as a 
molecular switch, and the C terminus of TnI moves away from actin (dark blue conformation).      Chapter 1  Introduction   
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1.5.2.4. Modification of TnI by phosphorylation 
Phosphorylation of myofilament proteins represents a major mechanism for the 
modulation of myofilament calcium sensitivity and contractile properties. A number of 
cardiac proteins are phosphorylated in response to cAMP signal transduction cascades, 
including the RyR and LTCC (Bers 2004), leading to enhanced cardiac output. TnI has been 
extensively studied in this regard, as it contains a number of phosphorylation sites for 
different kinases which may modify its effects (Solaro 2008). The most important 
phosphorylation of TnI is mediated by PKA. 
 
PKA Phosphorylation of TnI 
 
Phosphorylation of TnI by PKA is required to allow the heart to respond appropriately to 
increased physiological demands. Physiological stressors, such as exercise and fear, result 
in a rise in the levels of the circulating catecholamines adrenaline and noradrenaline. 
Catecholamines bind to and stimulate β-adrenergic receptors on the surface of cardiac 
myocytes. This triggers increased intracellular generation of the second messenger cAMP, 
which activates PKA, leading to the phosphorylation of key downstream targets involved 
in excitation-contraction coupling. These include the RyR at the SR and myofilament 
proteins such as TnI. The net result is to increase the rate and efficiency of myocyte 
contraction, and improve cardiac output (Mudd & Kass 2008) (Figure 1-17).  
 





Figure 1-17  Regulation of myofilament contraction by a cAMP/PKA signal transduction cascade. 
β1-adrenergic stimulation couples the receptor to the stimulatory G protein Gαs. This activates 
adenylyl cyclase isoforms, leading to the generation of cAMP and activation of PKA. PKA then 
goes on to phosphorylate key proteins involved in ECC, such as TnI at the cardiac myofilament. 
PKA phosphorylation of TnI has both positive inotropic and lusitropic effects. The right panel 
illustrates the location of the Tn complex on the thin filament.  
 
TnI is phosphorylated by PKA at two neighbouring serine residues (Ser 22/Ser23 in mouse, 
Ser23/Ser24 in humans) on a unique 32 amino acid N terminal region of the protein only 
present in cardiac isoforms of the protein (Solaro et al 1976). This dual phosphorylation 
causes a conformational change in TnI which diminishes its interaction with TnC, resulting 
in a desensitisation of the myofilament to Ca
2+  which promotes relaxation (Stelzer et al 
2007). Cardiac relaxation is also referred to as lusitropy. Earlier relaxation facilitates rapid 
filling of the heart with blood during diastole, contributing to improved cardiac output.  
 
Transgenic (TG) mouse models expressing TnI PKA phosphorylation site mutants have 
been invaluable in investigating the functional consequences of this modification in vivo. 
TG mice were generated with cardiac expression of the short skeletal muscle (ss) isoform 
of TnI. This isoform lacks the unique N terminal extension containing the PKA sites (Figure 
1-18). ssTnI transgenic mice demonstrated attenuation of the lusitropic response to -
adrenergic stimulation (F'Entzke et al 1999). Mice with Ser22/Ser23 to Alanine mutations 
(cTnI-S22A/S23A) showed a similar response, with abolition of the expected reduction in 
myofilament sensitivity to Ca
2+ following -stimulation (Pi et al 2002, Pi et al 2003).     Chapter 1  Introduction   
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Conversely, animals overexpressing an S22D/S23D mutant version of full length TnI, 
which mimics constitutive phosphorylation, showed enhanced left ventricular relaxation 
in vivo (Takimoto et al 2004). Thus, PKA phosphorylation of TnI on Ser22/Ser23 in 
response to -agonist stimulation contributes to the enhanced rate of myocardial 
relaxation which is necessary to cope with increased cardiac demand (Biesiadecki et al 





Figure 1-18  Mutations in TnI PKA sites have important functional consequences for relaxation 
of the heart.  
TG mice expressing TnI mutants lacking a PKA-phosphorylatable N terminus demonstrate 
reduced lusitropy, whereas lusitropy is enhanced in TnI phospho-mimic animals. Efficient 
lusitropy (relaxation) aids the rapid filling which is required at high heart rates. 
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PKA phosphorylation of TnI also has positive effects on cardiac contraction (inotropy). The 
positive inotropic response to β-agonists is blunted in S22A/S23A animals (Layland et al 
2005), while S22D/S23D animals display significantly enhanced contractile function at 
baseline and an increased rate of crossbridge cycling (Takimoto et al 2004). Thus, 
Ser22/Ser23 phosphorylation of TnI by PKA increases both the force of cardiac 




α1-adrenergic signaling cascades activate PKC isoforms. TnI is a potential substrate for 
PKC at 5 sites: Ser22/Ser23, Ser43/Ser45 and Thr144. The most physiologically relevant of 
these are Ser43/Ser45 and Thr144 (Layland et al 2005). Cardiac myocytes stimulated with 
PKC activators show immediate phosphorylation of Thr144, followed by Ser43/Ser45, 
with Ser22/Ser23 only being phosphorylated following prolonged α-agonist exposure 
(Westfall et al 2005).  
 
The functional outcome of PKC phosphorylation of Ser22/Ser23 is also now disputed, 
though early work suggested it may confer similar effects to PKA (Noland et al 1995). In 
fact, phosphorylation of Ser22/Ser23 by PKC may depend greatly on the status of 
downstream phosphorylation sites, as studies of TnI-S43A/S45A transgenic mice showed 
enhanced PKCε phosphorylation of Ser22/Ser23 (Roman et al 2004).  
 
PKC phosphorylation of Thr144 has been proposed to sensitise the myofilaments to 
calcium (Burkart et al 2003, Solaro 2008). Thr144 is the most easily accessible of the 
potential PKC sites on TnI, and it is proposed that this modification decreases the sliding 
velocity of the myofilaments, contributing to a negative inotropic response (Burkart et al 
2003).  
 
Ser43/Ser45 phosphorylation also contributes to the negative inotropic response. 
Phosphorylation at these sites was achieved in reconstituted detergent-skinned fibre 
bundles by stimulation with α-agonists, or by mutation to glutamine (S43D/S45D) to     Chapter 1  Introduction   
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mimic constitutive phosphorylation. In both cases, maximum Ca
2+-activated muscle 
tension was reduced, probably by decreasing the rate of crossbridge detachment (Burkart 
et al 2003, Layland et al 2005). This pathway may contribute to the systolic dysfunction 
observed in heart failure (Layland et al 2005).  
 
1.6 Control of cellular processes by cAMP       
compartmentalisation 
The concept of intracellular compartmentalisation of cAMP arose almost two decades ago 
from seminal studies performed in cardiac myocytes. Activation of β-adrenergic receptors 
and prostaglandin receptors was shown to result in similar increases in cellular cAMP; 
however, whereas β-adrenergic stimulation coupled to cardiac myocyte contraction and 
PKA phosphorylation of downstream effectors such as TnI, prostaglandin receptor 
stimulation did not (Brunton et al 1981, Buxton & Brunton 1983). These differences in 
response could only be explained if cAMP was compartmentalised within the cell. More 
recently, the use of genetically encoded cAMP sensors has provided further evidence for 
this concept, allowing the real time direct visualisation of compartmentalised cAMP 
gradients within intact cardiac myocytes  (Zaccolo et al 2005, Zaccolo & Pozzan 2002).  
 
1.6.1 Measurement of cAMP gradients using FRET 
Measurement of cAMP gradients has relied largely on fluorescent microscopic 
techniques, which utilise the phenomenon of fluorescence resonance energy transfer 
(also known as Förster resonance energy transfer (Förster 1948), or FRET). Real time 
spatial and temporal changes in cAMP at a subcellular level can be measured with high 
resolution, illustrating the complexity of cAMP compartmentalisation in living cells (Di 
Benedetto et al 2008). FRET describes the process of energy transfer between two 
fluorophores, a donor and an acceptor, which are often cyan- and yellow- fluorescent 
proteins (CFP and YFP). Excitation of the donor by a particular wavelength will lead to a 
characteristic emission by the donor. However, if the donor and acceptor are in close 
proximity, and their emission and excitation spectra overlap, intermolecular FRET occurs     Chapter 1  Introduction   
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and the acceptor emission is predominantly detected (Figure 1-19). FRET can be used to 
measure protein-protein interactions, when the donor and acceptor fluorophores are 
linked to a pair of interacting proteins, and to monitor conformational changes in a single 
protein (Nikolaev & Lohse 2006).  
 
Figure 1-19  Genetic engineering of different FRET sensors to monitor real time changes in cAMP 
levels in the heart.   
A. Sensor based on PKA, with CFP and YFP linked to the R and C subunits of PKA respectively. In 
basal conditions, cAMP is low and PKA is in its inactive conformation. Excitation of CFP at 
440nm will result in FRET, as CFP and YFP are in close proximity, and YFP emission at 545nm. In 
stimulated cells, cAMP rises. Two molecules of cAMP bind to each PKA-R subunit, leading to 
dissociation of active catalytic units. CFP and YFP thus diffuse further apart and FRET is reduced, 
leading to detection of CFP emission at 480nm. Changes in FRET ratio (480/545nm) are directly 
proportional to R/C subunit dissociation, and therefore to cAMP levels (Zaccolo & Pozzan 2002).  
B. FRET sensor with CFP and YFP linked to the cAMP-binding domain of Epac1. Binding of cAMP 
leads to a conformational change in the sensor that moves the fluorophores further apart, 
abolishing FRET (Nikolaev et al 2004).  C. New FRET sensors have now  been developed where a 
targeting sequence is linked to one of the  fluorophores to localise the sensor to a particular 
intracellular region. This enables monitoring of cAMP gradients in different subcellular micro-
compartments (Herget et al 2008).      Chapter 1  Introduction   
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The actions of cAMP are mediated by three types of effector: PKA, cyclic nucleotide-gated 
channels, and Epac (Bos 2003) (Section 1.3). To date, a variety of FRET sensors based on 
PKA and Epac have been used to monitor cardiac cAMP dynamics. In fact, the first direct 
observation that diffusion of cAMP was restricted in the heart was made using a 
genetically encoded PKA-based cAMP sensor. Zaccolo and Pozzan fused CFP and YFP to 
the R and C subunits of PKA respectively (Zaccolo & Pozzan 2002). Thus, in conditions of 
low cAMP, the PKA holoenzyme is intact and FRET can occur. When cAMP rises, it binds to 
the R subunits, leading to a conformational change that releases active C subunits. The 
distance between CFP and YFP is increased, and FRET is abolished. Using this technique, 
β-adrenergic stimulation of neonatal cardiac myocytes was shown to generate multiple 
discrete microdomains of high cAMP which activated a subset of PKA within the cells 
(Figure 1-20C). Treatment with the non-specific PDE inhibitor IBMX destroyed these 
gradients, indicating that PDEs limit the diffusion of cAMP and help to shape cAMP 
gradients within cells (Figure 1-20D) (Zaccolo & Pozzan 2002).  
 
Figure 1-20  Discrete microdomains of cAMP in cardiac myocytes measured by FRET. Adapted 
from (Zaccolo & Pozzan 2002).  
Localised increases in cAMP are illustrated in neonatal cardiac myocytes co-transfected with 
PKA C-YFP and PKA R-CFP. A. Distribution of C-YFP. B–D. FRET ratios (480/545nm) of the same 
cell as pseudocolour images. B. Resting cell with relatively uniform distribution of basal cAMP. 
C. Cell stimulated with 10µM noradrenaline to activate the β-adrenergic signaling pathway. 
Changes in FRET ratio, which are proportional to cAMP concentration, are seen to occur within 
discrete subcellular regions, corresponding to cellular striations. D. Same cell treated with 
100µM IBMX to non-specifically inhibit phosphodiesterase activity. The compartmentalisation 
of cAMP generated in response to noradrenaline stimulus is destroyed, indicating that PDE 
activity limits free diffusion of cAMP, and is necessary to maintain cAMP compartmentalisation.     Chapter 1  Introduction   
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Several refinements of FRET techniques have been suggested, including the use of 
genetically engineered mice, which express a FRET sensor as a transgene. Such transgenic 
sensor animals would express the sensor uniformly across a particular tissue, introducing 
the possibility of measuring cAMP levels in intact organs or even in whole animals. This 
approach has already been successfully used to monitor neuronal cAMP levels in 
transgenic fruit flies with tissue-specific expression of a PKA-based sensor (Lissandron et 
al 2007, Lissandron & Zaccolo 2006). FRET sensors fused to individual PDE isoforms have 
also been developed which have, for the first time, allowed measurement of changes in 
cyclic nucleotide concentration around particular PDEs (Herget et al 2008). 
 
One major drawback of using FRET has been the conversion of measured FRET ratios into 
absolute cAMP concentrations. Recently, Böerner et al addressed this issue using a 
protocol which allows more precise measurement of cAMP concentrations and kinetics. 
By calibrating FRET sensors in vivo, first by inhibiting adenylyl cyclase activity so that 
cAMP drops below the threshold detectable by the sensor, then by fully stimulating the 
sensor with a cell permeable cAMP analogue, actual cAMP levels can now be accurately 
estimated during a FRET experiment (Boerner et al 2011).  
 
The use of FRET-based techniques has addressed the need for monitoring real time 
spatial and temporal changes in cAMP. Methods based on activation of all three effectors 
of cAMP (PKA, Epac and cyclic nucleotide-gated channels) have been developed, and 
combining these with new approaches, such as sensors linked to PDEs, and transgenic 
sensor animals, is likely to provide a wealth of information on compartmentalised cAMP 
signaling at distinct intracellular locations.  
 
1.6.2 PDEs shape cAMP gradients 
cAMP is freely diffusible, and could potentially flood the interior of the cell, leading to 
inappropriate phosphorylation and activation of downstream PKA targets (Houslay et al 
2007). This situation is avoided by the opposing action of cyclic nucleotide 
phosphodiesterases (PDEs). Members of the PDE superfamily provide the only means of     Chapter 1  Introduction   
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hydrolysing cAMP within the cell, and intracellular targeting of PDEs enables the creation 
of sub-cellular compartments with high levels of cAMP relative to the surrounding 
environment (Baillie 2009). Thus, PDEs have the capacity to influence activation of PKA, 
and the phosphorylation status of PKA target proteins.  
 
1.6.3 Physical compartmentalisation of PKA by AKAPs 
The idea of physical compartmentalisation as a mechanism to confer specificity upon the 
cAMP signaling pathway was first suggested in 1977, when Corbin and co-workers 
determined that PKA existed in cells as soluble and particulate fractions. Stimulation of 
the cells with prostaglandin E1 activated the soluble fraction, whereas stimulation with 
the synthetic β-agonist isoproterenol activated both fractions (Corbin et al 1977). It is 
now accepted that particulate PKA is in fact PKA bound to scaffold proteins known as A-
kinase anchoring proteins (AKAPs) (Kapiloff & Chandrasekhar 2011). AKAPs are a 
functionally related group of scaffold proteins that organise cellular signaling pathways by 
physically tethering PKA and other signaling enzymes to specific locations within the cell. 
The first AKAP was identified in brain tissue, when PKA type II was found to associate with 
the microtubule-associated scaffold protein MAP2 (Theurkauf & Vallee 1982). Since then, 
various techniques have been developed to identify AKAPs, often using PKA-RII as a 
probe. Lohmann and co-workers used radio-labelled RII subunits to probe nitrocellulose 
membranes, and were able to identify a number of RII binding proteins in bovine brain 
and heart (Lohmann et al 1984). This “RII overlay” technique has now been adapted and 
used to characterise many other AKAPs, and, to date, more than fifty AKAPs have been 
discovered (Kapiloff & Chandrasekhar 2011, Welch et al 2010).  
 
Due to slight differences in their electrophoretic properties between species, and 
alternative splicing patterns, a complex nomenclature for AKAPs has evolved. For 
example, the AKAP5 gene gives rise to three products: AKAP79 (human), AKAP150 
(mouse) and AKAP75 (bovine). As well as their diverse nomenclature, the subcellular 
localisations and associations of AKAPs are also diverse (Table 1-5): 
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AKAP name(s)  Gene  Associations  Localisation 
 
AKAP-Lbc  AKAP13  PKD, PKCη, Rho, 14-3-3  Cytoplasm, actin cytoskeleton 
 
AKAP18 (α, β, γ, 
δ isoforms) 
AKAP15 
AKAP7  Aquaporin-2, PDE4D; 
SERCA2 and 
phospholamban (δ) 
Plasma membrane (α, β), cytosolic 






AKAP5  β1-adrenergic receptor, 
PP2B, NMDA receptor 






AKAP6  PDE4D3, Epac, ryanodine 
receptor, ERK5, AC5 
Nuclear envelope, sarcoplasmic 
reticulum 
 
Gravin (α, β, γ) 
AKAP250 








AKAP9  PP1, PP2A, KCNQ1 
potassium channel, 
NMDA receptor 




MAP2    Tubulin, F-actin  Microtubules 
 
AKAP220  AKAP11  PP1, GSK3β  Vesicles 
 
 
Table 1-5  Subcellular localisation of a number of important AKAPs. Adapted from (Welch et al 
2010).  
 
The defining characteristic of an AKAP is its ability to anchor PKA holoenzyme. AKAPs 
possess an amphipathic helix of 14-18 amino acids, which creates a hydrophilic region of 
high binding affinity on the surface of the AKAP (Carr et al 1991). This region associates 
tightly with a groove in the dimerisation/docking (D/D) domain at the N terminal of the R 
subunit (Newlon et al 1999, Scott et al 1990). Most AKAPs exhibit high affinity for PKA RII 
subunits; however, a number of AKAPs have now been identified which can also interact 
with RI subunits, although typically with 10-100 fold lower affinity. These are referred to 
as dual specificity AKAPs, and include ezrin and AKAP220 (Herberg et al 2000). Recently, 
RI-specific AKAPs have also been discovered. At the mitochondria, sphingosine kinase 
interacting protein (SKIP) binds RI with a nanomolar dissociation constant, similar to the 
affinity of interaction observed with RII-specific AKAPs (Means et al 2011).      Chapter 1  Introduction   
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1.6.4 Cardiac AKAPs and modulation of excitation-
contraction coupling 
As an important second messenger that regulates multiple pathways within the cardiac 
myocyte, cAMP signals must be tightly controlled and integrated with those from other 
second messengers such as calcium. The formation of macromolecular signaling 
complexes, referred to as “signalosomes”, or signaling nodes, by AKAPs allows co-
ordination of cAMP and other upstream signals with downstream effectors, by 
incorporating components of different signaling pathways and signal terminating 
enzymes. Many AKAPs have been characterised in the heart (Figure 1-21), and several of 
these are known to play a role in excitation-contraction coupling via modulation of 
calcium handling. For example, AKAP18 isoforms target PKA to SERCA2 (Lygren et al 
2007), AKAP79/150 directs PKA phosphorylation of the cardiac LTCC (Gao et al 1997), and 
mAKAP targets PKA to ryanodine receptors at the SR (Marx et al 2000). The 
macromolecular complexes that regulate the cardiac RyR, SERCA and voltage-gated 
potassium channel will be described in more detail below. 
 
 
Figure 1-21 Co-ordination of signaling events  in the heart is achieved by localised scaffolding of 
PKA by AKAPs. Adapted from (Welch et al 2010).  
Multiple roles for AKAPs have been identified in cardiac myocytes, including excitation-
contraction coupling and hypertrophic remodelling, which are described in more detail below. 
AKAPs have been shown to associate with and regulate the function of a number of key cardiac 
proteins, including the RyR (mAKAP), LTCC (AKAP18/AKAP79), β-adrenergic receptor 
(AKAP79/gravin), voltage-gated potassium channel sununit KCNQ1 (yotiao), SERCA2 and 
phospholamban (AKAP18) (see Table 1-5).      Chapter 1  Introduction   
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1.6.4.1. mAKAP and the ryanodine receptor 
The macromolecular complex formed by the muscle-specific A-kinase anchoring protein 
(mAKAP) and the ryanodine receptor (RyR) has been well characterised, and will be used 
as an example of how cAMP/PKA signals can be finely regulated and integrated with other 
signaling pathways in the heart. 
 
mAKAP is a 250kDa anchoring protein which directs PKA to the nuclear membrane and 
sarcoplasmic reticulum (SR) in cardiac myocytes (Kapiloff et al 1999, Marx et al 2000, 
Ruehr et al 2003). The cardiac isoform of the ryanodine receptor (RyR2) is a calcium 
release channel located predominantly at the SR of cardiac myocytes. A small amount of 
RyR2 is also located at the nuclear envelope. During EC coupling, calcium influx through L-
type calcium channels at the sarcolemma triggers the release of larger quantities of 
calcium ions from SR stores, via RyR2. This leads to activation of the myofilaments and 
cardiac contraction (Bers 2004). mAKAP anchors PKA to RyR2, positioning it in close 
proximity to a known PKA phosphorylation site, Serine 2808, on RyR2. PKA 
phosphorylation of this residue has been proposed to enhance the open probability of 
the channel (Marx et al 2000). Anchoring of PKA via mAKAP would allow the 
phosphorylation status of the channel, and therefore its open probability, to be regulated 
locally, thus linking compartmentalised cAMP signaling with calcium signals (Ruehr et al 
2003). However, it should be noted that controversy exists as to the relevance of Ser 2808 
phosphorylation by PKA in modulating channel function (Bers 2012, Xiao et al 2005). A 
recent study employing transgenic mice, in which this RyR2 phosphorylation site was 
mutated to alanine, found no discernible difference in either cardiac contractility or 
calcium handling after induced myocardial infarction between transgenic and wildtype 
mice (Zhang et al 2012). A number of phosphorylation sites have been identified on RyR2, 
which may function to regulate channel opening, including a second PKA site at Ser 2030, 
and CaMKII phosphorylation of the nearby Ser2814 site; however, the relative importance 
of these sites is also controversial (Ai et al 2005, Huke & Bers 2008, Xiao et al 2005). 
 
Recently, the N terminus of mAKAP has been shown to selectively bind AC5 in the heart 
(Cooper & Crossthwaite 2006, Kapiloff et al 2009). AC5 and AC6 are the most abundant 
cyclase isoforms in cardiac myocytes (Hanoune & Defer 2001); however, mAKAP-    Chapter 1  Introduction   
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associated AC activity is totally absent in AC5 knockout hearts, indicating a specific 
association between the two (Cooper & Crossthwaite 2006). mAKAP association can 
regulate activity of AC5 via a negative feedback loop. cAMP synthesis by AC5 activates 
mAKAP-bound PKA, which then phosphorylates AC5, inhibiting further cAMP production 
(Figure 1-22). The participation of adenylyl cyclases in AKAP macromolecular complexes 
together with cAMP effectors and downstream targets illustrates how a localised pool of 
cAMP generated by an AC can lead to specific physiological effects (Dessauer 2009).  
 
Signal-terminating enzymes (PDEs and protein phosphatases (PPs)) which counteract the 
effects of second messengers are increasingly being shown to participate in 
macromolecular signaling complexes. mAKAP is known to directly associate with PDE4D3 
(Dodge et al 2001). Tethering of PDE4D3 in close proximity to PKA allows it to regulate the 
activity of mAKAP-bound PKA, via hydrolysis of local cAMP. PP2B, also known as 
calcineurin, has also been shown to associate with mAKAP, along with PP2A (Dodge-Kafka 
et al 2010, Pare et al 2005).  
 
cAMP is considered to act principally through the effector PKA to mediate many of its 
intracellular effects. However, it is now widely accepted that it may also mediate its 
effects via the activation of other proteins, such as Epacs (de Rooij et al 1998). Epac1 co-
purifies with mAKAP in rat heart extract (Dodge-Kafka et al 2005). Interestingly, this 
interaction is indirect, and is in fact mediated via PDE4D3. cAMP has long been known to 
regulate growth factor signalling, and PDE4D3 is phosphorylated on Ser579 by ERK, 
leading to reduced activity of the PDE (Baillie et al 2000, Hoffmann et al 1999). Dodge-
Kafka and co-workers predicted that the mAKAP complex might also include a MAP kinase 
to counterbalance actions of the anchored PDE. Cellular binding studies showed that 
PDE4D3 functions as a scaffolding protein for both ERK5 and Epac1 in the mAKAP complex 
(Dodge-Kafka et al 2005). Activation of Epac1 by cAMP leads to the induction of a Rap1 
signaling pathway, which inhibits mAKAP-associated ERK5 (Figure 1-22) (Dodge-Kafka et al 
2005). 
 





Figure 1-22  The mAKAP/RyR2 macromolecular signaling complex regulates cAMP 
compartmentalisation at multiple levels in the heart. 
mAKAP directly scaffolds PKA, AC5, the cardiac ryanodine receptor, PDE4D3, and protein 
phosphatases PP2A and PP2B. Epac1 and ERK5 also participate in the mAKAP/RyR complex via 
their association with PDE4D3. Following generation of cAMP, PKA (shown here in its R2C2 form) 
is activated and can phosphorylate AC5, RyR, PDE4D3 and PP2A. This leads to inhibition of the 
cyclase, and enhanced PDE4D3 activity, contributing to a reduction in cAMP levels. However, 
phosphorylation of PP2A within the complex counteracts this negative feedback loop by 
promoting dephosphorylation of the anchored PDE. Phosphorylation of PDE4D3 by ERK5 also 
reduces activity of the PDE; however, this effect is opposed by the actions of an Epac1-Rap1-
mediated pathway. PKA phosphorylation of RyR has been proposed to increase the open 
probability of the channel. Thus, cAMP, calcium and growth factor signals are integrated by the 
same macromolecular signaling complex in the heart. A green P indicates an activating 
phosphorylation and a red P indicates a deactivating phosphorylation.  
 
1.6.4.2. Yotiao and the voltage-gated potassium channel  
Several other AKAPs have been identified in the heart that compartmentalise PKA in 
proximity to a variety of effectors of EC coupling, such as ion channels and the contractile 
machinery (Scott & Santana 2010). Yotiao (AKAP9) associates with the KCNQ1 subunit of 
the voltage-gated cardiac potassium channel IKS. Scaffolding by Yotiao brings PKA into the 
vicinity of KCNQ1, where it phosphorylates it on Serine 27 in response to β-adrenergic 
stimulation. This allows regulation of cardiac action potential duration by increasing the 
slow outward potassium ion current (Chen & Kass 2011, Marx et al 2002). Mutations in 
Yotiao which disrupt its binding to IKS have been linked with long QT syndrome, a     Chapter 1  Introduction   
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propensity to ventricular tachyarrhythmias, syncope and sudden cardiac death (Chen et al 
2007). The Yotiao/potassium channel complex has now been shown to contain the signal 
terminating enzymes PP1 and PDE4D3 (Marx et al 2002, Terrenoire et al 2009). Thus, 
scaffolding of various signaling elements by Yotiao allows the creation of a 
compartmentalised signaling environment that finely regulates IKS function.  
 
1.6.4.3. AKAP15/18 isoforms and phospholamban 
The AKAP18δ isoform facilitates PKA phosphorylation of the SERCA2-associated 
regulatory protein phospholamban (PLB) (Lygren et al 2007). SERCA2 controls calcium 
reuptake into the SR, which is a rate-limiting step for relaxation and adequate filling of 
the heart during diastole (Szentesi et al 2004). Phospholamban negatively regulates 
SERCA2 by binding to it and reducing its ATPase activity, effectively inhibiting its Ca
2+ 
pumping action (MacLennan & Kranias 2003). PKA phosphorylation of phospholamban on 
Serine 16 leads to dissociation of the protein from SERCA2, and relieves this inhibitory 
effect. Thus, β-adrenergic stimulation enhances cardiac relaxation, allowing for more 
rapid filling and enhanced cardiac output (Lygren et al 2007).  
 
By scaffolding PKA, PDEs and protein phosphatases within the same complex, very fine 
regulation of local cAMP levels can be achieved via the actions of multiple feedback loops 
and the integration of multiple signaling pathways. New binding partners which 
participate in these complexes are constantly being discovered, which is helping us to 
understand how cAMP signals are compartmentalised within cardiac myocytes. 
 
1.6.5 Abnormal cAMP signaling is associated with cardiac 
pathophysiology 
Extraordinarily tight regulation of cAMP can be attained by cardiac myocytes, with cAMP 
signals being integrated with those from calcium and MAP kinases, and disruption of any 
of these signaling elements may lead to cardiac disease.  
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AC5 activity in the heart has been associated with pathological remodelling. AC5 knockout 
mice are resistant to cardiac stress, show protection against cardiac hypertrophy, 
apoptosis, and fibrosis, and have an increased median lifespan of around 30% (Yan et al 
2007). Disruption of endogenous AC-mAKAP complexes by overexpressing the mAKAP AC-
binding domain increased cellular cAMP and led to a hypertrophic phenotype in cardiac 
myocytes (Kapiloff et al 2009). Inhibition of AC binding to the AKAP would prevent its 
phosphorylation by PKA, and decrease its proximity to mAKAP-anchored PDE4D3, thus 
favouring cAMP production.  Therefore, regulation of AC5 activity through its association 
with the mAKAP macromolecular complex appears to be important in hypertrophic 
signaling. 
 
Levels of PDE4D3 associated with the ryanodine receptor complex have also been linked 
with the development of cardiac disease. PDE4D knockout mice are associated with 
development of progressive cardiomyopathy and cardiac arrhythmias (Lehnart et al 
2005). PDE4D3 levels were found to be decreased in the RyR2 complex of failing human 
hearts, and it has been proposed that this leads to hyperphosphorylation of the channel 
by PKA, and a ‘leaky channel’ phenotype associated with cardiac dysfunction and 
increased risk of arrhythmias (Lehnart et al 2005). However, it should be noted again that 
some studies have disputed these findings (discussed further in Section 1.6.4.1.). Thus 
mAKAP-associated defects could result in hypertrophy, while RyR-associated 
hyperphosphorylation is associated with heart failure and arrhythmias in some studies.  
 
Interfering with the tight control of cAMP signaling co-ordinated by macromolecular 
complexes can lead to severe pathological outcomes, and further studies are clearly 
required to determine the physiological effects of RyR hyperphosphorylation by PKA.  
 
1.6.6 AKAP-Lbc  
The scaffold protein AKAP-Lbc (AKAP13) is expressed at high levels in the heart, where it 
plays a number of important roles. AKAP-Lbc is a product of the Lbc (Lymphoid blast 
crisis) oncogene. This gene was first discovered in 1994 when DNA from a chronic myeloid     Chapter 1  Introduction   
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leukaemia acute phase sample was found to be tumorigenic in nude mice (Toksoz & 
Williams 1994). It is now known that the oncogenic product of the Lbc gene is  in fact a 
truncated form of AKAP-Lbc lacking regulatory domains (Sterpetti et al 1999). Full length 
AKAP-Lbc has a molecular weight of 320kDa, and contains an N terminal EF hand motif 
followed by dbl oncogene homology (DH) and pleckstrin homology (PH) domains (Figure 
1-23). The DH domain is associated with guanine nucleotide exchange activity for small 
GTPases such as Rho, and so AKAP-Lbc functions as a guanine nucleotide exchange factor 
(GEF) for Rho. In addition to PKA, AKAP-Lbc also scaffolds isoforms of PKC and PKD 
(Carnegie et al 2004). AKAP-Lbc has, therefore, been implicated in the control of a myriad 
of cellular processes, including transcriptional regulation, cell cycle progression and 
cytoskeletal reorganisation (Cerione & Zheng 1996, Welch et al 2010). The PKA anchoring 
domain of AKAP-Lbc contains the Ht31 peptide sequence, which has been extensively 
used to characterise PKA-AKAP interactions (Carr et al 1992). Synthetic peptides based on 
this sequence, which represents the region required for PKA-RII binding, are used in 
assays to block interactions of suspected AKAPs with RII, and downstream effects on the 




Figure 1-23  Domain structure and kinase anchoring sites of AKAP-Lbc.  
AKAP-Lbc contains tandem DH and PH domains. The DH domain has intrinsic Rho-GEF activity 
for the small GTPase Rho. Activation of Rho GTPase is associated with cell cycle progression, 
gene transcription and cytoskeletal organisation (Cerione & Zheng 1996).  The PH domain 
anchors PKCη isoforms, and PKD is anchored at the C terminus of the protein. The C1 domain is 
homologous to the N terminal of PKC, and binds diacylglycerol (Azzi et al 1992). PKA RII is 
anchored by an N terminal region of AKAP-Lbc containing the Ht31 peptide sequence (Asp
493-
Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys-Ala-Ala-Tyr) (Carr et al 
1992).      Chapter 1  Introduction   
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1.6.6.1. AKAP-Lbc and cardiac hypertrophy 
As a scaffold protein with intrinsic Rho-GEF activity that anchors multiple protein kinases, 
it is unsurprising that AKAP-Lbc has important cardiac effects. AKAP-Lbc is abundant in 
the heart, where it shows predominantly cytosolic localisation (Carnegie et al 2008). 
AKAP-Lbc has been found to assemble an activation complex for anchored PKD in cardiac 
myocytes. PKCη isoforms which are recruited to the anchoring protein phosphorylate 
Serine 744 and Serine 748 within the catalytic domain of PKD, leading to PKD activation. 
PKA then directs phosphorylation of Serine 2737 at the C terminus of PKD to facilitate 
release of the activated kinase from the scaffold protein into the cytoplasm (Carnegie et 
al 2004).  
 
AKAP-Lbc has been implicated in the development of cardiac hypertrophy. Cardiac 
expression of AKAP-Lbc is increased in response to hypertrophic stimuli such as 
phenylephrine, which activates α1-adrenoceptors (Appert-Collin et al 2007, Carnegie et al 
2008). As AKAP-Lbc functions to assemble an activation complex for anchored PKD, 
increased expression of the scaffold protein augments PKD signaling pathways. PKD-
mediated phosphorylation of class II histone deacetylases (HDACs) occurs in the nucleus. 
This promotes nuclear export of HDACs, and results in derepression of the transcription 
factor myocyte enhancer factor 2 (MEF2). MEF2 in turn promotes transcription of 
hypertrophic genes involved in cardiac contraction and cellular metabolism (Figure 1-24). 
This genetic reprogramming of the cardiomyocyte leads to its reversion to a 
developmental phenotype, and is known as the fetal gene response (Carnegie et al 2008, 








Figure 1-24  AKAP-Lbc regulates cardiac hypertrophy via a PKD-HDAC5-MEF2-dependent 
signaling pathway. Adapted from (Carnegie et al 2008).  
Hypertrophic stimuli such as phenylephrine, which activates α1-adrenoceptors, endothelin, and 
phorbol esters, lead to increased expression of AKAP-Lbc. This augments activation of PKD, 
leading to serine phosphorylation and nuclear export of the class II histone deacetylase HDAC5, 
derepression of MEF2 transcription factor in the nucleus and initiation of a fetal gene response.  
Fetal cardiac genes which are expressed include β-myosin heavy chain (β-MHC) and atrial 
natriuretic factor (ANF) which can affect cardiac energy consumption and cardiac output 
(Patrizio et al 2008). 
 
 
The importance of AKAP-Lbc in normal cardiac development is illustrated further by a 
recent study using knockout mice. Cardiomyocytes from AKAP-Lbc null mice exhibited 
deficient sarcomere formation, developing hearts appeared thin-walled with reduced 
trabeculation, and cardiac development arrested at embryonic day 10, suggesting a role 
for AKAP-Lbc in cardiomyocyte differentiation. The condition was lethal around 
embryonic day 13.  Knockout mice were found to have reduced expression of MEF2, 
whereas overexpression of AKAP-Lbc in H9C2 cells augmented MEF2 activity (Mayers et al 
2010).  
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The small GTPase Rho is a long established mediator of cardiac hypertrophy via the α1-
adrenergic signaling pathway (Sah et al 1996). In cardiomyocytes, RhoA promotes the 
activation of protein kinase N and various stress-activated protein kinases which control 
the transcription of hypertrophic genes (Appert-Collin et al 2007). The RhoGEF activity of 
AKAP-Lbc is crucial for α1-adrenergic activation of Rho. Suppression of AKAP-Lbc 
expression with either short hairpin RNA (shRNA) or small interfering RNA (siRNA) to 
specifically knockdown AKAP-Lbc expression in neonatal rat ventricular cardiac myocytes 
significantly reduced phenylephrine-induced cardiac hypertrophy (Appert-Collin et al 
2007, Carnegie et al 2008). When AKAP-Lbc expression was rescued with a mutant 
version lacking Rho-GEF activity, the agonist-induced hypertrophic phenotype was 
restored. However, this effect was blocked when cells were rescued with a truncated 
form of AKAP-Lbc that does not bind PKD1, indicating that scaffolding of PKD by AKAP-Lbc 
is a key factor in mediating this hypertrophic response (Carnegie et al 2008). 
 
1.6.6.2. AKAP-Lbc and cancer signaling 
Aberrant phosphorylation events by protein kinases are known to play a significant role in 
the development of cancers, therefore protein kinase signaling is tightly regulated within 
cells (Smith et al 2011). It has recently been shown that AKAP-Lbc associates with another 
scaffold protein, Kinase Suppressor of Ras-1 (KSR-1), to form the core of a signaling 
network (Smith et al 2010). KSR-1 scaffolds kinase members of the ERK/MAPK family. 
Thus, cAMP signals can be integrated with those of the Ras/Raf/MEK/ERK signaling 
pathway, which couples growth factor signaling to cell proliferation (Kolch 2005). PKA 
anchored to AKAP-Lbc phosphorylates KSR-1 on Ser838, and this phosphorylation event 
appears to be necessary for maximum stimulation of the ERK pathway, as mutation of 
Ser838 to Alanine impaired growth factor-stimulated ERK activation in HEK293 cells 
(Smith et al 2010). AKAP-Lbc also anchors Raf, therefore AKAP-Lbc can enhance ERK 
signaling by anchoring Raf in the vicinity of MEK, and by promoting PKA phosphorylation 
of Ser 838 on KSR-1 (Smith et al 2010).  
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1.7 Heat shock proteins in the heart 
Heat shock proteins (Hsps) are a diverse group of molecular chaperones that are 
upregulated in response to cellular stress. Originally described in Drosophila 
melanogaster as a group of proteins whose expression was increased at elevated 
temperatures (Tissieres et al 1974), Hsps have been extensively characterised, and a 
variety of cellular triggers for their induction have now been identified, such as 
ischaemia/reperfusion (I/R) injury (Qian et al 2009), oxidative stress (Morimoto 1993) and 
glucose deprivation (Sciandra & Subjeck 1983). The chaperone activities of Hsps include 
the prevention of protein misfolding, refolding of denatured proteins, and their targeting 
for proteolytic degradation (Willis & Patterson 2010). Many heat shock proteins are now 
known to play essential protective roles in the cardiovascular system. 
 
Heat shock proteins may be broadly classified according to their molecular weights as 
either high molecular weight or low molecular weight/small heat shock proteins (sHsps). 
 
1.7.1 High molecular weight Hsps 
Two of the most studied high molecular weight heat shock protein families are Hsp90 and 
Hsp70. Hsp90 is the most abundant chaperone in the cytosol, and is induced by cellular 
stress (Pearl & Prodromou 2006). Hsp90 plays a pivotal role in signal transduction, as it is 
essential for maintaining the conformation of many protein kinases and cell receptors 
within signaling networks (Zhao et al 2005). Hsp70 family members are also abundant in 
the cytosol, and can also be induced by stress (Young et al 2004). Like Hsp90, Hsp70 
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1.7.2 Small/low molecular weight Hsps 
The sHsps, which include Hsp20, are less frequently induced by heat stress, and several 
family members, such as Hsp27 and alphaB-crystallin, are known to be abundant in 
cardiac and skeletal muscle, where they increase in response to stress to protect against 
muscle ischaemia (Fan & Kranias 2010, Willis & Patterson 2010). sHsps are a diverse 
group of proteins with different subcellular localisations and tissue distributions (Fan et al 
2005a). To date, 10 sHsp isoforms have been identified (Table 1-6), and these are formally 
classified as HspB1-B10 (Kappe et al 2003). sHsps range in size from 12 to 43 kDa, and are 
characterised by a stretch of amino acids in their C termini known as an alpha-crystallin 
domain, which facilitates their chaperone activities (Kappe et al 2003).  
 
 





HspB1  Hsp27  +  Ubiquitous 
 
HspB2  MKBP  -  Cardiac 
 
HspB3  HspL27  -  Cardiac 
 
HspB4  CRYAA  -  Eye 
 
HspB5  CRYAB  +  Ubiquitous 
 
HspB6  Hsp20  -  Ubiquitous 
 
HspB7  cvHsp  ?  Cardiac 
 
HspB8  Hsp22  +  Ubiquitous 
 
HspB9  None  ?  Testis 
 
HspB10  ODF1  ?  Testis 
 
 
Table 1-6  An overview of small heat shock proteins. 
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1.7.3 Hsp20  
1.7.3.1 Structure of Hsp20 
Hsp20, also known as HspB6, is expressed at high levels in cardiac, skeletal and vascular 
smooth muscle, where it represents up to 1% of total protein (Dreiza et al 2010, Fan et al 
2005a).  In addition to the alpha-crystallin domain common to sHsps, Hsp20 also 
possesses an N terminal domain which is involved in inhibiting platelet aggregation, and a 
region similar to the inhibitory region of troponin I, which is thought to be involved in 
actin binding (Figure 1-25) (Fan & Kranias 2010). Hsp20 has long been a focus of interest 
in the field of cardiovascular research, as it is the only sHsp to contain a cAMP/cGMP-
dependent protein kinase (PKA/PKG) consensus phosphorylation sequence, R
13-R-A-S
16- 
within its N terminus (Beall et al 1999, Fan et al 2005a). Thus, Hsp20 may be regulated by 
the β-adrenergic/cAMP/PKA signaling pathway, which is known to be chronically 
activated in heart failure.  
 
 
Figure 1-25  The domain structure of Hsp20.  
Hsp20 is a 160 amino acid protein. A 9 amino acid motif (W
11LRRASAPL
19) at its N terminus has 
been shown to inhibit platelet aggregation (Fan & Kranias 2010). This region encompasses a 
PKA/PKG consensus phosphorylation sequence, RRAS
16, which allows the function of the 
protein to be regulated by cAMP levels via the β-adrenergic signaling pathway. The C terminal 
alpha-crystallin domain is common to all sHsps, and aids in their chaperone activities (Qian et al 
2009). In Hsp20, this domain also encompasses a region similar to the inhibitory region of 
troponin I (GFVAREFHRRYRL), shown here in green, which may facilitate its interaction with 
actin (Fan & Kranias 2010). PKG phosphorylation of Hsp20, in response to nitric oxide 
stimulation of guanylyl cyclases, and generation of cyclic GMP, has been shown to modulate 
smooth muscle relaxation, (Beall et al 1999, Flynn et al 2003, Rembold et al 2000).  
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1.7.3.2. Cardioprotective actions of Hsp20   
Heart failure, resulting from ischaemic heart disease and cardiomyopathy, presents an 
increasing medical and financial burden. Strategies which selectively modulate 
components of the β-adrenergic signaling pathway have long been of interest in the 
search for more effective treatments for heart failure (Mudd & Kass 2008). Hsp20 has 
been well studied in the cardiovascular system, due to the unique ability of this 
chaperone to be phosphorylated by PKA. Hsp20 is phosphorylated by PKA in response to 
β-adrenergic stimulation in ischaemic mice hearts (Qian et al 2009). Levels of PKA-
phosphorylated Hsp20 are also increased in failing human hearts compared with donor 
hearts (Qian et al 2009). It is now established that Hsp20 has a range of cardioprotective 
functions, which are described below, and it is of considerable interest as a potential 
therapeutic target in cardiac disease. 
 
Ischaemia/reperfusion injury   
One of the commonest causes of heart failure is myocardial ischaemia, with subsequent 
progression to infarction. Ischaemia, resulting from restriction of coronary blood flow, 
leads to a characteristic sequence of pathological changes, which manifest clinically as 
ventricular dysfunction and cardiac failure (Buja 2005). Even transient ischaemia can lead 
to myocardial necrosis and apoptosis. Coronary reperfusion is the major therapeutic 
strategy employed to reduce morbidity and mortality following myocardial ischaemia to 
prevent progression to infarction, though it is now recognized that reperfusion itself may 
have deleterious effects. Improved tissue oxygenation after reperfusion allows 
resumption of ATP generation, but damage to the electron transport chain leads to the 
generation of oxidative stress by the mitochondria, in the form of reactive oxygen species 
(ROS), which result in myocardial necrosis and apoptosis (Buja 2005, Murphy & 
Steenburgen 2008). This phenomenon is known as ischaemia/reperfusion (I/R) injury.  
 
It is now established that Hsp20 plays a major role in protecting against I/R injury in the 
heart. Major evidence in support of this role has come from the use of transgenic (TG) 
mouse models. TG mouse lines with cardiac-specific overexpression of Hsp20 display a 6-
fold reduction in infarct size and improved functional recovery of contractile performance     Chapter 1  Introduction   
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during the reperfusion period compared with wildtype hearts (Fan et al 2005b) (Figure 1-
26). When subjected to in vivo ischaemia/reperfusion, via coronary artery ligation, TG 
hearts also showed a significantly lower infarct region-to-risk ratio and total LDH levels 
released from TG hearts were half that of wildtype, indicating reduced necrotic damage 
(Fan et al 2005b). Many of the cardioprotective effects of Hsp20 are known to depend on 
PKA phosphorylation of Ser16 at the N-terminal of Hsp20 (Fan et al 2004a). Levels of 
phospho-Ser16 Hsp20 were significantly increased in TG hearts following I/R (Fan et al 
2005b). Moreover, in an Hsp20 mouse model overexpressing phospho-null Hsp20 (Ser16 
substituted for Alanine), TG hearts demonstrated complete reversal of the 
cardioprotective phenotype observed with overexpression of wildtype Hsp20. The 
phospho-null animals exhibited reduced recovery of contractile function post-I/R, and 
increased necrotic and apoptotic damage (Qian et al 2009). The differences in response 
observed between animals expressing wildtype or phospho-null Hsp20 may be due to 
differential activation of autophagy pathways. Autophagy is a physiological catabolic 
pathway by which the cell degrades and recycles damaged organelles and is upregulated 
under conditions of myocardial stress including ischaemia/reperfusion and cardiac failure 
(Gustaffson & Gottlieb 2009). Autophagy was activated in wildtype hearts, but inhibited 
in S16A hearts post-I/R.  Pretreatment of S16A hearts with an activator of autophagy 
(rapamycin, which inhibits mTOR) improved their functional recovery (Qian et al 2009). 
These results suggest that the increased susceptibility of TG hearts overexpressing the 
phospho-null Hsp20 may therefore be linked to an inability to activate autophagy. The 
role of Hsp20 in ischaemia has been further cemented by the observation that Hsp20 
expression levels may be altered by micro-RNA in ischaemic hearts. Micro-RNAs are small 
non-coding RNAs, which regulate gene expression at the post-transcriptional level, via 
RNA destruction or the formation of silencing complexes. Hsp20 expression is regulated 
by the micro-RNA miR-320, which targets the 3’UTR of Hsp20, acting as a negative 
regulator of translation. miR-320 is upregulated in ischaemic hearts (Ren et al 2009), thus 
raising the possibility that manipulation of miR-320 levels may provide a therapeutic 
strategy for limiting I/R injury.  
 





Figure 1-26 Overexpression of Hsp20 protects against ischaemia/reperfusion injury in the heart. 
Adapted from (Fan et al 2005b).  
Transgenic (TG) overexpression of Hsp20 significantly reduced in vivo infarct size after 30 
minutes of myocardial ischaemia compared with wildtype (WT) animals. Ischaemia was 
produced via occlusion of the left anterior descending coronary artery (LAD). Infarcted tissue 




Apoptosis (programmed cell death) can occur under both physiological and pathological 
conditions, including I/R. Apoptosis is characterised biochemically by the activation of a 
cascade of cysteine proteases (caspases) and damage to the mitochondria with 
subsequent release of cytochrome c, and morphologically by double stranded DNA 
fragmentation and cell shrinkage (Buja 2005).  Apoptosis can be triggered in 
cardiomyocytes following chronic -adrenergic stimulation and it has recently been 
shown that Hsp20 can counter this effect by physically interacting with key pro-apoptotic 
signaling proteins (Fan et al 2005b). Overexpression of wildtype Hsp20 protects cultured 
rat cardiac myocytes from -agonist-induced apoptosis, as determined by a reduction in 
the number of pyknotic nuclei, TUNEL (terminal deoxynucleotidyltransferase-mediated 
dUTP nick-end labeling) assay, reduction in caspase-3 activity and DNA laddering (Fan et 
al 2004a). Moreover, a phospho-mimic mutant of Hsp20 (Ser16 to Asp substitution) 
expressed in isolated adult cardiac myocytes conferred full protection from apoptosis 
whereas the phospho-null mutant (Ser16 to Ala) did not. These results highlight the 
importance of Ser16 phosphorylation in switching Hsp20 to a more cardioprotective 
state. Consistent with the importance of Ser16 phosphorylation in cardioprotection, a 
single nucleotide polymorphism (C59T) has recently been identified in Hsp20 that results     Chapter 1  Introduction   
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in a Proline to Leucine substitution at position 20, just downstream of the PKA consensus 
phosphorylation site. This P20L variant of Hsp20 is associated with reduced Ser16 
phosphorylation, and attenuation of anti-apoptotic effects (Nicolaou et al 2008). The anti-
apoptotic effects of Hsp20 are thought to be mediated by its interaction with the pro-
apoptotic protein Bax (Fan et al 2005b). This association prevents Bax translocation from 
the cytosol to the mitochondria during I/R, where it could damage mitochondrial integrity 
by releasing cytochrome c, with subsequent activation of caspase-3. Consistent with 
Hsp20 physically preventing translocation of Bax, caspase-3 activity was repressed 
following I/R injury in TG hearts overexpressing Hsp20. Post-I/R infarct size was also 
greatly reduced in TG hearts, as was apoptotic cell death, as measured by DNA 
fragmentation (Fan et al 2005b). Other Hsps, such as the mitochondrial protein Hsp60 
and -crystallins, have also been shown to form complexes with Bax (Kirchhoff et al 2002, 
Mao et al 2004). Thus, Hsps may critically regulate the Bax-caspase pathway to protect 
against I/R-induced cardiomyocyte apoptosis.  
 
Cardiac hypertrophy 
Cardiac hypertrophy may be a physiological response, induced by exercise, or a 
pathological response, usually to pressure/volume overload from hypertension or 
valvular heart disease (Willis & Patterson 2010). In both cases, there is an increase in 
cardiomyocyte size. In physiological hypertrophy, for example, in the case of elite 
athletes, this leads to an improvement in cardiac function, however pathological 
hypertrophy eventually leads to cardiac failure, via mechanisms that are still not 
completely understood. Expression levels of a number of cardiac chaperones, including 
the sHsps Hsp20 and Hsp22, and the high molecular weight Hsp70 family, have been 
shown to increase in response to hypertrophic stimuli such as aortic constriction and 
chronic β-adrenergic stimulation. Hsp20 expression is increased in response to 
hypertrophic stimuli, such as chronic β-adrenergic stimulation (Fan et al 2004b, Qian et al 
2009). TG mice with cardiac-specific overexpression of Hsp20 and subject to chronic β-
adrenergic stimulation with the synthetic agonist isoproterenol, are protected from the 
increases in heart weight/body weight ratio and cardiomyocyte size that are the 
hallmarks of cardiac hypertrophy (Fan et al 2006). In addition, TG hearts show reduced 
induction of the fetal gene response that accompanies hypertrophy. These effects have     Chapter 1  Introduction   
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been linked to suppression of ASK-1 (apoptosis signal-regulating kinase 1) signaling, with 
reduced activation of the downstream JNK(c-Jun N terminal kinase)/p38 signaling 
pathway (Fan et al 2006). 
 
The importance of phosphorylation of Hsp20 at Serine 16 in protection against cardiac 
hypertrophy has recently been highlighted by a study from our laboratory, investigating a 
unique role for cAMP-specific phosphodiesterases (PDEs). Members of the PDE4 family 
were shown to form a complex with Hsp20, which maintains it in a dephosphorylated 
state until chronic β-adrenergic stimulation and a consequent sustained rise in cAMP 
saturates the PDE, allowing phosphorylation of Hsp20 (Sin et al 2011). Using peptide array 
technology and in vitro binding assays, the docking site for Hsp20 on PDE4 was mapped 
to the conserved catalytic region of the PDE. This sequence information was then used to 
design a cell-permeable disruptor peptide which specifically inhibited the interaction 
between Hsp20 and PDE4. Treatment of neonatal rat cardiomyocytes with this peptide 
disruptor led to highly phosphorylated endogenous Hsp20, and attenuation of β-agonist-
induced hypertrophy, as determined by a reduction in cardiomyocyte size and 
measurement of fetal gene expression (Sin et al 2011). This study provides further direct 
evidence that alteration of the phosphorylation status of Hsp20, and not just the 
expression level of the protein, is required for its full cardioprotective effects. 
 
Myofilament effects 
Under basal conditions, Hsp20 is found predominantly in the cytoplasm  (Fan et al 2004a); 
however, under ischaemic stress, Hsp20 translocates to the myofilaments in adult rat 
heart and skeletal muscle (Golenhofen et al 2004). Similarly, following isoproterenol 
stimulation of isolated adult rat cardiomyocytes, Hsp20 has been observed to redistribute 
to the myofilaments, where it co-localises with actin (Fan et al 2004a). Myofilament 
regulatory and cytoskeletal proteins are lost or degraded in hearts subjected to I/R, and 
this is an important part of the pathogenesis of ischaemic injury to the myocardium (Van 
Eyk et al 1998). Transgenic hearts overexpressing Hsp20 displayed less damage to the 
myofilaments post-I/R, suggesting that Hsp20 functions to maintain muscle integrity 
during I/R (Fan et al 2005b). Thus, following ischaemic stress, Hsp20 may translocate to     Chapter 1  Introduction   
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the myofilaments to protect them from further damage. Hsp20 is widely recognised as an 
actin binding protein (Brophy et al 1999a, Brophy et al 1999b) and it may act to stabilise 
the cytoskeleton under conditions of stress (Dreiza et al 2005, Fan et al 2004a) or 
sequester damaged intracellular proteins to the cytoskeleton (Verschuure et al 2002). 
This protection of the cytoskeleton is also linked to the phosphorylation status of Hsp20, 
as the interaction between Hsp20 with actin is augmented following phosphorylation of 
the heat shock protein (Brophy et al 1999b, Fan et al 2005b, Fan et al 2004b).  
 
Vascular smooth muscle effects 
As well as being highly expressed in the heart, Hsp20 is also constitutively expressed in 
vascular, airway, uterine smooth muscle and skeletal muscle (Dreiza et al). Activation of 
cyclic nucleotide signaling pathways leads to the vasorelaxation of most types of smooth 
muscle. An 11 amino acid region of Hsp20’s highly conserved α-crystallin domain shares 
significant sequence homology with part of the inhibitory region of the thin filament 
protein TnI (Rembold 2007). TnI interacts closely with actin and associated thin filament 
proteins to regulate crossbridge formation and force generation in response to 
fluctuations in intracellular calcium levels (Engel et al 2004). Hsp20 has also been shown 
to interact directly with the actin cytoskeleton (Tessier et al 2003) and this interaction is 
increased by Ser16 phosphorylation (Rembold et al 2000) Thus, like TnI, phosphorylated 
Hsp20 may interact with actin to modulate smooth muscle relaxation. Phospho-Hsp20 
has been linked with the relaxation of saphenous vein (McLemore et al 2005, Tessier et al 
2004), relaxation of cultured vascular smooth muscle cells (Brophy et al 2002), and 
vasorelaxation of porcine coronary artery  (Tessier et al 2004). 
 
Platelet aggregation  
Platelets become tethered to the extracellular matrix at sites of vascular injury via 
glycoprotein receptor complexes expressed on their surfaces to stop excessive 
haemorrhage after vascular trauma (Davi & Patrono 2007). The local release of 
inflammatory mediators, such as thromboxane-A2, serves to amplify this response, 
leading to the formation of a platelet plug. Fibrinogen and von Willebrand factor form     Chapter 1  Introduction   
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inter-platelet bridges, further stabilising the growing thrombus to achieve haemostasis 
(Davi & Patrono 2007). During atherosclerotic plaque rupture, the platelet response, with 
subsequent formation of arterial thrombus, and luminal occlusion, may lead to the 
development of acute coronary syndrome (ACS) (Choi & Mintz 2010), a spectrum of 
unstable coronary artery diseases ranging from unstable angina to myocardial infarction. 
Anti-platelet agents form a major part of the treatment of ACS, and are well recognised as 
reducing cardiovascular morbidity and mortality (Sakhuja et al 2010). Hsp20 possesses 
potent anti-platelet activity and has been shown to inhibit thrombin-induced platelet 
aggregation in a dose-dependent manner, and to specifically bind human platelets, with a 
kD of 310nM (Niwa et al 2000). Recombinant Hsp20 linked to the TAT protein 
transduction domain also inhibited collagen-induced platelet aggregation in human 
citrated whole blood in a dose-dependent manner (McLemore et al 2004). Furthermore, 
levels of Hsp20 were found to be markedly lower in an in vivo hamster model of carotid 
artery endothelial injury, suggesting that it may be secreted from the vascular wall 
immediately after endothelial injury, to act as a regulator of platelet function in the 
circulation (Kozawa et al 2002). The mechanism behind the anti-platelet activity of Hsp20 
is not fully understood but is partially due to inhibition of thrombin-induced calcium influx 
in platelets (Niwa et al 2000) and reduced phosphoinositide hydrolysis by phospholipase 
C (Kozawa et al 2002). Other sHsps may have effects on platelet aggregation, as synthetic 
peptides isolated from both Hsp20 and alphaB-crystallin have potent anti-platelet effects 
in vitro (Matsuno et al 2003). Thus, modulation of local levels of sHsps such as Hsp20 may 
provide a new therapeutic strategy in acute coronary syndromes.   
 
 





cAMP signaling to PKA is tightly regulated in space and time, both by the physical 
compartmentalisation of PKA by AKAPs, and by the creation of localised cAMP gradients 
by phosphodiesterase enzymes. PKA phosphorylation of cardiac proteins is critical to 
many essential cardiac processes, such as excitation-contraction coupling and 
cardioprotection. Two such proteins are the myofilament protein troponin I (TnI), and the 
cytosolic small heat shock protein Hsp20.  
 
cAMP-dependent PKA phosphorylation of TnI on Ser22/Ser23 enhances the efficiency of 
cardiac contraction in response to physiological stress. To date, little is known about the 
PDEs and AKAPs which regulate cAMP/PKA signaling at the myofilament. The aims of this 
study were: 
 
   to discover which PDE isoforms regulate cAMP levels at the myofilament, and 
thereby influence PKA activation, and phosphorylation of TnI 




Hsp20 protects against a number of pathological cardiac processes, including cardiac 
hypertrophy and apoptosis.  Following β-adrenergic stimulation, Hsp20 is phosphorylated 
on Ser16 by PKA, and its cardioprotective abilities are enhanced by this phosphorylation 
event. Selective targeting of signaling elements that can enhance this modification could        
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represent a new therapeutic avenue for the prevention and treatment of myocardial 
remodelling and ischaemic injury. Recent work from our laboratory implicates members 
of the PDE4 family in regulating local cAMP levels around Hsp20 via a direct interaction 
between Hsp20 and the catalytic domain of the PDE (Sin et al 2011); however, no AKAP 
has been identified to scaffold the pool of PKA that phosphorylates Hsp20.  
 









All materials and chemicals were from Sigma-Aldrich (Gillingham, Dorset, UK), unless 
otherwise stated. 
 
3.2 General Molecular Biology Procedures 
3.2.1 Transformation of Chemically Competent Cells 
Chemically competent TOP10 cells (Invitrogen) were stored at -80°C and thawed on ice 
for 10 minutes immediately prior to use. 10ng of plasmid DNA was added per 50µl aliquot 
of competent cells on ice, and mixed gently. Tubes were incubated for 15 minutes on ice, 
heat shocked for 30 seconds at 42°C, and returned to ice for a further 2 minutes. 450µl of 
pre-warmed SOC media (Invitrogen) was added to the cells, and tubes incubated at 37°C 
for 1 hour in a shaking incubator. Agar plates were prepared by autoclaving LB broth (1% 
(w/v) tryptone, 0.5% (w/v) yeast extract, 170mM NaCl), cooling the mixture to handling 
temperature, then adding the appropriate antibiotic for the plasmid antibiotic resistance 
gene, before pouring into 90mm Petri dishes to set. 50-200µl of the transformation mix 
was spread onto pre-warmed agar plates and plates incubated upside down overnight at 
37°C. Colony growth indicated successful transformation of cells. Unused agar plates 
were stored sealed at 4°C for up to one month.      Chapter 3  Materials and Methods       
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3.2.2 Preparation of Plasmid DNA 
Single colonies were picked from agar plates using a sterile pipette tip, and grown 
overnight in 5ml of LB containing the appropriate antibiotic at 37°C in an orbital shaker 
set at 220rpm. 0.8ml of culture was removed for preparation of glycerol stocks (Section 
3.2.3). The remaining culture was saved for plasmid isolation using a QIAprep Spin 
Miniprep Kit (Qiagen), following the manufacturer’s protocol for plasmid purification with 
a microcentrifuge. Alternatively, the remaining culture was used to inoculate 250ml of LB 
plus antibiotic in a 1L flask, and incubated overnight at 37°C with shaking. The Qiagen 
Plasmid Maxi Kit was then used to isolate larger amounts of plasmid DNA. Purified 
plasmid DNA was eluted in sterile dH20 and stored at -20°C.  
 
3.2.3 Storage of Plasmid DNA 
0.8ml of overnight culture was added to 0.2ml of autoclaved glycerol in a cryovial. This 
plasmid stock was then snap frozen on dry ice and stored at -80°C. In general, plasmids 
were transformed into DH5α chemically competent cells (Invitrogen), which are suitable 
for long term storage. When plasmid DNA was required from glycerol stocks, the stock 
was scraped with a pipette tip to collect cells, and the tip placed in 5ml of sterile LB 
containing the appropriate antibiotic for plasmid selection. This was then grown 
overnight at 37°C with shaking and either mini-prepped or used to inoculate a larger 
culture for a maxi-prep (Section 3.2.2). 
 
3.2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was employed to separate DNA molecules by size, by moving 
negatively charged DNA through an agarose matrix via the application of an electrical 
charge. The Bio-Rad Sub-Cell GT electrophoresis system was used. A 1% agarose solution 
was prepared by dissolving agarose in 1x TAE buffer (40mM Tris-Cl, 20mM glacial acetic 
acid, 1mM EDTA) by heating in a microwave oven. The solution was cooled to handling 
temperature, and 1:10 000 SYBR Safe DNA gel stain (Invitrogen) added. The solution was 
then poured into a gel mould and allowed to set. DNA samples were prepared for loading 
using a 1:6 dilution of 6x DNA loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF and 40% (w/v) sucrose). 10µl of GeneRuler 100 bp or 1kb ladder     Chapter 3  Materials and Methods       
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(Thermo Scientific) was added to the first lane to enable identification of the size of 
individual DNA fragments. DNA samples were then loaded and subjected to gel 
electrophoresis in a tank submerged in 1x TAE buffer at 100V for approximately 1 hour. 
DNA molecules were visualised under ultraviolet transillumination.  
 
3.2.5 Quantification of DNA concentration 
A NanoDrop 2000 micro-volume spectrophotometer (Thermo Scientific) was used to 
accurately quantify DNA concentration. Absorbance was measured at 260nm, and purity 
estimated using the 260nm:280nm absorbance ratio.  
 
3.2.6 DNA Sequencing 
DNA sequencing was performed by the University of Dundee Sequencing Service, 
http://www.dnaseq.co.uk/  or the University of Washington Biochemistry DNA 
Sequencing Facility, http://dnaseq.bchem.washington.edu/bdsf/. DNA samples were 
supplied as per the web instructions, and sequencing carried out using either standard or 
custom primers. Analysis of DNA sequencing was performed using Geneious software, 
version 5.5.  
 
3.2.7 Generation of Hsp20-V5-His Plasmid 
To produce Hsp20 with a V5 epitope tag, pcDNA3.1-Hsp20-V5-His-TOPO (referred to in 
the text as Hsp20-V5) was generated by amplifying the open reading frame (ORF) of 




pcDNA6.2-Hsp20 was kindly provided by Dr Jon Day. 
   
The reaction mixture for PCR was as shown below (final volume 50µl). Enzyme and PCR 
buffer were from Thermo Scientific:     Chapter 3  Materials and Methods       
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  DNA template  0.2µl (approx. 100ng) 
  Forward and Reverse primers (10mM stocks)  1.5µl of each 
  dNTPs (10mM stock)  2µl 
  10x PCR buffer  5µl 
  Sterile dH20  38.8µl 
  Phusion II enzyme  1µl 
 
The following PCR conditions were used:  
  95°C for 2 minutes 
  95°C for 30 seconds 
  70°C for 60 seconds            for 25 cycles 
  72°C for 60 seconds 
  4°C hold 
 
The PCR product was subjected to electrophoresis on a 1% agarose gel (Section 3.2.4). 
When viewed under ultraviolet transillumination, a product of around 500bp was 
identified in the PCR lane, corresponding to the 483bp Hsp20 ORF. This band was cut out 
and gel purified using a Qiagen Gel Purification Kit, according to the manufacturer’s 
instructions. The purified product was then quantified and TOPO cloned into the 
pcDNA3.1-V5-His-TOPO vector (Invitrogen) by incubating 5ng of purified PCR product with 
1µl of salt solution (Invitrogen) and 1µl of TOPO vector in a total volume of 5µl with 
sterile dH20 at room temperature for 15 minutes. 3µl of this reaction mixture was then 
transformed into chemically competent TOP10 cells (Section 3.2.1).  
 
3.3 Mammalian Cell Culture 
All cell culture was performed in a class II tissue culture hood using an aseptic technique. 
All reagents were filter-sterilised or autoclaved prior to use. 
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3.3.1 HEK293 cells 
3.3.1.1. Cell maintenance 
The HEK293 cell line is derived from transformed human embryonic kidney cells. HEK293 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 1% penicillin (10 000 U/ml)/streptomycin (10mg/ml) and 
2mM L-glutamine. Cells were maintained in an atmosphere of 37°C and 5% CO2, and 
passaged at 70-90% confluence. To passage, the growth media was removed and 2ml of 
1x trypsin-EDTA added per 10cm
2 of growth area. Cells were incubated at 37°C until they 
were seen to detach when viewed under a light microscope. 8ml of growth media was 
then added to inactivate trypsin. Cells were collected by centrifugation at 150g for 3 
minutes, and the cell pellet resuspended in 5-10ml fresh growth medium to remove the 
trypsin, then 1ml of suspended cells and 9ml of complete growth medium was added per 
10cm dish. Cells were then re-incubated at 37°C and 5% CO2 until required. Media was 
changed every 48 hours. 
 
3.3.1.2. Transient transfection of plasmid DNA 
Cells were transfected using TransIT-LT1 transfection reagent (Mirus Bio, Madison, USA). 
Cells were passaged 24 hours before transfection to ensure 40-60% confluence on the 
day of transfection, and maintained as described above (Section 3.3.1.1.). For transfection 
of one 10cm dish, 3µg of plasmid DNA was used. 12µl of Mirus transfection reagent was 
added to 1.5ml of Opti-MEM (Invitrogen), and the solution pipetted briefly to mix, then 
incubated at room temperature for 5 minutes. 3µg of plasmid DNA was then added, the 
solution pipetted once more to mix, and incubated at room temperature for a further 15 
minutes. Meanwhile, the cell media was replaced with 9ml of complete growth medium. 
The transfection solution was then added drop-wise to the dish and swirled to mix. Cells 
were incubated at 37°C and 5% CO2 for 24-48 hours to allow plasmid expression, prior to 
performing experiments. 
 
3.3.1.3. Preparation of whole cell lysates 
Cells were treated as described in the text, the culture medium aspirated and adherent 
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HEPES, 50mM NaCl, 2.5mM EDTA, 50mM NaF, 30mM Na pyrophosphate, 10% glycerol, 
1% Triton X-100, pH 7.5) containing 1x complete EDTA-free protease inhibitor cocktail 
(Roche, Burgess Hill, UK). 500µl of lysis buffer was used for one 10cm dish. Cells were 
incubated with lysis buffer on ice for 5 minutes, then collected using a plastic cell scraper 
and transferred to pre-chilled Eppendorf tubes. Lysates were centrifuged at 4°C and 600g 
for 10 minutes to pellet insoluble material. The supernatant containing cellular proteins 
was retained and subjected to protein assay, or snap frozen and stored at -80°C prior to 
use. 
 
3.3.2 Neonatal Rat Ventricular Cardiac Myocytes 
3.3.2.1. Isolation of Neonatal Rat Cardiac Myocytes 
Neonatal rat ventricular cardiac myocytes (NRVM) are a commonly used cell model to 
study cardiac biochemistry and cell signaling processes, as they are not terminally 
differentiated and can therefore be cultured in vitro.  NRVM were isolated from 1-5 day 
old Sprague-Dawley rats, in accordance with local animal handling protocols. Hearts were 
immediately placed in ice cold ADS buffer (120mM NaCl, 20mM HEPES, 1mM NaH2PO4, 
5mM glucose, 5.4mM KCl, 0.8mM MgSO4, pH 7.4), and dissected on ice to remove non-
ventricular tissue. Ventricles were minced into 1mm
3 pieces and subjected to 4-5 rounds 
of enzymatic digestion at 37°C for 20 minutes, in 0.06% (w/v) pancreatin and 0.03% (w/v) 
type II collagenase (Worthington Biochemical Corporation, Lakewood, NJ) in sterile ADS 
buffer. Digestions were stopped by the addition of FBS. Cells were pelleted at 260g for 5 
minutes, then gently resuspended in plating medium comprising a 4:1 ratio of 
DMEM/Medium 199 (M199) supplemented with 10% horse serum, 5% FBS, 1% penicillin-
streptomycin and 2mM L-glutamine. Cells were pre-plated for 2 hours at 37
°C and 5% CO2 
in sterile tissue culture flasks to allow preferential attachment of cardiac fibroblasts. Non-
adherent cardiomyocytes were then removed, pelleted as before, and resuspended in 
fresh plating medium ready for cell counting. Cardiac myocytes were seeded as described 
in Section 3.3.2.2. and incubated at 37°C and 5% CO2. After 24 hours, the media was 
replaced with maintenance medium comprising DMEM/M199 (4:1) supplemented with 
5% horse serum, 1% penicillin-streptomycin and 2mM L-glutamine. The cardiac myocyte 
population isolated by this method was approximately 95% pure, as confirmed by α-




Figure 3-1 Immunofluorescence staining of enzyme-purified cardiac cells indicates a high 
population of cardiac myocytes. 
α-actinin is a component of the contractile machinery of cardiac myocytes, therefore allows 
differentiation between myocytes and cardiac fibroblasts which could contaminate the culture. 
Left panel:  > 95% pure cardiac myocyte population. Right panel: close-up of a single cardiac 
myocyte demonstrating characteristic α-actinin staining  pattern. Scale bars represent 20µM. 
 
 
3.3.2.2. Cell seeding 
For immunocytochemistry and FRET experiments, sterile glass coverslips were coated 
with 1µg/cm
2 mouse laminin (BD Biosciences, Oxford, UK), rinsed with sterile dH20, air-
dried and stored in 6 well plates at 4°C. Prior to use, plates were warmed at 37°C. 700 000 
cells were added per well in a final volume of 3ml media. For all other experiments, 
NRVM were grown in sterile tissue culture dishes or plates coated with 1% (w/v) bovine 
gelatin. 
 
3.3.2.3. Transient transfection of plasmid DNA 
NRVM were transiently transfected in 6 well plates with plasmid DNA using TransFectin 
lipid reagent (Bio-Rad). 3µg of plasmid DNA was used per well. DNA was added to 250µl 
of M199 medium. 9µl of TransFectin reagent was added to a further 250µl of M199. 
Tubes were incubated separately for 5 minutes at room temperature before combining 
and incubating for a further 20 minutes at room temperature. Meanwhile, the cell growth 
medium was replaced with 2.5ml of fresh maintenance medium per well. The 
transfection solution was then added drop-wise, and plates incubated at 37°C and 5% CO2
 
overnight. Media was replaced with 3ml of fresh maintenance media after 24 hours, and     Chapter 3  Materials and Methods       
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cells were used for experiments 24-48 hours after transfection, to allow expression of 
plasmid DNA.  
 
3.3.2.4. Preparation of NRVM cellular lysates 
Cells were treated as described in the text and Table 3-1, the culture medium aspirated 
and adherent cells rinsed twice in ice cold PBS. Cells were harvested in ice cold RIPA lysis 
buffer (50mM Tris, 150mM NaCl, 5mM EDTA, 50mM NaF, 12mM Na deoxycholate, 1% 
NP40, 0.1% SDS, pH7.4) containing 1x complete EDTA-free protease inhibitor cocktail 
(Roche). 150µl of lysis buffer was used per well of a 6 well plate. Cells were incubated 
with lysis buffer on ice for 5 minutes, then collected using a plastic cell scraper and 
transferred to pre-chilled Eppendorf tubes. Lysates were passed twice through a 26 gauge 
needle, and centrifuged at 4°C and 600g for 10 minutes to pellet insoluble material. The 
supernatant containing cellular proteins was retained and subjected to protein assay, or 
snap frozen and stored at -80°C prior to use. 
 
 
Compound  Mode of action  Final 
concentration 
EHNA  PDE2 inhibitor 
 
10µM 
Cilostamide  PDE3 inhibitor 
 
10µM 
Rolipram  PDE4 inhibitor 
 
10µM 
Zaprinast  PDE5 inhibitor 
 
10µM 
Dipyridamole  PDE8 inhibitor 
 
100µM 
IBMX  Non-specific PDE inhibitor  
 
100µM 








(see text for 
details) 
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3.3.3 Human Cardiac Myocytes 
Human cardiac myocytes (HCM) (ScienCell Research Laboratories, Carlsbad, CA) are 
isolated from human ventricles.  Cells were preserved at -80°C, and thawed at 37°C 
immediately prior to use. HCM were cultured in Human Cardiac Myocyte medium 
supplemented with 5% FBS, 1% penicillin-streptomycin and 1% Cardiac Myocyte Growth 
Supplement (all from ScienCell), and maintained in an atmosphere of 37°C and 5% CO2. 
Cells were plated onto 10cm tissue culture dishes which had been pre-coated with 
3µg/cm
2 of poly-L-lysine, rinsed twice with sterile dH20, and air-dried. HCM cannot be 
passaged often as they terminally differentiate in culture, and the cardiac fibroblast 
population takes over the culture, so they are only used up to passage 6. To passage 
HCM, 2ml of 1x trypsin-EDTA solution was added per 10cm dish, once the cells had 
reached greater than 90% confluence, and cells incubated for a short time at room 
temperature, until they were seen to round up under a light microscope. 8ml of complete 
growth medium was then added to neutralise the trypsin, and cells centrifuged at 160g 
for 3 minutes, before gently resuspending in 10ml complete growth medium. HCM were 
then counted and plated out at a density of 5000 cells/cm
2, as per the manufacturer’s 
instructions.  
 
3.4 General Biochemical Techniques 
3.4.1 Protein Assay 
The concentration of protein in cell lysates, and of purified recombinant proteins, was 
determined using the Bradford method (Bradford 1976). Protein assays were performed 
in clear 96 well plates. All samples were prepared in a final volume of 50μl sterile dH20, 
and were tested in triplicate. A standard curve of known BSA concentrations between 0 
and 5 μg was prepared. Each protein sample of unknown concentration was then diluted 
1:50 – 1:200 in sterile dH20. Bradford reagent (Bio-Rad) was diluted 1:5 in sterile dH20, 
and 200μl of diluted reagent added per well. Samples and standards were analysed with a 
595nm filter on an Anthos 2010 plate reader using ADAP software. Protein concentrations 
were calculated using a curve derived from the BSA standard values, and adjusted for 




Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins by molecular weight. Proteins were separated using the Invitrogen 
NuPage Novex gel system. Protein samples were denatured and reduced for gel 
electrophoresis by diluting in 5x Laemmli protein sample buffer (Bio-Rad) and boiling for 5 
minutes, then 1-100µg of protein per well was loaded directly onto 4-12% Bis-Tris NuPage 
gels. Gels were immersed in NuPage MES (for <50kDa proteins) or MOPS (for >50kDa 
proteins) running buffer. 3µl of Bio-Rad Precision Plus Dual Colour Protein Standard was 
added to the first well of each gel. This is a pre-stained standard protein ladder used to 
aid analysis of the molecular weight of the protein samples. Protein samples were 
subjected to gel electrophoresis at 180V for approximately 1.5 hours, or until protein 
separation was achieved.  
 
3.4.3. Western Immunoblotting 
Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes using the 
Invitrogen XCell II Blot Module and 1x NuPage transfer buffer containing 20% methanol 
(v/v), as per the manufacturer’s instructions. Proteins were transferred either at 30V for 
1.5 hours, or 12V for 16 hours. Efficacy of transfer was assessed by visualisation of the 
pre-stained molecular weight marker on the nitrocellulose membrane. Membranes were 
then incubated for 1 hour at room temperature with constant agitation in 5% (w/v) milk 
solution consisting of Marvel milk powder in 1x TBST (20mM Tris-Cl pH 7.6, 150mM NaCl, 
0.1% Tween 20) to block non-specific antibody binding sites. Primary antibody against the 
protein of interest was added to fresh 1% milk solution at the appropriate dilution (see 
Table 3-2 for details of primary antibodies used), and incubated with the membrane 
overnight at 4°C with constant agitation. The membrane was then washed 3 times for 5 
minutes in 1x TBST, and incubated in fresh 1% milk solution with the appropriate HRP-
conjugated secondary antibody at a dilution of 1:5000 for 1 hour at room temperature, 
with constant agitation (see Table 3-3 for details of secondary antibodies used). The 
membrane was washed 3 times for 5 minutes in TBST, and subjected to analysis using the 
enhanced chemi-luminescence (ECL) method (Amersham BioSciences, Little Chalfont, UK) 
to detect antibody complexes bound to proteins of interest. Membranes were rinsed with 
ECL solution for 1 minute and then exposed to light-sensitive autoradiography film, which     Chapter 3  Materials and Methods       
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was developed on a Kodak X-Omat Model 2000 processor. Images were quantified using 
Image J (NIH, Bethesda, MD) and statistical significance determined as described  in 



























Specificity/Immunogen  Dilution  Supplier  Application 
α-actinin  Mouse 
monoclonal; 
EA-53 
Purified rabbit skeletal 
muscle α-actinin 






Epitope between amino 













derived from mouse TnI 
around phosphorylation site 
(RRSSA) 
1:5000  Abcam  WB 
Hsp20  Rabbit 
polyclonal 
Native Hsp20 purified from 
human skeletal muscle 








derived from human Hsp20 
around S16 phospho site 
(RASAP) 
1:1000  Abcam  WB 
HspB6  Mouse 
monoclonal; 
HSP20-11 
















WB, IP, IF 
Pan-PDE4D  Sheep serum  Conserved C terminal region 




In-house  WB, IP, IF 
PDE4D9  Rabbit 
polyclonal 
Isoform-specific N terminal 
sequence 
1:1000  Millipore  WB, IP, IF 
Pan-PDE4A        Rabbit serum 
 
Conserved C terminal region 
of rat PDE4A isoforms 
1:2000  In-house  WB, IP 
Pan-PDE4B  Sheep serum 
 
Conserved C terminal region 
of PDE4B isoforms  in all 
species 
1:5000  In-house  WB, IP 
GST  Mouse 
monoclonal; 
B-14 
Full length protein  1:1000  Santa Cruz  WB 
Rack1  Mouse 
monoclonal; 
B-3 
Amino acids 131-317 of 
human RACK1 
1:1000  Santa Cruz  WB 
V5  Mouse 
monoclonal; 
R960-25 
V5 epitope tag  1:5000  Invitrogen  WB, IP 
FLAG-M2  Mouse 
monoclonal; 
M2 
FLAG epitope tag  1:1000  Sigma  WB, IP 











Reacts with free and bound 
digoxigenin 
1:4000  Abcam  WB 
PKA RI  Mouse 
monoclonal; 
18/PKA[RI] 
Mouse PKA RI, amino acids 
225-381 
1:1000  BD 
Biosciences 
WB 




Mouse PKA RIIα, amino acids 
1-404; human PKA RIIβ, 
amino acids 1-418 








Human PKA C, amino acids 
18-347 
1:1000  BD 
Biosciences 
WB 
WB, Western immunoblotting; IP, immunoprecipitation; IF, immunofluorescence 





Type  Specificity/Immunogen  Dilution  Supplier; Cat no  Application 
FLAG-HRP  Mouse 
monoclonal; 
M2 
FLAG peptide  1:5000  Sigma  WB 
V5-HRP  Mouse 
monoclonal; 
R961-25 
V5 epitope tag  1:5000  Invitrogen  WB 
Anti-mouse-
HRP 
Sheep  IgG  1:5000  GE Healthcare  WB 
Anti-rabbit-
HRP 
Goat  IgG  1:5000  Sigma  WB 
Anti-goat-
HRP 




Donkey  IgG heavy and light 
(H+L) chains from 
sheep 
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3.4.4 Coomassie Staining 
Coomassie staining was used to visualise some proteins following SDS-PAGE. Pre-cast 
NuPage gels were removed from the plastic cassettes and rinsed in sterile dH20. Gels 
were then incubated in 50ml of Coomassie stain (1.25g Coomassie Brilliant Blue R250, 
444ml methanol, 56ml acetic acid in a final volume of 1L dH20) at room temperature for 2 
hours with gentle agitation. Coomassie stain was then replaced with destain (444ml 
methanol, 56ml acetic acid in a final volume of 1L dH20) and agitated at room 
temperature for 6-12 hours, changing the destain every 4-6 hours, until all residual 
Coomassie stain was removed. Coomassie stain remained bound to all of the proteins 
present in the gel, allowing the identification of overexpressed proteins by comparison to 
the molecular weight markers. 
 
3.4.5 siRNA knockdown of AKAP-Lbc 
AKAP-Lbc knockdown was achieved using a small interfering RNA (siRNA) oligonucleotide 
against the AKAP-Lbc gene (AKAP13). Silencer select validated siRNA (sequence: 
GCAUAUUGCUUGUAACUCA) and control siRNA were obtained from Ambion (Austin, TX). 
Cells were passaged into 6 well plates and transfected at 40% confluence. For one well, 
4µl of DharmaFECT I (Dharmacon - Thermo Scientific) transfection reagent was incubated 
in 200µl of Opti-MEM for 5 minutes at room temperature. 10µl of 20µM siRNA 
(0.2nmoles) was then added using barrier tips, and the tube mixed and incubated at room 
temperature for a further 20 minutes. 200µl was added per well, the growth medium 
changed after 24 hours, and cells harvested at 72 hours. Efficiency of knockdown was 
determined by Western immunoblotting.  
 
3.5 Protein-Protein Interactions 
3.5.1 Co-immunoprecipitation (Co-IP) 
All steps were performed at 4°C. Following cell lysis and determination of protein 
concentration, samples were equilibrated to 1µg/µl in lysis buffer. 20µl of protein A/G 
beads (Santa Cruz Biotechnology, CA, USA) were added per 1ml of lysate in an Eppendorf 
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lysate of any proteins which might non-specifically bind to the beads. Beads were pelleted 
at 16 000g for 1 minute and the pre-cleared supernatant removed to a fresh tube. 100µl 
of supernatant was removed and boiled for 5 minutes in an equal volume of 2x protein 
sample buffer, and stored at -20°C. This represented the IP “input”. The remaining 
supernatant was divided between 2 tubes (450µl per tube), and 20µl of resuspended 
protein A/G beads added to each tube. 1-4µg of antibody to the protein of interest (or its 
epitope tag, if using transfected cells) was added to one tube (the “IP”) and an equal 
amount of isotype-matched non-specific IgG (Cell Signaling Technology, Danvers, MA) 
added to the second tube as a control. Tubes were incubated overnight with rotation, 
then beads were pelleted at 6000g for 30 seconds and the supernatant carefully 
discarded. Beads were washed with 1ml of either HSE buffer (20mM HEPES, 150mM NaCl, 
5mM EDTA) or 3T3 lysis buffer 3 times as above, then finally resuspended in an equal 
volume of 2x protein sample buffer and boiled for 5 minutes. All samples (input, control, 
IP) were separated by SDS-PAGE, and then transferred to nitrocellulose and 
immunoblotted, as described in Section 3.4.3. 
 
3.5.2 Expression and Purification of GST Fusion Proteins 
3.5.2.1. GST-PDE4D9 
pGEX-6P1-PDE4D9 was kindly provided by Dr Allan Dunlop. This plasmid was transformed 
into BL21-CodonPlus competent cells (Stratagene, La Jolla, CA) as described in Section 
3.2.1, and grown overnight at 15°C in 10ml of LB broth containing the appropriate 
antibiotic with orbital shaking at 220rpm. This starter culture was then used to inoculate a 
500ml LB culture containing antibiotic, which was grown at 15°C with shaking for 2-3 
hours. 1ml of this culture was removed at regular intervals, and the optical density at 
600nm (OD600) measured against 1ml of sterile LB using a spectrophotometer. Once 
OD600 reached 0.6-1, bacteria could be assumed to be in a log phase, where they are 
growing exponentially. Expression of the fusion protein was then induced by adding 1mM 
isopropyl β-D-1-thiogalactoside (IPTG), and the culture grown for a further 3 hours and 
pelleted at 4400g for 10 minutes at 4°C. The pellet was resuspended in 10ml of ice cold 
GST lysis buffer (50mM Tris-Cl pH8.0, 100mM NaCl) and frozen overnight at -20°C. Upon 
thawing, 1mM DTT, 1mg/ml lysozyme and 1x protease inhibitor cocktail (Roche) were     Chapter 3  Materials and Methods       
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added, and the suspension sonicated 4 times for 30 seconds on ice to encourage further 
cell lysis, with 1 minute between each sonication. Cell debris was pelleted at 12 000g for 
30 minutes, and the supernatant removed to a fresh tube. 500µl of pre-washed 
glutathione beads (GE Healthcare, Little Chalfont, UK) in a 50% slurry with GST lysis buffer 
were added, and tubes incubated for 2 hours with end-over end rotation at 4°C. Beads 
were then collected in a gravity flow column and washed 3 times with 10ml of GST lysis 
buffer. Following the final wash, the column was capped and 0.5-1ml of GST elution 
buffer (50mM Tris-Cl pH8.0, 10mM reduced glutathione) incubated with the beads for 5 
minutes. The cap was then removed and the eluent collected. This elution step was 
performed 3 times in total. Eluent was dialysed overnight in 2L of GST dialysis buffer 
(50mM Tris-Cl pH8.0, 100mM NaCl, 5% (v/v) glycerol) to remove glutathione. Samples 
were removed at each stage, boiled in 5x protein sample buffer, and analysed by SDS-
PAGE and Coomassie staining as described in Sections 3.4.3 and 3.4.4, to determine 
protein expression.   
 
3.5.2.2. GST-AKAP-Lbc fragments and GST pulldown assay 
pGEX-4T1-AKAP-Lbc fragments 1-6 plasmids were kindly provided by Donelson Smith. 
Plasmids were transformed into BL21(DE3)pLysS cells (Stratagene), as described in 
Section 3.2.1, and grown overnight at 15-37°C in LB media with appropriate antibiotic. 
These starter cultures were then used to inoculate larger cultures, as in Section 3.5.2.1., 
and grown at 15-37°C with shaking for 2-3 hours unti OD600 reached 0.6-1. Fusion 
protein expression was then induced and the culture grown for a further 3 hours and 
pelleted as described in Section 3.5.2.1. Proteins were purified as in Section 3.5.2.1. 500µl 
of pre-washed glutathione beads in 50% slurry with GST lysis buffer were added to 
supernatants containing purified proteins, and tubes were incubated for 2 hours with 
end-over end rotation at 4°C. Beads were then washed 3 times with 15ml of GST binding 
buffer (25mM Tris pH7.4, 150mM NaCl, 1mM EDTA), with 0.5% Triton-X100 added for the 
final wash. Finally, beads were suspended in 500µl of GST binding buffer and used for GST 
pulldown assays. For pulldown assays, 500µl of HEK293 lysate containing overexpressed 
Hsp20-V5 was added per tube, tubes incubated at 4°C for 2 hours with gentle agitation, 
then washed 4 times in chilled HSE buffer containing 0.1% NP-40 at 200g for 5 minutes. 
Beads were then boiled in 4x protein sample buffer, and lysates separated by gel 
electrophoresis.     Chapter 3  Materials and Methods       
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3.5.3 Solid phase peptide array 
Peptide arrays are generated by direct synthesis of peptides onto Whatman cellulose 
membranes. Arrays of overlapping 25mer peptides, sequentially shifted by 5 amino acids, 
are generated, as shown in Figure 3-2. These arrays cover the entire sequence of the 
protein of interest, and are able to bind purified fusion proteins, providing information on 
protein-protein interactions, and the sites critical for these interactions (Bolger et al 2006, 
Frank 2002). Peptide arrays were synthesised in-house, using an AutoSpot-Robot ASS 222 
(Intavis Bioanalyical Instruments, Köhn, Germany). Arrays were stored dry at 4°C prior to 
use. To investigate possible protein-protein interactions, peptide arrays were first 
activated by rinsing for 1 minute in 100% ethanol, then washed in 1x TBST for 10 minutes. 
Non-specific binding was blocked by incubating with 5% milk solution for 2 hours at room 
temperature with gentle agitation. The array was then incubated with 10µg/ml of the 
purified protein of interest in 1% milk solution at 4°C overnight. After 16 hours, the array 
was washed 3 times for 10 minutes in TBST and incubated with primary antibody to the 
purified protein of interest at the appropriate dilution for 2 hours at room temperature. 
After a further 3 washes in TBST, the appropriate HRP-conjugated secondary antibody 
was added for 1 hour at room temperature. Finally, the array was washed 3 times in TBST, 
and exposed to ECL and film (as in Section 3.4.3).  
 
Peptide arrays were stripped in stripping buffer (20mM dithiothreitol, 70mM SDS, 60mM 
Tris-Cl pH6.8) by heating to 70°C for 30 minutes, then rinsed twice in TBST for 10 minutes. 
Arrays were air dried and stored sealed in plastic at 4°C. Arrays were reused a maximum 
of 2 times, and were re-probed with primary and secondary antibody to check stripping 
efficiency prior to use.  
 
For each peptide array experiment with a GST-tagged fusion protein, the array was first 
incubated with GST alone as a control to identify sites which might bind the GST tag 
rather than the protein of interest. Where potential binding sites were identified on film 
as spots, the 25mer amino acid sequence corresponding to the spot was identified and an 
“Alanine Scan” of the region generated by producing a peptide array consisting of the 
wildtype spot, and then each residue sequentially mutated to alanine. If the original 
residue was alanine, it was mutated to aspartate instead. The resulting alanine scan was     Chapter 3  Materials and Methods       
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then probed with the protein of interest as above. If mutation of a residue to alanine 
abolished binding of the fusion protein of interest, this provided evidence for it being 






Figure 3-2 Schematic representation of a peptide array approach. Adapted from Dr George 
Baillie. 
A series of overlapping peptides are generated from the amino acid sequence of the protein of 
interest. Individual amino acids are then precisely spotted onto a cellulose membrane to 
generate each of these overlapping peptides (1,2, 3, etc). The array is then incubated with a 
purified protein that is thought to interact with the protein of interest. Primary antibody 
against the potential interacting protein is then added, followed by HRP-linked secondary 
antibody, and immunoblots are developed using the ECL method described in Section 3.4.3. 
Dark spots on the film indicate potential interaction sites on the protein of interest.  
  




3.6.1 Fluorescence Resonance Energy Transfer  
Fluorescence resonance energy transfer (also known as Förster resonance energy transfer 
or FRET) describes the process of energy transfer between two fluorophores, a donor and 
an acceptor, which are often CFP and YFP. Excitation of the donor by a particular 
wavelength leads to a characteristic emission by the donor. However, if the donor and 
acceptor are in close proximity, and their emission and excitation spectra overlap, 
intermolecular FRET occurs, and the acceptor emission is predominantly detected (Figure 
1-19).  
 
3.6.1.1. FRET Sensors 
FRET sensors can be linked to other proteins. The FRET sensors employed in this study 
were based on the Epac1-camps sensor (Nikolaev et al 2004), which consists of the cAMP-
binding domain of Epac1 sandwiched between CFP and YFP (Figure 3-3). Binding of cAMP 
to Epac results in a conformational change which increases the distance between the two 
fluorophores, reducing the FRET signal. 
 
 
Figure 3-3 Schematic of Epac1-camps FRET sensor. Adapted from (Nikolaev et al 2004). 
Residues E157 to E316 of Epac1, which encompass the cAMP binding domain of the protein, are 
cloned between YFP and CFP fluorophores to produce the intact sensor.  
 
Generation of Hsp20:Epac1-camps FRET sensor 
TnI:Epac1-camps and Hsp20:Epac1-camps targeted FRET sensors were generated by Dr 
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the Ultimate ORF clone IOH57317 (Invitrogen) using the following primers to incorporate 
HindIII restriction sites at both 5′ and 3′ ends:  
 
Forward primer:  5′-GCACAAGCTTATGGAGATCCCTGTGCCTGTGC-3′ 
Reverse primer:  5′-GCACAAGCTTGGCTGCGGCTGGCGGTGG-3′  
 
The resulting fragment was cloned, in frame, into the HindIII site 5′ to the Epac1-based 
sensor. Clones were screened for correct orientation of insert and correct clones were 
sequenced. 
 
Generation of TnI:Epac1-camps FRET sensor 
TnI:Epac1-camps was cloned as above. Primer sequences are detailed below: 
Forward primer:  5′-GCACAAGCTTACCATGGCGGATGGGAGCAGCGATGC-3’ 
Reverse primer:  5′-GCACAAGCTTGCTCTCAAACTTTTTCTTGCG -3′  
 
 3.6.1.2. FRET Imaging 
Neonatal rat ventricular cardiac myocytes were isolated and seeded onto glass coverslips 
at a density of 700 000 cells per coverslip, as described in Sections 3.3.2.1. and 3.3.2.2. 
Targeted FRET sensors were transiently transfected 24 hours after seeding, as described 
in Section 3.3.2.3. The Epac1-camps sensor was used as a control for all experiments. 
Cells were imaged 24-48 hours following transfection. Measurements were obtained 
from cells buffered in a pH7.4 solution of 125mM NaCl, 5mM KCl, 20mM HEPES, 1mM 
Na3PO4, 1mM MgSO4, 1mM CaCl2 and 5.5mM glucose, at room temperature. Cells were 
stimulated in real time with 1nM isoproterenol, 10M rolipram, 10µM cilostamide, 50µM 
forskolin and 100µM IBMX, and imaged on an Olympus IX71 inverted microscope with a 
100x oil immersion objective (Zeiss). The microscope was equipped with a beam splitter 
optical device (Photometrics) which splits emitted light into two beams using a dichroic 
filter. Wavelengths shorter than 505nm, including 480nm CFP emissions, are directed to a 
CFP emission filter, and wavelengths longer than 505nm, including 545nm YFP emission, 
are directed to a YFP emission filter. Therefore, both YFP and CFP images can be 
collected.       Chapter 3  Materials and Methods       
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3.6.1.3. Data Acquisition 
Images were acquired using MetaFluor software (Molecular Devices). First, one 
transfected cell was focused upon under the 100x objective. Only beating cells were 
imaged, to ensure no fibroblasts were included, as these can be difficult to distinguish 
from cardiac myocytes morphologically. Only one cell can be imaged per coverslip, so 
typically an n of 6-10 coverslips was used for one experimental condition. The exposure 
time, during which the sample was illuminated by excitation at 440nm and CFP and YFP 
signals acquired, was set at 200ms. Data was acquired every 10 seconds from a user-
defined region of interest (ROI) within the cell. These conditions resulted in minimal 
photo-bleaching of samples, and allowed selection of specific cell areas from which data 
could be acquired. A background ROI was also selected, to allow subtraction of 
background noise for CFP and YFP data. FRET changes were measured following 
background subtraction by dividing the intensity of emissions at 480nm and 545nm, 
following excitation at 440nm, to give a FRET ratio. Data are expressed as dR/R0, where R 
= FRET ratio at time t (sec), R0 = FRET ratio at time zero, and dR = R – R0. Graphs are 
presented as means +/- SEM. 
 
3.6.2. Immunocytochemical staining of cardiac myocytes 
Cells were fixed on glass coverslips in ice cold paraformaldehyde and methanol solution 
for 5 minutes (0.6:9.4 ratio of 16% paraformaldehyde to 100% methanol), then washed 
twice for 5 minutes in PBS with gentle agitation. Coverslips were protected from light at 
all times from this point. Cells were permeabilised for 20 minutes at room temperature 
with PBST (0.1% Triton-X100 in PBS), then washed for 5 minutes in PBS alone. Non-
specific antibody binding sites were blocked by incubating with blocking buffer (0.2% fish 
gelatin (w/v), 0.3% BSA (w/v) in PBS) for either 30 minutes at room temperature, or 
overnight at 4
°C, then coverslips were washed twice in PBS for 5 minutes. One or two 
primary antibodies were diluted to the desired concentrations in blocking buffer, 100µl of 
the solution applied to parafilm, and coverslips laid face down onto the antibody for 2 
hours at room temperature. For each coverslip treated with primary antibody, an IgG 
control was also prepared, using equal amounts of the appropriate normal IgGs. 
Coverslips were then washed three times for 10 minutes in PBS, and incubated with 1:500 
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500µl per coverslip (Table 3-2). This step took place for either 1 hour at room 
temperature, or overnight at 4
°C. Following secondary antibody incubation, coverslips 
were washed once in PBS and mounted onto glass slides using ProLong Gold antifade 
reagent with DAPI (4’,6-diamidino-2-phenylindole) nuclear stain (Molecular Probes) and 
air dried. Coverslips were stored at 4°C and protected from light. 
 
3.6.3 Confocal Microscopy 
Cells were imaged using a 63x Zeiss oil immersion objective on a Zeiss Pascal LSM510 
laser-scanning confocal microscope (Carl Zeiss, Germany). An argon laser was used to 
excite 488nm fluorescently labelled secondary antibodies. Helium/neon lasers were used 
to excite 568nm fluorescently labelled secondary antibodies. Zeiss Pascal software was 
used to collate image files. 
 
3.7 Cell-based assays 
3.7.1 Phosphodiesterase activity assay 
PDE activity was measured in a two step radioactive assay of cAMP hydrolysis, which has 
previously been described (Marchmont & Houslay 1980). In the first step, samples are 
incubated with 8-[3H]-labelled cAMP substrate, and PDEs in the sample hydrolyse this to 
[3H]-5’-AMP. In the second step, addition of snake venom hydrolyses the 5’AMP to [3H]-
adenosine, and incubation with an anion exchange resin binds any negatively charged, 
unhydrolysed cAMP, separating it from the adenosine. The amount of [3H]-adenosine is 
then calculated by scintillation counting, to determine the rate of cAMP hydrolysis.  
 
All steps were performed at 4°C unless indicated. Samples were measured in triplicate. 
cAMP substrate solution for the assay consisted of 2µl of 1mM cAMP and 3µl of 8-[3H]-
cAMP per ml of PDE assay buffer (20mM Tris-Cl pH 7.4, 10mM MgCl2). Cellular lysates 
were freshly prepared in KHEM buffer (50mM KCl, 50mM HEPES pH7.2, 10mM EGTA, 
1.9mM MgCl2). A volume of lysate containing the required amount of protein was diluted 
in PDE assay buffer to 50µl final volume (this amount was previously determined in a pilot 
assay using increasing amounts of protein). If the effect of a PDE inhibitor was to be     Chapter 3  Materials and Methods       
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assessed, 10mM stock solutions of inhibitors in DMSO were diluted 1:100 in KHEM, and 
10µl of diluted inhibitor solution or KHEM plus the equivalent amount of DMSO alone was 
added to 40µl of protein sample. 50µl of KHEM buffer was used as a blank control. 50µl of 
cAMP substrate solution was added per tube to give a total reaction volume of 100µl, 
tubes were mixed gently and incubated at 30°C for 10 minutes to allow cAMP hydrolysis 
to occur. Samples were then boiled for 2 minutes to inactivate PDEs and terminate the 
reaction.  
 
Tubes were cooled on ice for 15 minutes and 25µl of 1mg/ml snake venom from 
Ophiophagus Hannah added per tube. Tubes were mixed gently and incubated at 30°C for 
10 minutes to allow conversion of AMP to adenosine. 400µl of Dowex anion exchange 
resin:H20:100% ethanol (1:1:1 ratio) was added per tube, tubes were vortexed and 
incubated on ice for 15 minutes to allow binding of negatively charged unhydrolysed 
cAMP to the resin. Tubes were then re-vortexed, and centrifuged for 3 minutes at 16000g 
to pellet the Dowex. 150µl of supernatant was removed from each tube and added to a 
fresh 1.5ml tube containing 1ml of Opti Flow SAFE 1 scintillant. 50µl of cAMP substrate 
solution was also added to 1ml of scintillant, to assess total counts per minute for the 
assay. All tubes were then vortexed thoroughly, and the amount of 8-[3H]-adenosine in 
the supernatant (which is proportional to cAMP hydrolysis) determined by counting on a 
Wallac 1409 Liquid Scintillation Counter. Radioactive waste was handled and disposed of 
according to local protocols. 
 
The specific PDE activity of each sample was corrected for background using the blank 
reaction and calculated in pmol cAMP hydrolysed/min/mg protein as follows:  
PDE activity  = 2.61 x [(average counts of 3 repeats – average of blanks)/average total] 
x 10
-11 x 10
12 x (1000/µg protein) 
Where 2.61 corrects for the use of 150µl of supernatant from the Dowex stage (the total 
volume of the supernatant is 391.5µl), 
x 10
-11  corrects the value for the 10 mins over which hydrolysis occurs and corrects to 
moles of cAMP used, and x 10
12 corrects to pmoles, 
x (1000/µg protein) corrects for protein concentration.     Chapter 3  Materials and Methods       
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3.7.2 Caspase-3 apoptosis assay 
The Caspase-Glo 3/7 assay (Promega) was used to determine caspase-3 activity in cellular 
lysates. This is a luminescence assay, where luminescence is produced by caspase 
cleavage of the provided substrate, and is proportional to caspase-3 activity. All 
experiments were performed in triplicate. Relative luminescence was measured on a 
Mithras LB940 plate reader using 96 well white-walled tissue culture plates (Corning), and 
data collected using MikroWin 2000 software. Caspase-Glo reagent was added to 
untreated cells in media as a negative control. Purified caspase-3 enzyme (BIOMOL) was 
used as a positive control. Luminescence was measured for media and Caspase-Glo 
reagent alone (without cells) to obtain a blank value, and this was subtracted from other 
measurements. 
 
3.8 Statistical analysis 
In this thesis, all experiments were performed an n of 3 times, unless otherwise specified 
in the figure legend. Statistical significance was calculated using either an unpaired two 
tailed t-test in Microsoft Excel or by one way analysis of variance (ANOVA) using Graph 
Pad Prism software, as stated in the figure legend. A P value > 0.05 was considered not 
significant (ns), P < 0.05 was considered significant (*), P < 0.01 was considered very 
significant (**), and P < 0.001 was considered extremely significant (**).    
 
 
4.                                                                            
 
The phosphodiesterase isoform 
PDE4D9 regulates PKA 




Cyclic 3’5’ adenosine monophosphate (cAMP) is a ubiquitous second messenger. Signal 
transduction cascades involving cAMP regulate a vast array of intracellular processes, 
including gene transcription (Delghandi et al 2005), neurotransmission (O'Donnell & 
Zhang 2004), cardiac contractility (Stelzer et al 2007), growth and differentiation (Smith et 
al 2010), and aspects of the immune response (Smith et al 2003). Intracellular levels of 
cAMP depend on the balance between cAMP synthesis by adenylyl cyclase (AC) isoforms 
(Willoughby & Cooper 2007) and cAMP hydrolysis by phosphodiesterase (PDE) enzymes 
(Baillie 2009). Members of the PDE1 (Rybalkin et al 1997) , PDE2 (Stangherlin et al 2011), 
PDE3 (Reinhardt et al 1995), PDE4 (Houslay et al 2007), PDE5 (Giordano et al 2001) and 
PDE8 (Patrucco et al 2010) families are all expressed in the cardiovascular system to some 
extent; however, PDE3 and PDE4 are thought to mediate the majority of cAMP hydrolysis 
in the heart (Houslay et al 2007, Mongillo et al 2004). 
 
Over three decades ago, seminal studies in cardiac myocytes introduced the theory that 
cAMP is compartmentalised within cells (Brunton et al 1981, Buxton & Brunton 1983). 
Since then, a wealth of evidence has accumulated to support the concept of 
compartmentalised cAMP signaling (Baillie & Houslay 2005, Fischmeister et al 2006,     Chapter 4  Results       
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Lissandron & Zaccolo 2006, Zaccolo & Pozzan 2002). Once cAMP is generated by AC5 and 
AC6 isoforms at the plasma membrane of cardiac myocytes, it diffuses rapidly, and could 
potentially flood the cytosol (Hanoune & Defer 2001, Houslay et al 2007). Only three 
cAMP effectors have been identified, including the cyclic AMP-dependent protein kinase, 
PKA (Walsh et al 1968). PKA is found in macromolecular complexes, which may localise to 
the plasma membrane, the internal membranes of organelles, the nucleus, or remain 
soluble in the cytosol (Di Benedetto et al 2008, Kapiloff et al 1999, Perry et al 2002). PKA 
has the potential to phosphorylate a huge number of intracellular targets on the basis of 
its activation by one common second messenger signal from cAMP, and so very tight 
regulation of this process is necessary to maintain specificity within the cAMP/PKA signal 
transduction cascade. In other words, cAMP must specifically target a small group of 
downstream effectors, whilst inappropriate activation of others is prevented. It is now 
accepted that such a high degree of specificity is achieved by the compartmentalisation of 
cAMP effectors and the formation of subcellular cAMP gradients (Houslay 2010). 
 
Phosphodiesterases represent the only means of degrading cAMP within the cell, and are 
integral to the compartmentalisation of cAMP (Conti & Beavo 2007). Targeting of PDE 
hydrolytic activity to specific subcellular locations allows the simultaneous creation of 
multiple localised concentration gradients of cAMP. These cAMP microdomains can then 
activate specific subcellular pools of cAMP effector proteins (Baillie 2009). In this way, 
very fine spatial and temporal control of cAMP signaling can be achieved.   
 
PDEs are now known to be targeted to several of the complexes involved in cardiac β-
adrenergic signaling and excitation-contraction coupling (ECC). The long PDE4 isoform, 
PDE4D3, associates with the cardiac ryanodine receptor and PKA at the sarcoplasmic 
reticulum and nuclear envelope, where it participates in a negative feedback loop. Under 
basal conditions, tonic activity of the PDE maintains local cAMP levels below the 
threshold for PKA activation. Following β-adrenergic stimulation, a rise in cAMP both 
activates PKA and increases PDE activity (Dodge et al 2001) via PKA-mediated 
phosphorylation of PDE4D3 on Ser54 (Sette & Conti 1996). This favours cAMP hydrolysis 
and subsequent inactivation of PKA. Another PDE4 long isoform, PDE4D5, has been 
demonstrated to bind to the signaling scaffold protein β-arrestin via its unique N terminus     Chapter 4  Results       
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(Bolger et al 2006, Perry et al 2002). Recruitment of a β-arrestin-PDE4D5 complex to the 
agonist-occupied β2-adrenergic receptor leads to desensitisation of the receptor by β-
arrestin, lowering cAMP production by ACs. PDE4D5 then serves to hydrolyse cAMP which 
has already been produced in the sub-plasma membrane compartment, further 
downregulating the activity of local PKA (Baillie 2009). 
 
PKA phosphorylation events play a key role in enhancing cardiac contractility. The heart 
responds to physiological stress by altering its rate of contraction (chronotropy), force of 
contraction (inotropy) and rate of relaxation (lusitropy), resulting in an increased cardiac 
output to combat the precipitating stress (Triposkiadis et al 2009). This response is 
triggered by elevated levels of circulating catecholamines, such as adrenaline, which bind 
to β1-adrenergic receptors, leading to cAMP generation and PKA phosphorylation of 
cardiac myofilament proteins and proteins regulating excitation-contraction coupling. 
Phosphorylation of the cardiac myofilament protein troponin I (TnI) has been 
demonstrated to alter both the calcium sensitivity of the myofilament (Stelzer et al 2007) 
and its contractile properties (Takimoto et al 2004). PKA phosphorylates TnI on two 
neighbouring Serine residues within a unique N terminal region which is absent in skeletal 
muscle isoforms of the protein (Solaro et al 1976). PKA phosphorylation of TnI has been 
linked with an enhanced rate of relaxation and force of contraction in transgenic mouse 
hearts (Takimoto et al 2004). PKA phosphorylation events are tightly controlled due to 
the generation of localised cAMP gradients by PDEs. Although particular PDE isoforms 
have been linked with regulating the PKA phosphorylation of certain cardiac proteins 
involved in ECC, such as the ryanodine receptor (Dodge et al 2001) and the voltage-gated 
potassium channel (Terrenoire et al 2009), to date, nothing is known about PDEs that may 
regulate cAMP signaling and PKA phosphorylation of TnI at the myofilament. PDE activity 
in the vicinity of TnI would favour cAMP hydrolysis and inactivation of PKA. The actions of 
myofilament-associated PDEs would, therefore, influence cardiac contractility, and such 
enzymes would represent a novel therapeutic target in the treatment of diseases such as 
heart failure, where β1-adrenergic signaling pathways are known to be chronically 
downregulated (Triposkiadis et al 2009).  
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4.1.1 Experimental aims 
It has never been shown that specific PDEs regulate cAMP levels around TnI at the cardiac 
myofilament. The aim of the experimental work detailed in this chapter was to discover 
whether PDE isoforms hydrolyse cAMP around TnI, and thereby regulate the PKA 
phosphorylation status of TnI. The role of an AKAP in facilitating PKA phosphorylation of 
TnI was also investigated.  
 
4.1.2 Experimental procedure 
 
1) A FRET-based cAMP sensor which localised to TnI at the myofilament was 
developed. Expression and localisation of this sensor was tested in neonatal rat 
ventricular cardiac myocytes (NRVM).  
 
2) Cells expressing the TnI-linked cAMP sensor were treated with different PDE 
family inhibitors, and changes in myofilament cAMP dynamics were measured by 
FRET.  
 
3) Neonatal rat ventricular cardiac myocytes (NRVM) were treated with different 
PDE family inhibitors, and the effects on PKA phosphorylation of TnI were 
determined by immunoblotting. 
 
4) Specific association of TnI with different PDE subfamilies and individual 
isoforms was investigated by co-immunoprecipitation and colocalisation studies.  
 
5) The interaction sites for PDEs on TnI were mapped by peptide array. 
 
6) The presence of an AKAP to mediate PKA phosphorylation of TnI was 
investigated using Ht31 peptide and RII overlay techniques 
 




4.2.1 Expression and localisation of a TnI-linked cAMP 
FRET sensor 
Fluorescence resonance energy transfer (FRET) describes the process of energy transfer 
between two fluorophores, often cyan- and yellow- fluorescent proteins (CFP and YFP), 
which occurs when the fluorophores are in close proximity (Section 1.6.1). Epac1-camps is 
a genetically encoded cAMP sensor consisting of YFP and CFP fluorophores linked to the 
cAMP binding domain of Epac1 (Nikolaev et al 2004). When cAMP levels are low, 
excitation of CFP at 440nm will result in FRET and the detection of YFP emission at 
545nm, as the two fluorophores are close together. When cAMP levels rise, cAMP binds 
to the Epac1 component, leading to a conformational change in the sensor. The two 
fluorophores move further apart, FRET is reduced, and CFP emission at 480nm is detected 
instead (Figure 4-1A). Changes in FRET ratio (480/545nm) are directly proportional to 
cAMP levels in the cell (Zaccolo & Pozzan 2002). Epac1-camps is commonly used to study 
cAMP dynamics within intact cells. This sensor was selected for FRET experiments due to 
its high sensitivity, equal expression of YFP and CFP moieties, and its ability to measure 
changes in cAMP with high temporal resolution (Nikolaev et al 2004). Recently, novel 
Epac-based FRET sensors have been generated by linking them to other proteins, allowing 
their targeting to specific subcellular compartments (Herget et al 2008, Sin et al 2011). 
Thus, high spatial resolution of cAMP dynamics can also be achieved using these sensors. 
 
In order to measure cAMP dynamics at the myofilament, a novel fusion protein was 
generated by fusing Epac1-camps to the C terminus of TnI. This sensor was kindly 
provided by Dr Jon Day at the University of Glasgow. The novel sensor was designated 
TnI:Epac1-camps (Figure 4-1B).  






Figure 4-1  FRET measured by the Epac1-camps sensor.  
A. In this sensor, the GFP variants cyan fluorescent protein (CFP) and yellow fluorescent protein 
(YFP) are linked by residues E157-E316 of the cAMP binding domain of Epac1 (Nikolaev et al 
2004). In the absence of cAMP, the 2 fluorophores are in close proximity and FRET can occur. 
When cAMP levels rise, cAMP binds to the sensor leading to a conformational change in the 
Epac1 domain, the fluorophores are moved apart, and FRET is abolished. B. Schematic 
representation of the TnI:Epac1-camps sensor. TnI was cloned 5’ of this sensor to generate a 
novel fusion protein which localised to the myofilament.   
 
Epac1-camps and TnI:Epac1-camps were transfected into cultured neonatal rat 
ventricular cardiac myocytes (NRVM). NRVM are terminally differentiated cells, and are a 
widely used model to study cardiac physiology and pathophysiology due to their ability to 
beat spontaneously, respond to pharmacological stimuli and undergo gene transfer 
(Maass & Buvoli 2007). All experiments in this thesis were performed in this cell type, 
unless otherwise stated. Expression and appropriate localisation of the two sensors was 
determined by fluorescence microscopy of YFP (Figure 4-2). Epac1-camps showed 
uniform distribution throughout the cytosol. This sensor contains only part of the cAMP 
binding domain of full length Epac1, and therefore lacks any localisation sequences.     Chapter 4  Results       
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Epac1-camps was used as a control for generalised cytosolic cAMP signaling during all 
subsequent FRET experiments. TnI-Epac1-camps localised with a striated pattern in 
NRVM. Myofilaments are composed of repeating contractile units known as sarcomeres, 
which comprise overlapping thin and thick protein filaments, giving them a characteristic 
striated appearance under the microscope. TnI forms part of the heterotrimeric Tn 
complex which is evenly spaced along the thin filament, with 1 Tn complex per 7 
monomers of actin (Engel et al 2004). Thus the appearance of TnI:Epac1-camps under YFP 
fluorescence is consistent with it localising to TnI at the myofilaments (Figure 4-2A). The 
localisation pattern of TnI was confirmed in NRVM which had been fixed and 





Figure 4-2  Localisation of Epac1-camps and TnI:Epac1-camps FRET sensors in NRVM.   
A. TnI:Epac1-camps localises to the myofilament, leading to a characteristic striated distribution 
pattern. Epac1-camps shows cytoplasmic distribution, as it lacks any localisation sequences. 
Images were obtained from live cells using a laser confocal microscope at 100x magnification. B. 
Immunocytochemical analysis and fluorescence microscopy of a fixed NRVM stained with anti-
TnI antibodies, showing identical distribution to the TnI FRET sensor. Scale bar represents 
20µM.      Chapter 4  Results       
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4.2.2 Characterisation of the properties of TnI:Epac1-camps 
In order to test the efficiency of both FRET sensors in measuring cAMP levels within their 
respective subcellular compartments, the maximal activation of each sensor was 
determined. This characterisation was particularly important for the novel TnI:Epac1-
camps sensor, to ensure that fusion of TnI to the CFP fluorophore did not interfere with 
the ability of the sensor to detect changes in cAMP levels. NRVM were transfected with 
either the TnI-targeted sensor or Epac1-camps. A large quantity of intracellular cAMP was 
then generated by real time stimulus of transfected cells with forskolin (FSK) and isobutyl-
methylxanthine (IBMX). FSK is an adenylyl cyclase activator and stimulates cAMP 
production by cardiac ACs, whereas IBMX is a non-specific PDE inhibitor that blocks cAMP 
degradation. Both sensors were able to rapidly detect the change in cAMP levels. The 
magnitude of response was similar for both FRET sensors (22.3% ± 2.0% for TnI:Epac1-
camps and 20% ± 1.7% for Epac1-camps) (Figure 4-3A),and there was no statistically 
significant difference between these two values, indicating that the presence of the TnI 
moiety does not significantly impair the ability of Epac1-camps to measure changes in 
cAMP levels.  
 
Changes in intracellular [cAMP] can be estimated from changes in FRET. FRET can be 
expressed as the ratio (R) of CFP emission intensity over YFP emission intensity following 
excitation of the cell at 440nm (R = CFP480/YFP545). Changes in this FRET ratio were 
expressed as the increase in CFP/YFP ratio over the CFP/YFP ratio at time zero (R0), as 
described in the Materials and Methods (Section 3.6.1.3) and (Mongillo et al 2004). As 
[cAMP] rises in the vicinity of the FRET sensor, the two fluorophores move further apart, 
and FRET is diminished, resulting in predominantly CFP emission. The CFP/YFP ratio 
therefore increases in proportion to the rise in [cAMP]i (Mongillo et al 2004, Zaccolo & 
Pozzan 2002).  
 







Figure 4-3 Maximal activation of Epac1-camps and TnI:Epac1-camps in response to saturating 
intracellular concentrations of cAMP.  
NRVM transfected with the different FRET sensors were stimulated with 50µM FSK and 100µM 
IBMX, and the changes in FRET ratio calculated as described in the text. A. Representative 
traces of change in FRET ratio over time for the 2 sensors. Arrows indicate the time at which the 
FSK/IBMX stimulus was applied for each sensor. B. Graph of the percentage change in FRET 
ratio for both sensors. No significant difference in the maximal FRET ratio was observed 
between the two sensors. Error bars indicate standard error of the mean (SEM), and n numbers 
for each experiment are shown in brackets. Each n number indicates a single measurement 
from an individual cell.  
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4.2.3 PDE4 regulates cAMP levels around TnI 
4.2.3.1. PDE4 provides the greatest cAMP hydrolytic activity in NRVM 
PDE 1, 2, 3, 4, 5 and 8 are known to be expressed in the heart to different extents; 
however their individual contributions to cAMP hydrolysis in NRVM have not all been 
assessed. As a first step to determining which PDE isoforms regulate cAMP around TnI at 
the myofilament, the individual contributions of each of the PDE families to cAMP 
hydrolysis in unstimulated NRVM lysates were measured (Figure 4-4). A variety of 
inhibitors of the different PDE families are available (Table 1-2). Lysates were treated with 
PDE family inhibitors, as described in the figure legend, and the amount of cAMP 
hydrolysis calculated by phosphodiesterase activity assay (Section 3.7.1) (Marchmont & 
Houslay 1980). As expected, treatment with the non-selective PDE inhibitor IBMX 
resulted in a dramatic decrease in cAMP hydrolysing activity. IBMX inhibits all PDE 
families, with the exception of PDE8 (Wang et al 2008). Rolipram, which inhibits all 
members of the PDE4 family, had a similar effect to IBMX , indicating that PDE4 is 
responsible for the majority of cAMP hydrolysing activity in this cell type. This is in 
agreement with previous data from Mongillo and co-workers, who looked at the relative 
contributions of PDE3 and PDE4 to cAMP hydrolysis in this cell type (Mongillo et al 2004). 
Inhibition of PDE5 with zaprinast, and PDE8 with dipyridamole also significantly reduced 
cAMP hydrolysis in these cells. Dipyridamole inhibits PDE8 with an IC50 of 4.5µM, and 
PDE5 with an IC50 of 0.9µM (Soderling et al 1998), and it may be that some off-target 
effects on other PDE families were observed with these inhibitors.  




Figure 4-4  cAMP hydrolysing activities of different PDE families in NRVM.  
NRVM lysates were treated with 10µM concentrations of different PDE family inhibitors 
(100µM IBMX), and cAMP hydrolytic activity assessed by the method of Marchmont and 
Houslay, described in Section 3.7.1. PDE activity was calculated in pmol cAMP 
hydrolysed/min/mg of protein. Inhibition of PDE1 (vinpocentine), PDE2 (EHNA) and PDE3 
(cilostamide) had no significant effect on cAMP hydrolysis in NRVM, whereas PDE5 (zaprinast) 
and PDE8 (dipyridamole) inhibition both led to significant reductions in cAMP hydrolysed when 
compared with untreated lysates (*P<0.05 and **P<0.01 respectively). PDE4 inhibition with 
rolipram was associated with the greatest reduction in cAMP hydrolysis (***P<0.001), 
comparable to that of the non-specific PDE inhibitor IBMX. Therefore, PDE4 appears to be the 
most important family regulating cAMP hydrolysis in NRVM. Each data point represents an n of 





4.2.3.2. A FRET sensor targeted to TnI reveals that PDE4 modulates the pool of 
cAMP around TnI 
Next, I wanted to determine the PDE(s) responsible for cAMP hydrolysis at the 
myofilament. The use of targeted FRET sensors has enabled the real time monitoring of 
cAMP levels within specific subcellular compartments. TnI:Epac1-camps is a novel 
genetically encoded cAMP sensor which measures cAMP levels around TnI. Given that the 
majority of cAMP hydrolytic activity in NRVM is contributed by PDE4, it seemed 
reasonable to assume that members of the PDE4 family might play a major role in 
regulating cAMP levels around TnI. TnI:Epac1-camps and Epac1-camps were transfected     Chapter 4  Results       
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into cells, and changes in FRET (and therefore [cAMP]) were measured following 
inhibition of PDE4 (Figure 4-5). The effect of PDE3 inhibition on FRET was also 
investigated, as PDE3 and PDE4 are thought to be the predominant families expressed in 
cardiac myocytes (Houslay et al 2007).  As in Figure 4-3, non-selective inhibition of PDEs 
with IBMX generated large changes in the FRET ratio, and the observed effects were 
similar for both sensors. In addition, both sensors responded similarly to cAMP generated 
via stimulation of β-adrenergic signaling pathways with the synthetic β-agonist 
isoproterenol (Iso). Treatment with the PDE4 inhibitor rolipram led to an increase in FRET 
measured by both sensors; however significantly greater FRET was measured by 
TnI:Epac1-camps (5.1% ± 1.1% compared with 2.9% ± 0.1% for Epac1-camps, P<0.05). 
Treatment with the PDE3 inhibitor cilostamide also led to a measurable increase in FRET 
for both sensors, but this time, Epac1-camps detected a greater FRET response (4.2% ± 
0.8% compared with 1.7% ± 0.9% for TnI:Epac1-camps, P<0.05). Thus, it appears that the 
two sensors are measuring changes in cAMP levels in two distinct subcellular 
compartments, the cytosol and the cAMP microdomain around TnI at the myofilament. 
Inhibition of PDE4 led to a larger rise in cAMP at the myofilament than inhibition of PDE3, 
indicating that PDE4 regulate cAMP levels around TnI, and may, therefore, regulate PKA 










Figure 4-5  Changes in FRET ratio in different intracellular compartments in response to PDE 
family inhibition.  
Cells were treated with either 1nM isoproterenol (as 10nM was found to be saturating), 10µM 
cilostamide or 10µM rolipram, followed by 100µM IBMX to saturate the sensors. The change in 
FRET ratio measured by TnI:Epac1-camps was significantly greater in the presence of rolipram 
than cilostamide (P<0.05), indicating that PDE4 plays the predominant role in regulating cAMP 
levels around TnI at the myofilament (n=7-10 for each experimental condition). No significant 
difference was observed between response of the two sensors to Iso (TnI:Epac1-camps, 6.9% ± 
2.1%; Epac1-camps, 7.5% ± 2.4%) or IBMX (TnI:Epac1-camps, 19.0% ± 2.1%; Epac1-camps, 20.3% 






The kinetics of the TnI:Epac1-camps sensor were also studied. FRET responses to Iso and 
IBMX measured by this sensor were very rapid, being detected almost immediately after 
application of the stimulus (Figure 4-6, grey arrows). Stimulation of the cells with rolipram 
resulted in a similar magnitude of change in FRET ratio as for Iso, but the effect was much 
slower. This could be explained by the fact that Iso acts on β-AR at the cell surface to 
generate intracellular cAMP, whereas rolipram must cross the plasma membrane to bring 
about its effects, and acts on basal cAMP levels. 
 




Figure 4-6  Representative traces of changes in FRET ratio measured by TnI:Epac1-camps in 
response to stimulation with rolipram or isoproterenol. 
Application of each stimulus is indicated by an arrow. Rolipram stimulus was applied first, and 
followed by IBMX stimulus once the response had plateaued. The magnitude of response was 
similar for isoproterenol (1nM; dark grey trace) and rolipram (10µM; light grey trace); however, 
the response to rolipram was much slower to develop. Rolipram has to cross the plasma 
membrane to mediate its effects on basal cAMP levels, whereas isoproterenol acts directly on 
β1-adrenergic receptors on the cell surface to mediate generation of the second messenger, and 
therefore leads to more rapid changes in FRET ratio. The response of both sensors to a 




4.2.3.3. PDE4 regulates PKA phosphorylation of TnI at the myofilament 
The experiments detailed so far using the novel targeted FRET sensor, TnI:Epac1-camps, 
demonstrate that PDE4 family members provide the majority of the cAMP hydrolysing 
activity around TnI. I next wanted to determine whether this modulation of cAMP levels 
translated into effects on the PKA phosphorylation status of TnI. To this end, NRVM were 
treated with inhibitors of the main PDE families expressed in cardiac myocytes, and the 
effects on PKA phosphorylation of TnI at Ser22/Ser23 determined by Western 
immunoblotting (Figure 4-7). Phosphorylation levels of TnI in untreated cells were used as 
a negative control, and Iso treatment (which is known to activate β-adrenergic signaling 
pathways, resulting in PKA phosphorylation of myofilament proteins such as TnI) acted as 
a positive control. Inhibition of PDE4 with rolipram resulted in a significant increase in 
PKA phosphorylation of TnI at Ser22/Ser23 (P<0.01), consistent with a role for this 
enzyme family in modulating cAMP levels around TnI. Dipyridamole treatment also led to 
significant increases in TnI phosphorylation (P<0.05). PDE8A has recently been shown to 
modulate ECC in cardiac myocytes. Experiments performed in PDE8A-/- mice indicate that     Chapter 4  Results       
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PDE8A is involved in modulating Ca
2+ transients at the L-type calcium channels and SR in 
response to β-adrenergic stimulation (Patrucco et al 2010). Thus, it is conceivable that 
PDE8A may also be involved in Ca
2+ responses at the myofilament. However, at the 
concentration used, dipyridamole is known to inhibit other PDE families in addition to 
PDE8, in particular the cGMP-selective PDEs PDE5, PDE6 and PDE11, and so it is likely that 
the observed increases in TnI phosphorylation represent off-target inhibitor effects.  
 
 
Figure 4-7  Effect of PDE family inhibitors on PKA phosphorylation of TnI at Ser22/Ser23. 
NRVM were treated with different PDE inhibitors (10µM: EHNA, cilostamide, rolipram, 
zaprinast, dipyridamole; 100µM IBMX) or isoproterenol (10µM, to saturate the response), for 
10 minutes. A. Cells were harvested, and the amounts of PKA-phosphorylated TnI and total TnI 
determined by Western immunoblotting. A representative immunoblot is shown. B. 
Quantification of data shown in part A by densitometry. Inhibition of PDE4 with rolipram 
significantly increased PKA phosphorylation of TnI at Ser22/Ser23 over basal levels (P<0.01), 
indicating that this PDE family regulates the pool of cAMP around TnI. Data shown represents 
the mean ± SEM of 3 separate experiments. * P<0.05; ** P<0.01; *** P<0.001. 
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The effects of PDE4 inhibition on TnI phosphorylation were investigated further over a 
rolipram time course (Figure 4-8). NRVM were pre-treated with rolipram and then 
stimulated with a submaximal concentration of Iso over time, or treated with Iso alone. 
Iso stimulation led to a very rapid and sustained phosphorylation of TnI at Ser22/Ser23, 
consistent with the role of TnI phosphorylation in enhancing cardiac output in response 
to β-AR signaling (Stelzer et al 2007, Takimoto et al 2004). Pre-treatment with rolipram 
increased the percentage of PKA-phosphorylated TnI at all the time points shown, 
indicating that generation of cAMP in response to Iso is augmented by local inhibition of 
PDE4-mediated cAMP hydrolysis. 
  
 
Figure 4-8  Time course of NRVM treatment with isoproterenol and rolipram. 
NRVM were treated with either Iso alone, or pre-treated with the PDE4 inhibitor rolipram for 10 
minutes, then stimulated with 10nM Iso for 1, 3, 5, 10, 20 or 60 minutes. A. Representative 
Western immunoblot of Iso and Iso + Rolipram time courses. Addition of PDE4 inhibitor 
increased PKA phosphorylation of TnI at Ser22/Ser23 over that observed with Iso alone. B. 
Quantification of data in part A. Data represents the average from an n of 3 experiments 
normalised to the maximum level of phosphorylation observed. * P<0.05.     Chapter 4  Results       
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4.2.4 TnI associates with members of the 
phosphodiesterase 4D subfamily 
The above experiments indicate that members of the PDE4 family regulate cAMP levels 
around TnI. The PDE4 family is large, consisting of 4 subfamilies: 4A, 4B, 4C and 4D, and 
over 20 different isoforms (Houslay et al 2007). Only the PDE4A, 4B and 4D subfamilies 
are expressed in the heart (Fischmeister et al 2006). Rolipram acts as a competitive 
inhibitor of cAMP at the common catalytic site of PDE4, and therefore cannot provide 
specific information on the activity of particular isoform(s) (Spina 2008). It has previously 
been shown that in NRVM the majority of PDE4 cAMP hydrolytic activity  is provided by 
the PDE4D subfamily, with a small contribution from PDE4B, and virtually no contribution 
from PDE4A or PDE4C (Mongillo et al 2004). It therefore seemed reasonable to 
investigate whether members of the PDE4D subfamily could regulate the myofilament 
pool of cAMP via an association with TnI. Consistent with this hypothesis, PDE4D co-
immunoprecipitated with TnI in NRVM lysates (Figure 4-9). Immunoprecipitation was 
performed using either anti-TnI antibody or normal IgG as a control, and an immunoblot 






Figure 4-9  Co-immunoprecipitation of PDE4D isoforms with TnI.  
An immunoblot of a TnI immunoprecipitation (IP) was performed using an in house Pan PDE4D 
antibody. The reciprocal IP could not be performed, due to the similarities in molecular weight 
of TnI and IgG light chains.  
 
     Chapter 4  Results       
107 
 
The association between TnI and PDE4D was investigated further by 
immunofluorescence. Adult rat ventricular cardiac myocytes (ARVM) were fixed and 
immunostained with antibodies against cardiac TnI and Pan PDE4D. Adult cardiac 
myocytes were selected as they have fully developed sarcomeres, with prominent 
striations which are easy to visualise under the microscope. As expected, TnI (red) 
showed a striated distribution, consistent with the regular spacing of the Tn complex 
along the thin filaments. PDE4D (green) also showed a degree of striation, although some 
PDE4D was also evident in the cytosol, in keeping with the variety of cellular roles that 
have been ascribed to members of this subfamily (Dodge et al 2001, Lehnart et al 2005). 
TnI and PDE4D could be seen to colocalise (yellow spots) at the sarcomeres, with a 
Pearson colocalisation coefficient of 0.748. The Pearson coefficient (r) quantifies the 
correlation between pixel intensity of the two channels measured. r values range 
between -1 and +1. A value of -1 indicates that when one channel signal increases, the 
other decreases accordingly (perfect negative correlation), and a value of +1 indicates 
that both channel signals increase in a similar ratio (perfect correlation) (Adler & Parmryd 
2010). Therefore, a Pearson co-efficient of 0.748 indicates that TnI and PDE4D are highly 
likely to colocalise within the cell.    
 
 
Figure 4-10  Colocalisation of PDE4D and TnI in the cardiac myofilament.  
Colocalisation (yellow regions) of TnI (red) and PDE4D (green) was determined by fixation of rat 
ventricular cardiac myocytes in methanol/paraformaldehyde as described in Section 3.6.2, and 
staining for immunofluorescence with anti-cardiac troponin I and anti-pan PDE4D antibodies. 
Images were obtained at 63x magnification on a Zeiss Pascal Confocal microscope, and collected 
using Zeiss Pascal software. A Pearson colocalisation coefficient (r) was calculated using Image J 
software. For these images, r = 0.748, indicating a high degree of colocalisation. Scale bars 
represent 20µM.     Chapter 4  Results       
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4.2.5 PDE4D9 associates with the myofilament protein TnI  
The importance of PDE4D in the cardiovascular system has previously been illustrated by 
studies involving PDE4D knockout mice. These mice develop progressive age-related 
cardiomyopathies and are susceptible to exercise-induced cardiac arrhythmias and 
sudden cardiac death, despite apparently normal global cAMP signaling (Lehnart et al 
2005). Furthermore, a number of studies have demonstrated that specific PDE4D 
isoforms associate with key ion channels, receptors and SR proteins to regulate 
cAMP/PKA signaling in the heart (De Arcangelis et al 2009, Dodge et al 2001, Perry et al 
2002, Terrenoire et al 2009). Members of the PDE4D subfamily have been shown here to 
co-immunoprecipitate with TnI from cellular lysates, and to colocalise with TnI at the 
cardiac myofilament. PDE4D consists of 11 isoforms, PDE4D1-11, and mRNA transcripts 
for 4D1, 4D2, 4D3, 4D5, 4D7, 4D8 and 4D9 isoforms have previously been detected in 
heart tissue (Richter et al 2005).  
 
4.2.5.1. PDE4D1, 4D5 and 4D9 mRNA transcripts are highly expressed in NRVM 
Quantitative PCR (qPCR) was performed to determine the relative mRNA expression 
levels of the different PDE4D isoforms in NRVM (Figure 4-11). This work was kindly 
performed by David Henderson at the University of Glasgow. 6 isoforms were expressed 
at significant levels, with PDE4D9 showing the highest expression. PDE4D7 transcripts 
were expressed at very low levels, consistent with previous data (Richter et al 2005). 
PDE4 isoforms are classified as long, short and super short, based on the presence or 
absence of various regulatory domains (Section 1.4.2.2.). Both long (4D3, 5, 7, 8 and 9) 
and short (4D1) transcripts were identified in NRVM. No function has yet been ascribed to 
the short forms, although a number of roles have been ascribed to long forms (described 
in Section 1.4.3).  




Figure 4-11   Relative mRNA expression levels of PDE4D isoforms in NRVM.  
Expression levels were determined by quantitative PCR . The PDE4D10 and PDE4D11 isoforms 
were identified after this experiment was performed (Chandrasekaran et al 2008, Lynex et al 
2008), and so are not included here. Data represents an n of 3 experiments on different 
cardiomyocyte preparations.  
 
 
4.2.5.2. PDE4D9 associates with TnI in NRVM 
During the course of my PhD, a number of PDE4D isoform-specific antibodies were 
developed by members of our laboratory. Much of the PDE4 amino acid sequence is 
common to all isoforms; however, each isoform possesses a unique N terminal sequence 
of variable length, which is involved in subcellular targeting and protein-protein 
interactions (Houslay 2010). The presence of this variable region also allows the isoforms 
to be differentiated by polyacrylamide gel electrophoresis on the basis of their molecular 
weights. PDE4D3, 4D8 and 4D9 are around 95kDa, while PDE4D5 and 4D7 appear slightly 
higher on gels, at around 105kDa. Based on their unique regions, N terminal-specific 
antibodies were successfully developed against PDE4D3, 4D5, 4D7 and 4D9 isoforms, 
which are all thought to be expressed in NRVM. TnI was immunoprecipitated from NRVM 
lysates, and isoform-specific antibodies used for immunoblotting (Figure 4-12). vsv-
tagged versions of different PDE4D isoforms were expressed and used as protein 
standards. All four isoform-specific antibodies were able to detect these standards at the     Chapter 4  Results       
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appropriate molecular weights. Small amounts of PDE4D3 and 4D5 proteins were 
detectable in the lysates, but no PDE4D7 protein was identified. 4D7 mRNA levels were 
very low, and mRNA levels do not necessarily correlate with protein expression, therefore 
this protein may either not be expressed in NRVM, or the expression level may be below 
the threshold for detection by this antibody. A significant amount of PDE4D9 was present, 




Figure 4-12  Co-immunoprecipitation of PDE4D9 with TnI.  
Immunoblots (IB) of TnI immunoprecipitations were performed using isoform-specific PDE4D 
antibodies. A. IB of PDE4D3. B. IB of PDE4D5.C. IB of PDE4D7. D. IB of PDE4D9. PDE4D9 co-
immunoprecipitated with TnI, whereas the other isoforms tested did not. The appropriate vsv-
tagged human PDE4D isoforms were used as standard markers. 
 
 
This association was confirmed using immunofluorescence techniques. Adult rat 
ventricular cardiac myocytes (ARVM) were fixed and immunostained with antibodies 
against cardiac TnI and PDE4D9. TnI (red) again showed a striated distribution. PDE4D9 
(green) also showed a striated pattern; however, staining for this enzyme was also 
positive in the cytosol and at the plasma membrane, where it has previously been shown 
to associate with the β-adrenergic receptor (De Arcangelis et al 2009, Richter et al 2008).      Chapter 4  Results       
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The Pearson colocalisation coefficient was 0.565 for TnI and PDE4D9, consistent with 
their colocalisation at the myofilament. 
 
 
Figure 4-13  Colocalisation of PDE4D9 and TnI. 
Colocalisation (yellow regions) of TnI (red) and PDE4D9 (green) was determined by fixation of 
rat ventricular cardiac myocytes and staining for immunofluorescence with anti-cardiac 
troponin I and anti-N terminal-specific PDE4D9 antibodies. The Pearson colocalisation 
coefficient (r) was calculated using Image J software to be 0.565 for these images, indicating a 
significant degree of colocalisation. Scale bars represent 20µM.  
 
 
4.2.5.3. PDE4D9 interacts with the flexible C terminus of TnI  
PDE4D9 has been shown to associate with TnI in NRVM. In order to determine the specific 
residues involved in this interaction, a peptide array approach was employed. Peptide 
arrays consist of short peptides immobilised on cellulose membranes. The peptide 
sequences overlap so that they cover the entire sequence of the protein of interest 
(Section 3.5.3). Cellulose peptide arrays are able to bind purified fusion proteins, and can 
therefore provide information on protein-protein interactions, and the residues critical 
for these interactions (Frank 2002). Peptide arrays have previously been used successfully 
to locate binding sites for the signaling scaffold protein β-arrestin and the 
cardioprotective chaperone Hsp20 on PDE4D5 (Bolger et al 2003, Sin et al 2011). A TnI 
peptide array was generated and probed with purified GST-PDE4D9 fusion protein. 
Binding sites for PDE4D9 on TnI were identified as black spots (Figure 4-14A, upper 
panel), following immunoblotting for GST. Purified GST alone was used as a control to     Chapter 4  Results       
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determine any regions of the array which bound non-specifically to the GST component of 
the fusion protein. The 25mer amino acid sequences of the TnI peptide array are listed in 
Figure 4-14B. Binding of GST-PDE4D9 was observed on TnI peptide spots corresponding to 
the C terminal region of the protein. The strongest signal was obtained for spot 33, 
therefore this region of TnI is likely to mediate interaction with the PDE. The peptide 
sequence corresponding to spot 33 (G
161TRAKESLDLRAHLKQVKKEDIEKE
185) was used to 
generate a second peptide array, known as an ‘alanine scan’, in which each residue was 
sequentially mutated to alanine. This was then probed with GST-PDE4D9 and GST as 
above. Alanine scans can provide information on particular amino acid residues that are 
critical for binding. If mutation of a residue to alanine abolishes binding of the fusion 
protein, it is likely to be required for the interaction between the two proteins (Bolger et 
al 2003). Mutation of two neighbouring lysine residues, K178 and K179, abolished binding 
of GST-PDE4D9 to TnI (Figure 4-14A, lower panel), indicating that these residues are likely 
















amino acid  
sequence 
       
1  M-A-D-E-S-S-D-A-A-G-E-P-Q-P-A-P-A-P-V-R-R-R-S-S-A  21  L-H-A-R-V-D-K-V-D-E-E-R-Y-D-V-E-A-K-V-T-K-N-I-T-E 
2  S-D-A-A-G-E-P-Q-P-A-P-A-P-V-R-R-R-S-S-A-N-Y-R-A-Y  22  D-K-V-D-E-E-R-Y-D-V-E-A-K-V-T-K-N-I-T-E-I-A-D-L-T 
3  E-P-Q-P-A-P-A-P-V-R-R-R-S-S-A-N-Y-R-A-Y-A-T-E-P-H  23  E-R-Y-D-V-E-A-K-V-T-K-N-I-T-E-I-A-D-L-T-Q-K-I-Y-D 
4  P-A-P-V-R-R-R-S-S-A-N-Y-R-A-Y-A-T-E-P-H-A-K-K-K-S  24  E-A-K-V-T-K-N-I-T-E-I-A-D-L-T-Q-K-I-Y-D-L-R-G-K-F 
5  R-R-S-S-A-N-Y-R-A-Y-A-T-E-P-H-A-K-K-K-S-K-I-S-A-S  25  K-N-I-T-E-I-A-D-L-T-Q-K-I-Y-D-L-R-G-K-F-K-R-P-T-L 
6  N-Y-R-A-Y-A-T-E-P-H-A-K-K-K-S-K-I-S-A-S-R-K-L-Q-L  26  I-A-D-L-T-Q-K-I-Y-D-L-R-G-K-F-K-R-P-T-L-R-R-V-R-I 
7  A-T-E-P-H-A-K-K-K-S-K-I-S-A-S-R-K-L-Q-L-K-T-L-M-L  27  Q-K-I-Y-D-L-R-G-K-F-K-R-P-T-L-R-R-V-R-I-S-A-D-A-M 
8  A-K-K-K-S-K-I-S-A-S-R-K-L-Q-L-K-T-L-M-L-Q-I-A-K-Q  28  L-R-G-K-F-K-R-P-T-L-R-R-V-R-I-S-A-D-A-M-M-Q-A-L-L 
9  K-I-S-A-S-R-K-L-Q-L-K-T-L-M-L-Q-I-A-K-Q-E-M-E-R-E  29  K-R-P-T-L-R-R-V-R-I-S-A-D-A-M-M-Q-A-L-L-G-T-R-A-K 
10  R-K-L-Q-L-K-T-L-M-L-Q-I-A-K-Q-E-M-E-R-E-A-E-E-R-R  30  R-R-V-R-I-S-A-D-A-M-M-Q-A-L-L-G-T-R-A-K-E-S-L-D-L 
11  K-T-L-M-L-Q-I-A-K-Q-E-M-E-R-E-A-E-E-R-R-G-E-K-G-R  31  S-A-D-A-M-M-Q-A-L-L-G-T-R-A-K-E-S-L-D-L-R-A-H-L-K 
12  Q-I-A-K-Q-E-M-E-R-E-A-E-E-R-R-G-E-K-G-R-V-L-S-T-R  32  M-Q-A-L-L-G-T-R-A-K-E-S-L-D-L-R-A-H-L-K-Q-V-K-K-E 
13  E-M-E-R-E-A-E-E-R-R-G-E-K-G-R-V-L-S-T-R-C-Q-P-L-V  33  G-T-R-A-K-E-S-L-D-L-R-A-H-L-K-Q-V-K-K-E-D-I-E-K-E 
14  A-E-E-R-R-G-E-K-G-R-V-L-S-T-R-C-Q-P-L-V-L-D-G-L-G  34  E-S-L-D-L-R-A-H-L-K-Q-V-K-K-E-D-I-E-K-E-N-R-E-V-G 
15  G-E-K-G-R-V-L-S-T-R-C-Q-P-L-V-L-D-G-L-G-F-E-E-L-Q  35  R-A-H-L-K-Q-V-K-K-E-D-I-E-K-E-N-R-E-V-G-D-W-R-K-N 
16  V-L-S-T-R-C-Q-P-L-V-L-D-G-L-G-F-E-E-L-Q-D-L-C-R-Q  36  Q-V-K-K-E-D-I-E-K-E-N-R-E-V-G-D-W-R-K-N-I-D-A-L-S 
17  C-Q-P-L-V-L-D-G-L-G-F-E-E-L-Q-D-L-C-R-Q-L-H-A-R-V  37  D-I-E-K-E-N-R-E-V-G-D-W-R-K-N-I-D-A-L-S-G-M-E-G-R 
18  L-D-G-L-G-F-E-E-L-Q-D-L-C-R-Q-L-H-A-R-V-D-K-V-D-E  38  N-R-E-V-G-D-W-R-K-N-I-D-A-L-S-G-M-E-G-R-K-K-K-F-E 
19  F-E-E-L-Q-D-L-C-R-Q-L-H-A-R-V-D-K-V-D-E-E-R-Y-D-V  39  D-W-R-K-N-I-D-A-L-S-G-M-E-G-R-K-K-K-F-E-G 




Figure 4-14  PDE4D9 binds to the C terminal region of TnI. 
The interaction site for PDE4D9 on TnI was mapped to the C terminal of the myofilament 
protein using peptide array technology. A. Peptide array of the full length sequence of rat 
cardiac TnI. Strongest binding of the PDE fusion protein to the array occurred at spot 33. 
Alanine scanning of this sequence identified two key lysine residues, K178 and K179, as 
important in mediating this interaction. B. List of 25mer amino acid sequences corresponding to 
numbered spots on the TnI peptide array. The amino acid sequence corresponding to spot 33 is 
highlighted in red.     Chapter 4  Results       
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K178 and K179 map to a region of TnI at the C terminal of the protein (Figure 4-15). The 
crystal structure of the core troponin complex has now been solved. Unfortunately, due 
to problems with crystallisation the N and C termini of TnI were not included in the 
crystallised complex; however, their relative positions have been predicted from the 
structural information that was obtained (Takeda et al 2003). K178/K179 reside within 
helix 4 of TnI, a flexible region which is known to be involved in mediating actin-
tropomyosin interactions in response to fluctuations in intracellular calcium levels 
(Galinska et al 2010, Takeda et al 2003). The folding of the TnI protein is such that this 
region is likely to be near the N terminal region of the protein where the PKA sites are 
located. Thus, the presence of PDE activity here could conceivably modulate local cAMP 





Figure 4-15  Model of TnI structure demonstrating the position of K178/K179. Adapted from 
(Takeda et al 2003).  
The crystal structure of residues 31-163 of TnI has been solved. A. Ribbon structure of the core 
troponin complex. TnI is shown in blue, TnT in yellow, and TnC in red. K178/K179 are located on 
helix 4 of TnI, a flexible region at the C terminal of the protein.  which mediates interactions 
with actin-tropomyosin on the thin filament during cardiac contraction B. Space-filling diagram 
of the Tn complex. The approximate positions of K178 and K179 are indicated in purple, and are 
close to the start of helix 1 (residue 43), therefore are likely to be located in proximity to 
Ser22/Ser23.      Chapter 4  Results       
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4.2.6 PDE4D9 regulates PKA phosphorylation of TnI  
4.2.6.1. Peptide disruption of the TnI-PDE4D9 complex enhances PKA 
phosphorylation of TnI 
It has been established that PDE4D9 interacts with TnI, and that this interaction is likely to 
be mediated by two neighbouring lysine residues at the C terminus of the myofilament 
protein. Next, I wanted to determine whether this PDE could influence cAMP levels 
around TnI, and thereby affect the phosphorylation status of TnI. Cell permeable peptides 
have previously been used to disrupt intracellular signaling complexes, leading to altered 
functional outcomes. For example, the MAPK kinase MEK1 interacts directly with β-
arrestin, promoting arrestin phosphorylation by ERK. A 25mer cell permeable β-arrestin 
peptide encompassing the MEK1 binding site blocked this association in HEK293 cells and 
reduced arrestin phosphorylation by ERK, favouring agonist-stimulated receptor 
internalisation (Meng et al 2009). More recently, specific peptide disruption of a complex 
formed between Hsp20 and PDE4D5 was shown to increase cardioprotective PKA 
phosphorylation of Hsp20, and confer protection against cardiac hypertrophy in cultured 
cardiac myocytes (Sin et al 2011). Thus, peptide disruptors are of considerable 
therapeutic interest, and constitute ideal biological tools for disrupting the localisation of 
a single pool of PDE, in this case PDE4D9.  
 
I used the TnI sequence information obtained from the peptide array experiments to 
design a specific peptide disruptor of the TnI-PDE4D9 interaction. A scrambled version of 
this peptide with identical molecular weight and charge was also designed to act as a 
control. Both peptides were stearylated, in order to make them cell permeable. 
Treatment of NRVM with increasing concentrations of the 4D9 disruptor peptide was 
associated with up to a 5 fold  increase in TnI phosphorylation at Ser22/Ser23 over 
baseline (P<0.001), and was comparable with the effect produced by Iso treatment, 
whereas treatment with equimolar amounts of scrambled control peptide had no effect 
(Figure 4-16). This effect on TnI phosphorylation was observed under basal conditions i.e. 
in the absence of any other stimulus, implying that basal levels of cAMP are sufficient to 






Figure 4-16 Peptide disruption of the TnI-PDE4D9 complex enhances phosphorylation of TnI at 
Ser22/Ser23. 
NRVM were treated with 10µM and 50µM disruptor and control peptides (GenScript) for 3 
hours at 37°C and 5% CO2. The TnI phosphorylation at Ser22/Ser23 was compared to untreated 
cells, or cells treated with 10µM Iso for 10 minutes to maximise TnI phosphorylation. A. 
Representative immunoblot of phospho and total TnI levels, with fluorescently labelled 
secondary antibodies (Molecular Probes). Images were scanned using an Odyssey imager (Licor 
Biosciences). B. Quantification of data in upper panel, from an n of 3 experiments. Disruptor 
peptide sequence: St-GTRAKESLDLRAHLKQVKKEDIEKE; control peptide sequence: St-
KTELKAERGIKSDVAKERELHDLGK. ** P<0.01; *** P<0.001. 
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The above data is consistent with a model whereby under basal conditions, PDE4D9 
maintains myofilament PKA in an inactive state by hydrolysing local cAMP, leading to low 
levels of phosphorylated TnI. When local cAMP levels rise, either following β-adrenergic 
stimulation, or due to disruption of the TnI-PDE complex, PDE activity is saturated. PKA is 
activated and phosphorylates TnI on Ser22/Ser23, leading to positive contractile effects 





Figure 4-17 Schematic representation of the role of PDE4D9 in regulating PKA phosphorylation 
of TnI.  
A. Under resting conditions, PDE4D9 is associated with the C terminus of TnI at the cardiac 
myofilament, and hydrolyses local cAMP, maintaining PKA in an inactive (R2C2) conformation. 
TnI remains hypophosphorylated at Ser22/Ser23. B. In response to physiological stress, the β1-
adrenergic signaling pathway is activated. cAMP levels rise in the myofilament compartment, 
saturating the hydrolytic abilities of PDE4D9, and activating the local PKA complement leading 
to the dissociation of the catalytic (C) and regulatory (R) subunits. TnI is phosphorylated by PKA 
at its N terminus. This reduces the Ca
2+ sensitivity of the myofilament and increases the force of 
contraction and rate of relaxation, resulting in increased cardiac output. Peptide disruption of 
the TnI-PDE4D9 interaction appears to have a similar effect on TnI phosphorylation. PDE4D9 is 
displaced from TnI, and basal cAMP levels are sufficient to activate PKA, leading to Ser22/Ser23 
phosphorylation.  
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4.2.7 Investigation into the regulation of PKA 
phosphorylation of TnI by AKAPs 
It has previously been shown that phosphorylation of TnI at Ser22/Ser23 is directed by 
AKAPs, though no AKAP has been specifically proposed for this role (Fink et al 2001). The 
above experiments provide convincing evidence for the role of PDE4D9 in modulating 
cAMP levels around TnI to control PKA activation and Ser22/Ser23 phosphorylation. 
AKAPs scaffold discrete pools of PKA in the vicinity of their subcellular targets; however, 
little is known about the AKAPs which regulate PKA phosphorylation of myofilament 
proteins. To determine whether an AKAP mediated PKA phosphorylation of TnI, I utilised 
the Ht31 and RII overlay techniques, which are commonly used to detect AKAPs.  
 
PKA is localised to specific subcellular regions through the interaction of its regulatory 
subunits with AKAPs. The binding surface for PKA on AKAPs is a stretch of between 14 and 
18 amino acids which are organised into an amphipathic helix to create a high affinity RII 
binding surface (Welch et al 2010). The first AKAP in which the amphipathic helix was 
identified was the human thyroid AKAP Ht31 (Carr et al 1991). Since then, synthetic 
peptide derivatives of this Ht31 sequence have been developed which can be used to 
selectively disrupt AKAP-PKA interactions, as they will compete with endogenous AKAPs 
for RII binding (Carr et al 1992, Fink et al 2001).  
 
Neonatal rat ventricular cardiac myocytes (NRVM) were treated with cell-permeable Ht31 
peptide, or a control peptide, Ht31P, which is unable to bind PKA RII. Treatment with the 
AKAP-disrupting Ht31 peptide had no effect on the phosphorylation of TnI at various time 
points of Iso stimulation (Figure 4-18). This may have been due to the experimental 
conditions employed. Cells were pre-treated with 10µM stearylated Ht31 peptides for 2 
hours prior to isoproterenol stimulation, and it may be that the peptides did not cross the 
plasma membrane in sufficient quantities to disrupt AKAP-PKA interactions.  




Figure 4-18 Treatment with cell permeable AKAP-competing Ht31 peptide did not disrupt AKAP-
PKA interactions in NRVM.  
A. Representative immunoblot of TnI phosphorylation in cells that had been pre-treated with 
10µM Ht31 peptide or 10µM control peptide (Ht31P) for 2 hours, and stimulated with 10nM 
isoproterenol for the indicated times. B. Quantification of data in part A, for an n of 3 
experiments. No significant difference in PKA phosphorylation of TnI was observed in response 
to Ht31 treatment. 
 
 
The defining characteristic of AKAPs is their ability to anchor PKA regulatory subunits. 
AKAPs retain their ability to bind RII following transfer to nitrocellulose membranes. 
Proteins can therefore be electrophoretically separated and transferred by conventional 
means, and the membrane probed with labelled RII subunits to locate any AKAPs present, 
in a modification of the Western blotting procedure. This method is known as an RII 
overlay, and has been used to identify numerous AKAPs (Carr & Scott 1992).  
 
To identify any RII binding proteins specifically associating with TnI, an 
immunoprecipitation (IP) of TnI was performed in NRVM, and subjected to RII overlay 
with 
32P-labelled RII subunits, followed by autoradiography (Figure 4-19A). The same     Chapter 4  Results       
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experiment was repeated on a PDE4D9 immunoprecipitation, in case the AKAP 
interaction was mediated by the phosphodiesterase (Figure 4-19B). A number of RII 
binding proteins were detected in the cardiac myocyte lysate (inputs), as would be 
expected, but no AKAP was detected in the immune complex with either TnI or PDE4D9. 
This may have been due to the IP conditions, or inadequate transfer of proteins onto the 
overlay membranes. Many AKAPs are very large proteins, and might therefore be difficult 




Figure 4-19 RII overlay techniques are unable to identify an AKAP for TnI.  
A. Immunoprecipitation of TnI was performed in NRVM and overlayed with radiolabelled RII 
subunits. Controls consisted of cellular lysate incubated with either beads alone or antibody 
alone. No RII binding proteins could be detected in association with the immune complex. B. 
PDE4D9 immunoprecipitations were treated as in part A. No RII binding proteins could be seen 
to associate with PDE4D9. 
32P RII overlays were performed at the Leibniz-Institut für Molekulare 
Pharmakologie, Berlin, under the supervision of Philipp Skroblin and Dr Enno Klussmann.  
 
 
Published data indicates that the PKA phosphorylation of TnI is mediated by an AKAP, and 
RII has been shown to localise to the myofilament with a similar distribution to TnI (Fink 
et al 2001). To exclude the possibility that TnI itself could act as an AKAP, and anchor PKA, 
TnI peptide arrays were overlayed with purified PKA R subunits. No binding over 
background was observed for either RI (Figure 4-20A) or RII subunits (Figure 4-20B). An RII     Chapter 4  Results       
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overlay was performed also on a TnI peptide array. As the 
32P RII overlay is relatively 
insensitive, and failed to detect any RII binding to TnI in a previous experiment, a 
modification of this technique was employed. It has been reported that a 5-10 fold 
increase in sensitivity of the overlay technique can be achieved using alternate RII 
labelling techniques (Carr & Scott 1992). To this end, PKA RII was labelled with the small 
molecule digoxigenin, which is highly immunogenic, and digoxigenin-RII applied to the TnI 
peptide array (Figure 4-20C).  A peptide encompassing the RII binding domain of AKAP79 
was used as an internal control (CONT). No RII binding to TnI could be visualised using this 
technique. Thus, a variety of techniques failed to identify an AKAP for TnI, and appear to 
exclude the possibility that TnI can act as an AKAP itself. Thus, based on this data, no 














Figure 4-20 PKA R subunits do not bind TnI peptide arrays. 
A. A full length TnI peptide array was probed with 10µg/ml purified PKA RI subunits, and 
immunoblotted with anti-RI antibodies. Primary and secondary antibodies alone were used as a 
control to detect non-specific antibody binding to the array. B. As in part A, except purified RII 
subunits were used. No binding above background could be detected for either RI or RII. 
Purified PKA R subunits were a kind gift from Dr Frank Christian, University of Glasgow. C. 
Digoxigenin-RII overlay of a TnI peptide array. The RII binding domain of AKAP79 was used as an 
internal control (CONT). The array was incubated with digoxigenin-labelled RII, and 
immunoblotted with anti-digoxigenin-HRP antibodies. No RII binding to TnI could be detected 
using this more sensitive method. Digoxigenin-RII was a kind gift from Dr Dave Canton, 
University of Washington, Seattle. Dig-RII overlays were performed in the laboratory of 
Professor John Scott, Department of Pharmacology, University of Washington, Seattle, 




The myofilament protein TnI forms the inhibitory subunit of the heterotrimeric troponin 
complex which regulates cardiac contraction (Engel et al 2004). Under basal conditions, 
the flexible C terminus of TnI interacts with actin-tropomyosin to maintain tropomyosin in 
a position which covers myosin binding sites on actin, preventing crossbridge formation 
and inhibiting contraction. Ca
2+ binding to TnC in the Tn complex leads to a 
conformational change in this protein which favours its interaction with TnI. This results 
in the release of tropomyosin by TnI, exposure of myosin binding sites on actin, and 
cardiac contraction (Galinska-Rakoczy et al 2008, Takeda et al 2003). This 28kDa protein is 
therefore an essential modulator of cardiac contraction.  
 
TnI mediates the myofilament response to stress. PKA phosphorylation of TnI at 
Ser22/Ser23 in response to β-adrenergic stimulation is associated with a desensitisation 
of the myofilament to Ca
2+, promoting earlier, more efficient relaxation (Stelzer et al 
2007), increased crossbridge cycling rate, and enhanced contractility (Takimoto et al 
2004). Initially, this response is beneficial, but if the stimulus is prolonged, it may be 
associated with heart failure. Heart failure is a clinical syndrome characterised by a 
decline in the pumping ability of the heart. Altered β-adrenergic signaling is a key feature 
of heart failure (Triposkiadis et al 2009). Prolonged β-adrenergic receptor activation 
downregulates β-AR and leads to their uncoupling from Gs (Bristow et al 1982). Thus, β-
blockers such as atenolol and metoprolol which oppose this process are one of the 
mainstays of treatment for heart failure. Reduced PKA phosphorylation of myofilament 
proteins is also seen in heart failure. Levels of PKA-phosphorylated TnI were found to be 
up to 50% lower in end-stage failure human hearts compared with healthy donor tissue 
(Van der Velden et al 2002, Zakhary et al 1999). Factors which promote this N terminal 
modification of TnI could therefore prove to be a useful adjunct in the treatment of heart 
failure, by ‘switching on’ the initial stress response at the myofilament. 
 
Phosphodiesterases provide the only route for cAMP degradation within cells. Targeting 
of PDEs to specific subcellular locations leads to the creation of microdomains of cAMP 
(Baillie 2009). PDE4 activity has been shown to be targeted to the ryanodine receptor and     Chapter 4  Results       
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the voltage-gated potassium channel in the heart, where local alterations in cAMP levels 
influence the activation of PKA and thereby the phosphorylation status of these key 
mediators of excitation-contraction coupling (Dodge et al 2001, Terrenoire et al 2009). 
PDE4 is of particular importance in the heart. PDE4 has been shown to provide the major 
cardiac cAMP hydrolysing activity (Mongillo et al 2004) (Figure 4-4), and FRET studies 
using a cAMP sensor targeted to TnI reveal for the first time that PDE4 activity modulates 
the pool of cAMP around TnI, and that PDE4 activity is higher in this compartment than in 
the cytosol (Figure 4-5).  
 
Multiple isoforms of PDE4 exist, which differ at their N termini. The non-redundant 
nature of these isoforms in the heart has previously been illustrated (Bolger et al 2003, De 
Arcangelis et al 2009, Richter et al 2008). Cells are now thought to be equipped with an 
array of PDE isoforms, which are targeted to discrete subcellular compartments via their 
unique N termini, where they regulate distinct signal transduction pathways, and mediate 
specific physiological outcomes (Baillie 2009, Houslay 2010, Richter et al 2005). A novel 
association between PDE4D9 and TnI has been demonstrated in this chapter (Figures 4-12 
to 4-14). Until recently, little was known about the physiological functions of this 95kDa 
isoform. PDE4D9 is widely expressed, with mRNA transcripts being detectable in the 
brain, spleen, lung, heart and kidney tissue of rats (Richter et al 2005), which would be 
consistent with a ubiquitous functional role for this isoform. PDE4D9 mRNA has also been 
isolated from osteoblasts, where it is postulated to play a role in bone formation 
(Nomura-Furuwatari et al 2008). Recently, PDE4D9 has been shown to associate with the 
β2-adrenergic receptor under basal conditions. Agonist stimulation induced dissociation 
of PDE4D9 and recruitment of PDE4D5, and knockdown of PDE4D9 expression with 
shRNA was associated with an enhanced basal contraction rate (De Arcangelis et al 2009). 
PDE4D9 was also shown to bind to the β1-AR, although to a lesser extent than PDE4D8 
(Richter et al 2008). De Archangelis and co-workers propose that PDE4D9 regulates basal 
cAMP levels at the β2-AR, while PDE4D5 regulates β-AR signaling after agonist binding, 
likely via its interaction with β-arrestin (De Arcangelis et al 2009). No functional role has 
been proposed for PDE4D9 which is released from β-ARs following ligand binding, and it 
would be interesting to employ localisation studies to determine whether this pool of the 
PDE is recruited to the myofilament to regulate TnI phosphorylation.      Chapter 4  Results       
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Peptide array studies mapped the binding site for PDE4D9 to the C terminal region of TnI 
(Figure 4-14). The crystal structure of the C terminus of TnI has not been resolved, due to 
its flexibility. Indeed, this region responds to changes in Ca
2+ levels by altering its 
association with actin-tropomyosin on the thin filament (Takeda et al 2003). This 
movement could conceivably influence the proximity of the PDE and anchored PKA, 
favouring cAMP hydrolysis and inhibition of the kinase at specific times in the cardiac 
cycle. The PDE4D9-TnI interaction was found to be mediated by two neighbouring lysine 
residues (K178/K179), and could be disrupted using a cell permeable peptide, resulting in 
robust phosphorylation of TnI at Ser22/Ser23 in the absence of other stimuli (Figure 4-
16). Cell permeable peptide disruptors have previously been shown by us to confer 
protection against cardiac hypertrophy in cultured NRVM, as determined by 
measurements of cell size, and expression of genes consistent with a hypertrophic 
response (Sin et al 2011). A number of strategies have been employed to attenuate PDE4 
activity in cells to date, such as the development of knockout mice (Lehnart et al 2005), 
and RNA interference techniques (De Arcangelis et al 2009, Lynch et al 2007). These 
strategies affect the expression of either whole subfamilies of PDE4, or the whole of one 
isoform, and therefore cannot give specific information on the role of a single pool of PDE 
within a macromolecular complex. Peptide disruption of a specific PDE complex 
represents a superior strategy for determining the localised actions of PDEs. This method 
is particularly useful for isoforms such as PDE4D9, which appear to have multiple roles 
within the cell. The novel TnI-PDE4D9 disruptor peptide increased basal levels of 
phosphorylated TnI, and might therefore be expected to promote cardiac contraction. 
Further experiments are needed to show that the effects observed on TnI 
phosphorylation are in fact due to peptide-induced dissociation of the TnI-PDE4D9 
complex, including attenuation of the co-immunoprecipitation and co-localisation of the 
two proteins. The peptide’s actions should also be confirmed in an ELISA assay using 
purified proteins. Clearly, the physiological effects of this peptide in cardiac cells also 
need to be investigated. TnI Ser22/Ser23 phosphorylation is necessary for the lusitropic 
response to β-agonists, and so the rate of relaxation of cardiac myocytes in the presence 
and absence of peptide should be determined. It would also be interesting to investigate 
whether any other feedback mechanisms of control exist within this complex. mAKAP-
associated PDE4D3 is phosphorylated by PKA following activation of the kinase, and this 
serves to enhance activity of the PDE, promoting cAMP hydrolysis. This process is     Chapter 4  Results       
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reversed by mAKAP-associated PP2A (Dodge-Kafka et al 2010). A similar mechanism of 
control may exist for the pool of PDE4D9 which is associated with TnI.  
 
Interestingly, the two lysine residues which mediate PDE binding to TnI form part of a 
predicted sumoylation site. SUMO (small ubiquitin-related modifier) is a reversible post-
translational modification of lysine residues which has been linked to an extremely 
diverse range of protein outcomes, including protein stability and cell trafficking (Geiss-
Friedlander & Melchior 2007). Recently, it was shown that SERCA2 is sumoylated at K480 
and K585, and that this modification is essential to maintain the stability and activity of 
the Ca
2+ pump (Kho et al 2011). Furthermore, the levels of SUMO1 and sumoylation of 
SERCA2 were found to be reduced in failing hearts (Kho et al 2011). The VK
178K
179E 
sequence on TnI is strongly predicted to be a sumoylation site using commercially 
available software (SUMOsp 2.0), and it would be fascinating to confirm this as a genuine 
SUMO site using in vitro sumoylation assays. If TnI is sumoylated at this site, this 
modification could potentially influence the physiological response to β-agonist 
stimulation by altering the stability of the myofilament protein, or perhaps induce a 
conformational change that alters PDE binding.  
 
The final experiments in this chapter aimed to identify an AKAP for the TnI-PDE4D9 
complex. Ht31 peptide experiments failed to show the presence of an AKAP in mediating 
the cAMP-dependent PKA phosphorylation of TnI. This directly contraindicates previous 
work from 2001 which found that the presence of Ht31 in cells significantly reduced PKA 
phosphorylation of TnI (Fink et al 2001). Fink and co-workers performed their 
experiments in adult rat ventricular myocytes infected with adenoviral-Ht31 constructs. 
These vectors may have been preferentially taken up into cells, in contrast with the 
stearylated peptide used in my experiments. Stearylation of peptides is a commonly used 
technique to improve their membrane permeability (Futaki et al 2001), but it is probable 
that at the concentration used, Ht31 did not reach the myofilament in significant 
quantities to interfere with AKAP-PKA interactions.  
 
Prior to commencing this study, very little was known about AKAP scaffolding of PKA at 
the myofilament, though immunocytochemical staining of cardiac myocytes had     Chapter 4  Results       
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demonstrated a striated distribution for RII, consistent with myofilament anchoring of 
PKA (Fink et al 2001). Two proteins associated with the myofilament, myospryn and 
synemin, have since been shown to possess RII binding domains. Myospryn is a large 
costameric protein which functions to couple sarcomeres to the sarcolemma (Sarparanta 
2008), and has been shown to localise with RIIα at the peripheral Z disc (Reynolds et al 
2007). Synemin performs a similar function, and was found to co-immunoprecipitate with 
RII in adult rat cardiac myocytes (Russell et al 2006). However, neither of these putative 
AKAPs have been shown to directly affect the phosphorylation of myofilament proteins 
such as TnI. Within the last 12 months, one study has identified cardiac troponin T as a 
novel dual specificity sarcomeric AKAP (Sumandea et al 2010). A yeast two hybrid screen 
of human heart cDNA libraries identified TnT as an RII interacting protein, and truncation 
analysis mapped the RII interaction site to residues 212-224 on TnT. As TnT and TnI exist 
in the same heterotrimeric complex within cells, it might be expected that a TnI 
immunoprecipitation would co-immunoprecipitate TnT and any associated PKA, and 
therefore give a positive RII overlay result. This could be verified by immunoblotting of TnI 
IPs for TnT, and if required, altering the IP conditions to ensure that this co-
immunoprecipitation is occurring, before repeating the overlays. Sumandea and co-
workers utilised a combination of co-expression of epitope-tagged TnT and PKA R 
subunits in HEK293 cells, GST pulldown assays and peptide arrays to demonstrate an 
interaction between PKA and TnT, and it would be interesting to determine whether this 
interaction is also observed endogenously in the heart, and whether disruption of the 
interaction affects the phosphorylation of TnI, and the physiological outcomes associated 
with this modification.  
 
TnT has been proposed to be a dual specificity AKAP, capable of binding both PKA RI and 
RII subunits. Most AKAPs are RII-selective, exhibiting high affinity for the N terminal 
region of PKA RII; however, several dual specificity AKAPs have now been identified, 
including ezrin and AKAP220 (Welch et al 2010). Dual specificity AKAPs are also able to 
interact with RI, but typically with lower affinity than RII, due to structural differences in 
the N terminal region of RI (Herberg et al 2000). RI binding to dual specificity AKAPs can 
be enhanced by the presence of an additional amino acid sequence in proximity to the 
amphipathic helix, termed an RI-specific region, or RISR (Welch et al 2010). Such a     Chapter 4  Results       
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sequence was identified in TnT (Sumandea et al 2010). If TnT in fact anchored 
predominantly PKA RI in cardiac myocytes, and TnI was phosphorylated by this pool of 
PKA RI, this would explain the failure of PKA RII-based overlays to detect AKAPs 
associated with TnI. Soluble Epac1-based cAMP FRET sensors fused to the AKAP-
anchoring domains of RI and RII have recently been used to study the relative 
localisations of RI and RII within cardiac myocytes (Di Benedetto et al 2008). RI-epac 
showed a tight striated distribution overlaying with the sarcomeric Z and M lines, 
whereas RII-epac corresponded more strongly with the M line. Prior to these 
experiments, RI was thought to have a primarily cytoplasmic distribution within cells 
(Brunton et al 1981). Thus, PKA RI is found in the same distribution as TnI, and could 
potentially mediate phosphorylation of the myofilament protein. However, β-adrenergic 
stimulation, which leads to PKA phosphorylation of TnI, has been shown to generate a 
pool of cAMP that selectively activates PKA RII over RI (Zaccolo & Pozzan 2002), which 
would infer that TnI is in fact phosphorylated by PKA RII. It would be interesting to 
specifically determine the colocalisation of TnI with both PKA RI and RII in cardiac 
myocytes, and whether selective disruption of AKAP-PKA RI interactions with RI-selective 
peptides influences the phosphorylation of TnI in any way.  
 
In summary, the data presented in this chapter indicate that PKA phosphorylation of TnI 
at Ser22/Ser23 is mediated by an anchored pool of PDE4 isoforms. PDE4D9 has been 
shown for the first time to bind directly to the flexible C terminus of TnI to regulate its 
PKA phosphorylation, and dissociation of this interaction using a novel peptide disruptor 
is sufficient to induce phosphorylation of TnI in the absence of other stimuli. Future 
experiments must investigate the physiological effects of this disruptor peptide in intact 
cells, as modulation of the TnI-PDE4D9 interaction may prove to be a novel therapeutic 
avenue for heart failure.   
    
 
 
5.                                                                            
 
AKAP-Lbc Scaffolding of PKA 
Facilitates Cardioprotective 




Reversible modification of protein function by PKA phosphorylation is critical for a vast 
array of intracellular events. The concept of compartmentalised cAMP signals activating 
discrete subcellular pools of PKA is now well accepted (Beavo & Brunton 2002). In 
addition to the generation of local cAMP gradients by PDEs, PKA is physically 
compartmentalised within the cell by AKAPs, thus limiting its availability to only a small 
subset of target proteins. AKAPs are a functionally related group of proteins characterised 
by their ability to anchor PKA (Smith & Scott 2006). AKAPs were originally envisaged as 
proteins with two motifs, one for PKA anchoring and one for subcellular targeting of the 
AKAP-PKA complex (Dodge & Scott 2000); however, the discovery that they could also 
anchor protein phosphatases highlighted another important property of AKAPs, their 
ability to scaffold other key signaling enzymes (Fraser & Scott 1999). It is now appreciated 
that AKAPs form the core of macromolecular signaling complexes, or ‘signalosomes’. 
Within these complexes, kinases and phosphatases are held in close proximity to 
effectors and substrates, facilitating the rapid and efficient transmission of intracellular 
second messenger signals (Welch et al 2010). Thus, AKAPs enable both the spatial and 
temporal regulation of compartmentalised cAMP/PKA signaling.      Chapter 5  Results       
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A number of macromolecular signaling complexes have been identified in the heart that 
function to regulate excitation-contraction coupling. One of the best characterised is the 
mAKAP-ryanodine receptor complex located at the sarcoplasmic reticulum and nuclear 
membrane of cardiac myocytes (described in Section 1.6.4.1). mAKAP positions PKA close 
to a consensus phosphorylation site on the RyR calcium release channel, and PKA 
phosphorylation at this site enhances the open probability of the channel (Marx et al 
2000). mAKAP also tethers adenylyl cyclase 5, PDE4D3 and the protein phosphatases 
PP2A and PP2B in addition to PKA and the RyR, and the anchored PDE4D3 recruits Epac1 
and ERK5 to the complex. Therefore, cAMP and Ca
2+ second messenger signals may be 
integrated with growth factor signals and specifically disseminated by one signaling 
network, which is subject to very intricate internal controls (Dodge-Kafka et al 2005). 
AKAP-nucleated signalosomes have now been described that regulate the voltage-gated 
potassium channel (Terrenoire et al 2009), the SERCA2 Ca
2+ ATPase (Lygren et al 2007) 
the L-type calcium channel (Gao et al 1997, Leroy et al 2011) and the β-adrenergic 
receptor (Wang et al 2006) in the heart. 
 
PKA phosphorylation events are integral to many essential cardiac processes, from the 
modulation of contraction dynamics described in Chapter 4, to cell survival and 
cardioprotection (Fan et al 2004a, Fan et al 2003). Myocardial ischaemia, resulting from 
impairment of coronary blood supply, is a major cause of morbidity and mortality in the 
Western world (Murphy & Steenburgen 2008). Ischaemia leads to apoptosis and necrosis 
(myocardial infarction) which manifests clinically as ventricular dysfunction and cardiac 
failure. Strategies which restore coronary perfusion and prevent progression to infarction 
reduce morbidity and mortality (Mudd & Kass 2008), and there is currently much interest 
in understanding the mechanisms by which the heart protects itself from ischaemic 
injury, in order to identify new therapeutic avenues.  
 
A variety of kinases are activated during myocardial ischaemia, including PKA and PKC 
(Heusch et al 2008). It is increasingly recognised that one of the major mediators of 
cardioprotective signaling is the small heat shock protein Hsp20. Hsp20 is phosphorylated 
by PKA (and PKG) on Serine 16 at its N terminus, and this modification enhances its 
cardioprotective actions (Beall et al 1999, Fan et al 2005a). Both Hsp20 expression levels     Chapter 5  Results       
131 
 
and its phosphorylation on Ser16 are increased in ischaemic myocardium. Phospho-
mimics of Hsp20 (Ser16 to Asp mutants) confer improved protection from β-agonist-
induced apoptosis in the heart, whereas phospho-null mutants (Ser16 to Ala) provide no 
protection (Fan et al 2004b).  Furthermore, naturally occurring mutants of Hsp20 at 
position 20 (P20L substitution) are associated with markedly reduced Hsp20 
phosphorylation at Ser16, and this lack of phosphorylation correlates with abrogation of 
Hsp20’s cardioprotective effects (Nicolaou et al 2008).   
 
Although the extracellular stimuli which invoke PKA phosphorylation at Hsp20-Ser16 have 
been well studied, the signaling events which regulate this modification were poorly 
understood until recently. Work from our laboratory has now identified a specific 
interaction between Hsp20 and PDE4 isoforms (Sin et al 2011). Inhibition of PDE4 is 
sufficient to induce Hsp20-Ser16 phosphorylation in resting cells, and to augment its 
phosphorylation in β-agonist-stimulated cells. Peptide array technology identified a 
binding site for Hsp20 on the conserved catalytic domain of PDE4, and this information 
was used to design a cell permeable peptide which inhibited the interaction of Hsp20 and 
PDE4. This peptide disruptor was shown to induce PKA phosphorylation of Hsp20 in 
unstimulated cells, and to protect against β-agonist-induced hypertrophy in neonatal 
cardiac myocytes, and could therefore represent a promising new therapeutic tool (Sin et 
al 2011). Hsp20 was also recently shown to interact with the protein phosphatase PP1 at 
the sarcoplasmic reticulum to modulate Ca
2+ handling (Qian et al 2011), and could 
therefore participate in one of the macromolecular signaling complexes described above. 
However, to date, no AKAP has been identified to scaffold the pool of PKA that 
phosphorylates Hsp20.  
 
 
5.1.1 Experimental aims 
Hsp20 associates with PDE4 and PP1, and is known to be phosphorylated by PKA at its N 
terminus. Preliminary studies using the AKAP-competing peptide Ht31 blunted PKA 
phosphorylation of Hsp20 in neonatal rat ventricular cardiac myocytes, indicating the     Chapter 5  Results       
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association of Hsp20 and an AKAP in a multi-protein complex. The aim of the 
experimental work detailed in this chapter was to identify this AKAP, and to determine 
whether disruption of the Hsp20-AKAP interaction significantly impacted upon Hsp20’s 
cardioprotective functions.  
 
5.1.2 Experimental procedure 
1)  The presence of an AKAP to mediate PKA phosphorylation of Hsp20 was 
confirmed using Ht31 peptide and RII overlay.  
 
2)  Association of Hsp20 with a cytosolic AKAP was demonstrated by co-
immunoprecipitation and co-localisation studies.  
 
3)  Specific siRNA-mediated knockdown of AKAP expression and transfection of AKAP 
binding mutants were used to determine changes in the PKA phosphorylation 
status of Hsp20 and the effects on apoptosis. 
 
4)  GST-tagged AKAP fragments were used in a pulldown assay to map the binding 
site for Hsp20 on the AKAP. 
 
5)  The presence of PDE4 in an AKAP-Hsp20 complex was confirmed by co-




5.2.1 An AKAP mediates Ser16 phosphorylation of Hsp20  
The small heat shock protein Hsp20 can be phosphorylated by PKA at Ser16 on its N 
terminus. To confirm that an AKAP mediated the scaffolding of the pool of PKA that 
phosphorylates Hsp20, an Ht31 peptide assay was used. Neonatal rat ventricular cardiac 
myocytes (NRVM) were treated with cell-permeable AKAP-disrupting Ht31 peptide (as in     Chapter 5  Results       
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Section 4.2.7) or a control peptide, Ht31P, which is unable to bind PKA RII. Cells were then 
stimulated with the β-agonist isoproterenol (Iso) to activate PKA, and levels of phospho-
Ser16 Hsp20 were assessed (Figure 5-1). In the absence of Iso, Hsp20 remained basally 
phosphorylated, and there was no significant difference in the phosphorylation of Hsp20 
in cells treated with Ht31, Ht31P, or no peptide. Following Iso stimulation, Hsp20 was 
rapidly phosphorylated at Ser16 by PKA in cells without peptide and in cells treated with 
the control Ht31P peptide, which is unable to disrupt AKAP-PKA interactions. However, in 
cells treated with the AKAP-competing peptide Ht31, Hsp20 showed significantly less PKA 
phosphorylation (P<0.01), strongly indicating that AKAP-mediated PKA anchoring is 
necessary for this phosphorylation event to occur (Figure 5-1). 
 
 




Figure 5-1 Effect of Ht31 treatment on PKA phosphorylation of Hsp20 at Ser16. 
NRVM were treated for 30 minutes with 50µM of Ht31 or Ht31P peptides (Promega), or 
remained untreated (no peptide). Peptides were stearated to increase their membrane 
permeability. Cells were then stimulated with 1nM isoproterenol (Iso) for 5 minutes to activate 
PKA, and levels of phosphorylated Ser16 Hsp20 and total Hsp20 determined by Western 
immunoblotting of cellular lysates and compared to unstimulated cells (no treatment). A. 
Representative immunoblot of phospho-Ser 16 and total Hsp20 levels. B. Quantification of data 
in part A. Ht31 treatment significantly reduced PKA phosphorylation of Hsp20 compared with 
Ht31P treatment or no treatment in Iso-stimulated cells (P<0.01). An n of 3 experiments were 
performed, and data normalised to the maximum level of phosphorylation. The graph 
represents means ± SEM. ** P<0.01.     Chapter 5  Results       
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5.2.2 RII overlay identifies a ~300kDa AKAP associated with 
Hsp20 
To identify AKAPs specifically associating with Hsp20, an immunoprecipitation (IP) of 
Hsp20 was performed in NRVM, and subjected to RII overlay (as in Section 4.2.7) with 
32P-
labelled RII subunits, followed by autoradiography (Figure 5-2A). Numerous RII binding 
proteins were detected in the cardiac myocyte lysate as expected (‘input’ lane); however, 
no AKAP could be shown to co-immunoprecipitate with Hsp20 by this method. 
 
The failure of the 
32P RII overlay could be due to either the immunoprecipitation 
conditions, or the sensitivity of the technique. Immunoprecipitation using an epitope tag 
can enhance the amount of precipitated protein. Hsp20 was therefore cloned into the 
pcDNA3.1/V5-His TOPO vector (Invitrogen) to add a V5 epitope tag, and the Hsp20 IP 
performed using anti-V5 antibody in lysate from HEK293 cells transfected with this 
plasmid. The overlay was repeated on an Hsp20-V5 IP using RII labelled with the small, 
highly immunogenic molecule, digoxigenin, in order to increase the sensitivity of the 
overlay (Figure 5-2B) (see Section 4.2.7). This time, a very faint band corresponding to an 
RII-binding protein could be detected which co-immunoprecipitated with Hsp20. This 
protein was large, with a molecular weight of approximately 300kDa. A corresponding 
band can be identified in the input lanes of the 
32P and digoxigenin overlays; however it is 
much fainter in the 




Figure 5-2 RII overlays of an Hsp20 immunoprecipitation.  
A. Autoradiograph of a 
32P RII overlay of an Hsp20 endogenous immunoprecipitation from 
NRVM. A number of RII binding proteins can be identified in the cellular lysate (input lane), but 
no AKAP can be identified co-immunoprecipitating with Hsp20. B. Digoxigenin (Dig)-RII overlay 
of a V5 IP. Hsp20-V5 was transfected into HEK293 cells, and immunoprecipitated using the V5 
epitope tag. A 300kDa AKAP can be identified in the Hsp20-V5 immune complex. 
 
 
5.2.3 Hsp20 interacts with the cytosolic AKAP Lbc 
A number of AKAPs have been identified in the heart (Table 1-5), including AKAP79/150, 
gravin (Wang et al 2006), AKAP15/18 (Lygren et al 2007), mAKAP (Dodge et al 2001) and 
AKAP-Lbc (Carnegie et al 2008). AKAP-Lbc is the 320kDa product of the AKAP13 gene, and 
on the basis of molecular weight, appeared most likely of these cardiac AKAPs to     Chapter 5  Results       
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represent the Hsp20-associated AKAP identified by the digoxigenin-RII overlay above. To 
test this hypothesis, HEK293 cells were co-transfected with Hsp20-V5 and Flag-AKAP-Lbc 
constructs, and co-immunoprecipitation studies were performed (Figure 5-3A and B). 
Hsp20-V5 was clearly detected in Flag immunoprecipitations of AKAP-Lbc (Figure 5-3A, 
upper panel). The reciprocal immunoprecipitation was then performed; however, only a 
small amount of Flag-AKAP-Lbc co-immunoprecipitated with Hsp20-V5 despite various 
conditions being tested (Figure 5-3B, upper panel). This may be due to stoichiometric 
reasons, or due to the difficulties of immunoprecipitating a complex containing such a 
large protein.  
 
In order to provide more physiological evidence for the Hsp20-AKAP-Lbc association, the 
experiment was repeated in NRVM. Endogenous Hsp20 was detected in AKAP-Lbc 
immunoprecipitations using an anti-AKAP-Lbc antibody (Figure 5-3C); however, the 












Figure 5-3 Immunoprecipitation studies of Hsp20 and AKAP-Lbc in transfected and 
untransfected cell lines. 
 A. Lysates from HEK293 cells co-transfected with Hsp20-V5 and Flag-AKAP-Lbc were 
immunoprecipitated using anti-Flag antibody or normal IgG as a control, separated by gel 
electrophoresis and immunoblotted with anti-V5 antibody to detect co-immunoprecipitation of 
Hsp20-V5. Prior to blotting, nitrocellulose membranes were cut at 100kDa and the upper half of 
the membrane immunoblotted with anti-Flag antibody to check the efficacy of the IP (lower 
panel).   B. Lysates from the same cells were immunoprecipitated with anti-V5 antibody and 
immunoblotted with anti-Flag and anti-V5 antibodies as indicated. The pEGFP-N1-Flag-AKAP-
Lbc plasmid and anti-AKAP-Lbc antibody (V096) were kind gifts from Dr Donelson Smith, 
University of Washington, Seattle. C. Endogenous AKAP-Lbc was immunoprecipitated from 
NRVM lysate using V096 antibody which is raised against the N terminus of AKAP-Lbc (Table 3-
1). Cellular lysates were immunoblotted for total Hsp20 and AKAP-Lbc. Hsp20 could be 
identified in the AKAP-Lbc immune complex. D. Prolonged exposure of AKAP-Lbc IP from part C, 
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Immunofluorescence microscopy was then used to visualise the distribution of these two 
proteins in cells. AKAP-Lbc has previously been shown to localise to the cytosol and peri-
nuclear region of NRVM (Carnegie et al 2008). NRVM were fixed and immunostained for 
Hsp20 and AKAP-Lbc as indicated. Analysis of these images confirmed that the 
distribution of Hsp20 and AKAP-Lbc overlapped in these cells with a Pearson co-efficient 
of 0.710, consistent with a high degree of colocalisation.  
 
 
Figure 5-4 Colocalisation of Hsp20 and AKAP-Lbc in neonatal rat cardiac myocytes.  
Colocalisation (yellow regions) of Hsp20 (red) and AKAP-Lbc (green) was determined by fixation 
of rat ventricular cardiac myocytes in methanol/paraformaldehyde as described in Section 
3.6.2, and staining for immunofluorescence with anti-HspB6 (Hsp20) and anti-V096 (AKAP-Lbc) 
antibodies. Images were obtained at 63x magnification on a Zeiss Pascal Confocal microscope, 
and collected using Zeiss Pascal software. A Pearson colocalisation coefficient (r) was calculated 
using Image J software. For these images, r = 0.710, indicating a high degree of colocalisation. 
Scale bars represent 20µM.  
 
 
5.2.4 AKAP-Lbc is required for PKA phosphorylation of 
Hsp20 
5.2.4.1. Selective knockdown of AKAP-Lbc abolishes β-agonist-induced increases 
in PKA phosphorylation of Hsp20 
The above experiments provide evidence for the existence of Hsp20 and AKAP-Lbc 
together in a complex within cells. In order to establish that AKAP-Lbc is responsible for 
scaffolding a pool of PKA that is able to phosphorylate Hsp20 within this complex, I 
examined the effects of AKAP-Lbc gene silencing on β-agonist-induced PKA 
phosphorylation of Hsp20. Small interfering RNA (siRNA) against AKAP-Lbc was used to     Chapter 5  Results       
140 
 
selectively knockdown AKAP-Lbc expression, and phosphorylation of Hsp20 at Ser16 in 
the presence and absence of Iso was determined by Western immunoblotting (Figure 5-
5). Scrambled siRNA was used as a control. AKAP-Lbc siRNA knockdown experiments were 
performed in human cardiac myocytes (HCM), which are isolated from human ventricles. 
The HCM cell line was chosen as significant knockdown of AKAP-Lbc expression could be 
achieved by this RNA interference technique. The efficiency of AKAP-Lbc knockdown was 
confirmed by immunoblotting. 
 
AKAP-Lbc siRNA-mediated knockdown resulted in a very marked reduction in the 
expression of AKAP-Lbc protein, whereas treatment with scrambled control siRNA had no 
effect on protein levels (Figure 5-5A, lower panel). In unstimulated cells, levels of PKA-
phosphorylated Hsp20 were low, as expected, and no significant difference was observed 
between levels of phosphorylated Hsp20 in control siRNA and AKAP-Lbc siRNA-treated 
cells (Figure 5-5A, upper panel; Figure 5-5B). Following β-adrenergic stimulation and 
activation of PKA, selective knockdown of AKAP-Lbc completely abolished the expected 
increase in PKA phosphorylation of Hsp20, whereas control siRNA treatment had no 
effect (P<0.05). Thus, AKAP-Lbc scaffolding of PKA is required for β-agonist-induced Ser16 








Figure 5-5 AKAP-Lbc gene silencing attenuates the PKA phosphorylation of Hsp20 observed in 
response to β-agonists. 
HCM cells were transfected with siRNA against AKAP-Lbc or scrambled control siRNA. Indicated 
cells were stimulated with 1nM Iso for 5 minutes immediately prior to harvesting. Lysates were 
separated by gel electrophoresis and immunoblotted with anti-phospho-Ser16 or total Hsp20 
antibodies. A. Upper panel: Representative immunoblots of phospho-Ser16 and total Hsp20 
levels. B. Lower panel: AKAP-Lbc immunoblot of the same samples using V096 antibody, 
indicating efficient knockdown of AKAP-Lbc protein expression. B. Quantification of data from 
part A. Means ± SEM are shown for an n of 3 experiments. Data are normalised to the 
maximum level of phosphorylation observed. Hsp20-Ser16 phosphorylation was significantly 




5.2.4.2. PKA anchoring mutants of AKAP-Lbc disrupt cAMP-dependent Hsp20 
phosphorylation 
The role of AKAP-Lbc in anchoring a pool of PKA that mediates phosphorylation of Hsp20 
was further confirmed in NRVM using an AKAP-Lbc mutant, AKAP-Lbc ΔPKA. AKAP-Lbc 
ΔPKA contains two proline mutations in its RII binding domain (Ala1251Pro and Ile 
1260Pro) that disrupt the secondary structure, rendering it unable to anchor PKA (Diviani 
et al 2001, Smith et al 2010). NRVM were transfected with either AKAP-Lbc ΔPKA or 
vehicle only (mock transfected), and levels of phosphorylated Hsp20 in the presence and 
absence of Iso stimulation were determined by Western immunoblotting (Figure 5-6). As 
expected, robust cAMP-dependent phosphorylation of Hsp20 at Ser16 was observed in     Chapter 5  Results       
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Iso-stimulated cells transfected with vehicle alone. Levels of Hsp20 Ser16 phosphorylation 
were significantly reduced in both Iso-stimulated and unstimulated cells transfected with 
AKAP-Lbc ΔPKA when compared to mock transfections (P<0.05 and P<0.01 respectively). 
This is consistent with the anchoring mutant exerting a dominant negative effect, in other 
words, ”competing out” wildtype AKAP-Lbc for the interaction with Hsp20. Thus, AKAP-
Lbc anchors PKA to facilitate Hsp20 phosphorylation on Ser16.  
 
Figure 5-6 A PKA anchoring mutant of AKAP-Lbc attenuates Hsp20 Ser16 phosphorylation.  
A. NRVM were mock transfected or transfected with AKAP Lbc ΔPKA, a PKA anchoring-defective 
mutant, and then stimulated with 1nM Iso for 5 minutes or left unstimulated (no treatment). 
Hsp20 phosphorylation was determined by Western immunoblotting. The pEGFP-N1-AKAP-Lbc 
ΔPKA plasmid was kindly provided by Donelson Smith.  A. Representative immunoblot of 
phospho-Ser16 and total Hsp20 levels. B. Quantification of data in part A. Data was from an n of 
4 experiments, and is presented as means ± SEM. In both Iso-treated and unstimulated cells, 
transfection with the ΔPKA mutant led to a significant reduction in PKA phosphorylation of 
Hsp20 (*P<0.05 and **P<0.01 respectively). 
 
 
5.2.5 AKAP-Lbc scaffolding of PKA is required for the anti-
apoptotic cardioprotective function of Hsp20 
The cardioprotective abilities of Hsp20 are known to be enhanced following PKA 
phosphorylation of the heat shock protein on Ser16 (Beall et al 1999, Fan et al 2004a). 
Overexpression of Hsp20 mutants where Ser16 has been mutated to Asp to mimic     Chapter 5  Results       
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constitutive phosphorylation (S16D) has previously been shown to protect against 
apoptosis induced by chronic β-adrenergic stimulation, resulting in a 25% reduction in 
caspase-3 activity (Fan et al 2004a).  However, cells transfected with phospho-null 
mutants (Hsp20-S16A) exhibit no protection from apoptosis. In order to determine 
whether disruption of the Hsp20-AKAP-Lbc interaction significantly impacted upon 
Hsp20’s cardioprotective functions, cells were transfected with the AKAP-Lbc ΔPKA 
anchoring defective mutant and the effects on apoptosis measured using a commercially 
available luminescence assay of caspase-3 activity (Section 3.7.2). Cells were chronically 
stimulated with Iso to induce apoptosis. Cells transfected with the ΔPKA mutant exhibited 
a doubling of caspase-3 activity, which is proportional to apoptosis (Figure 5-7). In order 
to show that this effect was due to a reduction in Hsp20 phosphorylation, cells were then 
co-transfected with either Hsp20-S16D or Hsp20-S16A mutants. S16D co-transfection was 
associated with a reduction in caspase-3 activity, whereas transfection of the S16A 
phospho-null mutant had no effect. Thus, Hsp20-S16D can partially rescue the apoptotic 
phenotype induced by AKAP-Lbc ΔPKA.  
 
Figure 5-7 Apoptosis is increased in NRVM transfected with PKA anchoring mutants of AKAP-
Lbc. 
NRVM were transfected with AKAP-Lbc ΔPKA alone, or in conjunction with Hsp20-S16D and 
Hsp20-S16A. Cells were stimulated with 10µM isoproterenol for 24 hours prior to the assay to 
induce apoptosis. Untransfected cells were used as a control. Caspase-3 activity was measured 
in a luminescence assay (described in Section 3.7.2). Hsp20-S16D conferred partial protection 
against β-agonist-induced apoptosis, as determined by a reduction in caspase-3 activity, 
whereas S16A mutants had no effect. Data represents the mean ± SEM of an n of 3 
experiments.     Chapter 5  Results       
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5.2.6 Hsp20 interacts with a central region of AKAP-Lbc  
The above data indicate a physical association between Hsp20 and AKAP-Lbc, and that 
AKAP-Lbc mediates the cAMP-dependent PKA phosphorylation of Hsp20 at Ser16. AKAP-
Lbc is a large 320kDa multi-domain protein which directly interacts with a number of key 
signaling enzymes, including PKA (Diviani et al 2001), PKCη and PKD (Carnegie et al 2004), 
B-RAF, and the signaling scaffold protein KSR-1 (Smith et al 2010). In order to gain insight 
into where Hsp20 binds on the AKAP, I utilised GST fusion proteins encompassing specific 
regions of AKAP-Lbc in a GST pulldown assay. These fusion proteins have previously been 
used by others to map the binding sites for PKA, PKC and PKD on AKAP-Lbc (Carnegie et al 
2004).  
 
GST-AKAP-Lbc fragments in pGEX-4T1 were expressed in BL21(DE3)pLysS cells and 
purified as described in Section 3.5.2.2. Six N terminally tagged fusion proteins were 
generated, covering the full length of AKAP-Lbc (Figure 5-8A). Each of these purified GST-
AKAP-Lbc fragments was then used in a pulldown assay, by incubating them with HEK293 
lysate containing overexpressed Hsp20-V5. Incubations of the same lysate with GST and 
with glutathione beads in the absence of fusion protein were also performed as negative 
controls. Expression of the AKAP-Lbc fragments was confirmed by gel electrophoresis of 
protein samples and Coomassie staining (Figure 5-8B, lower panel). Fragments 2-5 
showed reasonable expression; however fragments 1 and 6 were only poorly expressed, 
despite varying the conditions used for protein expression and purification, and some 
degradation of all fusion proteins was evident. 
 
Immunoblotting of GST pulldown supernatants with an antibody against the V5 epitope 
tag of Hsp20 demonstrated that fragment 4 of AKAP-Lbc interacted with Hsp20-V5 (Figure 
5-8B, upper panel). This 534 amino acid region, encompassing amino acids 1388-1922, is 
adjacent to the PKA anchoring domain of AKAP-Lbc (located within fragment 3), and 
binding of the heat shock protein here could be envisaged to favour its Ser16 




Figure 5-8 The interaction site for Hsp20 on AKAP-Lbc can be mapped to a central region of the 
AKAP using GST-AKAP-Lbc fusion proteins.  
pGEX-4T1 plasmids encoding GST fusion proteins encompassing specific regions of AKAP-Lbc 
were a kind gift from Donelson Smith. Fusion proteins were expressed in BL21(DE3)pLysS cells 
and purified as detailed in Section 3.5.2.2. Fusion proteins (Frags 1-6) or purified GST protein 
were attached to glutathione beads (Section 3.5.2.2), and incubated with lysate from HEK293 
cells overexpressing Hsp20-V5. Lysate was also incubated with glutathione beads (‘beads 
alone’) and purified GST alone as negative controls. Beads were washed to remove unbound 
proteins, boiled in protein sample buffer, and samples separated by gel electrophoresis and 
analysed by immunoblotting. A. Schematic representation of AKAP-Lbc fragments used for GST 
fusion proteins. The shaded area represents an Hsp20 binding fragment identified in part B. 
Adapted from (Smith et al 2010). B. Upper panel: Representative immunoblot of Hsp20-V5 
pulldown by GST-AKAP-Lbc fragment 4. Lower panel: Coomassie stain of GST-AKAP-Lbc fusion 
proteins and GST, separated by gel electrophoresis. Colours are inverted to enhance 
visualisation of the protein fragments.  
 
The above mapping study illustrates a direct interaction of Hsp20 with the central portion 
of AKAP-Lbc, between residues 1388 and 1922. AKAP-Lbc contains several protein 
interaction modules, including C terminal Dbl homology and pleckstrin homology     Chapter 5  Results       
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domains, and a cysteine-rich region homologous to the C1 domain of PKC, which is also 
located within fragment 4 (residues 1792-1830) (Diviani et al 2001). This mapping study 
must be interpreted with caution, as fragments 1 and 6 of AKAP-Lbc could only be 
expressed at very low levels, and therefore any binding of Hsp20 to these regions might 
not have been detected. In order to provide further evidence for a specific interaction 
between Hsp20 and the central region of AKAP-Lbc, I made use of equivalent N terminal 
Myc-tagged AKAP-Lbc fragments (Figure 5-9A). HEK293 cells were transfected with 
Hsp20-V5, and then co-transfected with vectors encoding Myc-AKAP-Lbc fragments 1-6. 
Lysates were then immunoprecipitated with anti-V5 antibodies or control IgG, separated 
by gel electrophoresis, and nitrocellulose membranes subjected to immunoblot analysis 
with anti-myc antibodies (Figure 5-9B, upper panels). Samples were also immunoblotted 
with anti-V5 antibodies to determine the efficacy of the immunoprecipitations (Figure 5-
9B, lower panels). Fragments 1 and 5 were expressed at lower levels, despite increasing 
the amount of transfected DNA in these cells. Myc-AKAP-Lbc fragment 4 was found to co-
immunoprecipitate with Hsp20-V5. This is consistent with the data from the GST 
pulldown assay described above; thus, it appears that an Hsp20 binding site is present 
within fragment 4 of AKAP-Lbc.  





Figure 5-9 Hsp20-V5 and Myc-AKAP-Lbc fragment 4 co-immunoprecipitate in HEK293 cells. 
Myc-AKAP-Lbc fragments in pDEST12-myc were provided by Donelson Smith. Each fragment 
was co-transfected into HEK293 cells with Hsp20-V5, and anti-V5 immunoprecipitation 
performed. A.  Schematic representation of Myc-Lbc fragments used in this experiment. AKAP 
fragments are identical to those used in the GST pulldown experiment above, but possess a Myc 
tag instead of GST. The shaded area represents an Hsp20 binding fragment. Adapted from 
(Smith et al 2010). B. V5 immunoprecipitations of transfected HEK293 cell lysates. Samples were 
separated by gel electrophoresis, transferred to nitrocellulose and membranes divided at the 
37kDa molecular weight marker. The top half of each membrane was immunoblotted with anti-
myc antibodies to determine which myc-AKAP-Lbc fragments formed an immunocomplex with 
Hsp20-V5 (upper panels). The bottom half of each membrane was probed with anti-V5 
antibody, to assess the efficacy of the IP (lower panels). 
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5.2.7 The AKAP-Lbc-Hsp20 macromolecular complex 
includes PDE4D 
5.2.7.1. Expression and localisation of an Hsp20-linked cAMP FRET sensor 
It is increasingly appreciated that the presence of phosphodiesterase enzymes in 
macromolecular complexes, along with AKAPs and other proteins, allows for the precise 
regulation of cAMP/PKA signal transduction cascades (Houslay 2010). The experimental 
work detailed so far in this chapter provides evidence for the specific association of AKAP-
Lbc with the small heat shock protein Hsp20, to mediate its cAMP-dependent PKA 
phosphorylation on Ser16. Recently, a study from our laboratory has demonstrated a 
novel interaction between Hsp20 and specific PDE4 isoforms (Sin et al 2011). In this 
publication, I employed a novel FRET sensor targeted to Hsp20, akin to the targeted 
TnI:Epac1-camps sensor described in Section 4.2.1, to investigate which PDEs modulate 
the pool of cAMP around Hsp20 (Figure 5-10A). This sensor was designated Hsp20:Epac1-
camps. 
 
Epac1-camps and Hsp20:Epac1-camps were transfected into cultured NRVM to monitor 
their expression levels and subcellular distribution patterns (Figure 5-10B). Hsp20:Epac1-
camps showed a cytosolic and peri-nuclear distribution under YFP fluorescence, similar to 
the localisation pattern observed in NRVM which had been fixed and stained for 
immunofluorescence with anti-Hsp20 antibodies (Figure 5-10C, Figure 5-4).  
 






Figure 5-10 Localisation of Epac1-camps and Hsp20:Epac1-camps FRET sensors in NRVM.   
A. Schematic representation of the Hsp20:Epac1-camps sensor. Hsp20 was cloned 5’ of Epac1-
camps sensor to generate a novel fusion protein  (Section 3.6.1.1.). Cloning was performed by 
Dr Jon Day. B. YFP fluorescence images of Hsp20:Epac1-camps and Epac1-camps sensors in 
transfected NRVM. Hsp20:Epac1-camps localises to the cytosol and peri-nuclear region of 
NRVM, while Epac1-camps shows purely cytoplasmic distribution, as it lacks any localisation 
sequences. Images were obtained from live cells using a laser confocal microscope at 100x 
magnification. These images are published in (Sin et al 2011). C. Immunocytochemical analysis 
and fluorescence microscopy of fixed NRVM stained with anti-HspB6 antibody against Hsp20, 
showing a similar distribution pattern to the Hsp20 FRET sensor.  
 
 
5.2.7.2. A targeted FRET sensor reveals that PDE4 modulates the pool of cAMP 
around Hsp20 
In Chapter 4 of this thesis, I demonstrated that the majority of cAMP hydrolytic activity in 
NRVM is provided by members of the PDE4 family, and that members of this family 
associate with cardiac troponin I to regulate its PKA phosphorylation. I therefore 
hypothesised that PDE4 family members might also regulate cAMP levels around Hsp20. 
To test this hypothesis, NRVM transfected with Hsp20:Epac1-camps were treated with 
the PDE4 inhibitor rolipram, and the FRET ratio (which is proportional to fluctuations in     Chapter 5  Results       
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cAMP levels) was measured (Figure 5-11). Epac1-camps was used as a control for all FRET 
experiments. The magnitude of response to β-adrenergic stimulation with Iso was similar 
for both Epac1-camps and the Hsp20-targeted sensor (12.9% ± 1.5% and 9.0% ± 1.7% 
change in FRET ratio respectively). Saturating levels of cAMP generated by non-selective 
inhibition of PDEs with IBMX also provoked a similar response from both sensors (Epac1-
camps, 26.4% ± 2.6%; Hsp20:Epac1-camps, 27.2% ± 2.4%) (Figure 5-11A and 5-11C).  
 
A change in FRET ratio of 4.6% ± 1.0% was measured by Epac1-camps in response to 
rolipram (Figure 5-11B and 5-11C). This is similar to the response measured in the 
previous chapter (Figure 4-5), indicating consistent behaviour of the control sensor across 
different experiments. The Hsp20:Epac1-camps sensor measured a much larger change in 
FRET ratio (11.1% ± 1.8%) than Epac1-camps (P<0.01). As the expression level of both 
sensors is similar (Figure 5-10B), this indicates that PDE4 isoforms are likely to regulate 










      
 
Figure 5-11 Measurement of cAMP levels in the vicinity of Hsp20 using a targeted FRET sensor. 
NRVM were transfected with either Hsp20:Epac1-camps or the control sensor Epac1-camps, 
stimulated with 1nM Iso, 10µM rolipram and 100µM IBMX as indicated, and FRET ratios 
measured. This figure is modified from data published in (Sin et al 2011). A. Representative 
traces of changes in FRET ratio measured by Hsp20:Epac1-camps (blue) and Epac1-camps (red) 
in response to real time stimulation with Iso. IBMX stimulation was applied once the response 
to Iso had plateaued. The magnitude of response to Iso and to IBMX stimuli was similar for both 
sensors. B. Representative traces of changes in FRET ratio measured by these sensors in 
response to real time stimulus of NRVM with rolipram, followed by IBMX. A much larger change 
in FRET ratio was detected by Hsp20:Epac1-camps with rolipram stimulus, consistent with a 
greater increase in local cAMP levels following PDE4 inhibition. C. Graph of the percentage 
change in FRET ratio for both sensors. Hsp20:Epac1-camps detected a significantly greater 
change in FRET ratio (11.1% ± 1.8%) than Epac1-camps (4.6% ± 1.0%) in response to rolipram 
stimulus (**P<0.01). Changes in FRET ratio over time are presented as dR/R0 (%), as described 
in Section 3.6.1.2. An n of 6-10 cells were used for each experimental condition.      Chapter 5  Results       
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5.2.7.3. PDE4D isoforms regulate PKA phosphorylation of Hsp20 
Following on from this observation, the phosphorylation of Hsp20 was shown to be 
modulated by PDE4 in HEKβ2 cells (Sin et al 2011), which are a cell line stably 
overexpressing the Flag- and GFP-tagged β2-adrenergic receptor (Houslay & Baillie 2006). 
This work was performed by Dr Xiang Li and Dr George Baillie. Concomitant rolipram-
induced inhibition of PDE4 coupled with Iso stimulation led to a greater increase in Ser16 
phosphorylation of Hsp20 over time than was seen following stimulation with Iso alone, 
indicating a crucial role for PDE4 in regulating this phosphorylation event (Figure 5-12A). 
PDE4D isoforms were also shown to co-immunoprecipitate with Hsp20 in this cell line 
(Figure 5-12B). Peptide array technology was then used to map the binding site for Hsp20 













Figure 5-12 PDE4D associates with Hsp20 to regulate its PKA phosphorylation via a region within 
the conserved catalytic domain of the PDE.  
This figure is adapted from (Sin et al 2011), a paper on which I am a co-author. The work 
detailed in this figure was performed by Dr Xiang Li and Dr George Baillie. A. HEKβ2 cells were 
treated with 1µM isoproterenol (isoprenaline) following pretreatment with 10µM rolipram, for 
the times shown. Lysates were immunoblotted for phospho-Ser16 and total Hsp20. 
Quantification of the data from an n of 3 experiments is presented. B. Hsp20 was 
immunoprecipitated from HEKβ2 lysates, using specific anti-sera, and lysates immunoblotted 
with anti-PDE4D antibodies. C. A PDE4D5 peptide array was overlayed with His-tagged Hsp20, 
or BSA as a control. Hsp20 was shown to bind to a sequence within the conserved catalytic unit 
of PDE4.      Chapter 5  Results       
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5.2.7.4. PDE4D isoforms and Hsp20 are present in a macromolecular complex 
with AKAP-Lbc 
The data presented so far indicate that Hsp20 associates with AKAP-Lbc and PDE4D 
isoforms. Although multiple protein kinases and other important signaling proteins have 
been shown to associate with AKAP-Lbc (Carnegie et al 2004, Diviani et al 2001, Smith et 
al 2010), as yet, no phosphodiesterase has been shown to participate in any AKAP-Lbc-
nucleated complex. Based on the experiments detailed above, I hypothesised that Hsp20 
and PDE4D should be found in a complex together with AKAP-Lbc. I therefore performed 
an immunoprecipitation of endogenous AKAP-Lbc from NRVM lysate using anti-AKAP-Lbc 
antibody (V096). A control immunoprecipitation with normal IgG was also performed. 
Both Hsp20 and PDE4D isoforms were identified as co-immunoprecipitants with AKAP-
Lbc, along with PKA R and C subunits (Figure 5-13A). PDE isoforms with a molecular 
weight corresponding to PDE4D3/8/9 and PDE4D5/7 were identified in the immune 
complex. However, it is not possible to say from  these experiments whether their 
interaction with the AKAP is direct, or is mediated by Hsp20.  
 
AKAP-Lbc immunoprecipitation complexes were then screened for PDE activity (Figure 5-
13B). The majority of PDE activity associated with AKAP-Lbc was from PDE4, consistent 
with the data above. However, there also appeared to be a smaller, but statistically 
significant, contribution from PDE3 as well. Our laboratory is currently working with 
collaborators to identify the specific PDE isoforms present in this complex.  




Figure 5-13 PDE4 activity is associated with AKAP-Lbc-Hsp20 complexes in NRVM.  
AKAP-Lbc was immunoprecipitated from NRVM using an anti-AKAP-Lbc antibody. A. Immune 
complexes were screened for the presence of PDE4D isoforms (upper panel), Hsp20 (second 
panel) and PKA subunits (lower panel) by immunoblotting with the appropriate anti-sera. 
AKAP-Lbc immunoblotting was also performed to test the efficacy of the IP (third panel). B. 
AKAP-Lbc IPs were treated with inhibitors of PDE3 (cilostamide; 10µM), PDE4 (rolipram; 10µM) 
or non-specific PDE inhibitor (IBMX; 100µM) and subjected to PDE activity assay (described in 
Section 3.7.1). All of the inhibitors tested caused a statistically significant reduction in PDE 
activity in the IP, in the following order of magnitude: non-specific PDE inhibition>PDE4 
inhibition>PDE3 inhibition. Data represents the mean ± SEM for an n of 3 experiments.                
* P<0.05; ** P<0.01. 
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Based on the experiments in this chapter, and data from (Sin et al 2011), a model of the 
macromolecular complex co-ordinated by AKAP-Lbc and Hsp20 in the heart can be 
proposed, whereby in resting cells, anchored PDE4 hydrolyses local cAMP, inactivating 
the pool of PKA anchored to AKAP-Lbc, and maintaining Hsp20 in a hypophosphorylated, 
less cardioprotective state. Following β-adrenergic stimulus, cAMP is generated and this 
saturates the tethered PDE4, leading to PKA activation and phosphorylation of Hsp20. 




Figure 5-14 Schematic representation of the macromolecular complex co-ordinated by AKAP-
Lbc and containing Hsp20 in the heart. 
AKAP-Lbc scaffolds the signaling enzymes PKA, PKCη and PKD (Carnegie et al 2008). This 
experiments presented in this chapter demonstrate a novel association between Hsp20 and 
AKAP-Lbc, which facilitates cardioprotective PKA phosphorylation of the heat shock protein on 
Ser16. Recent work from our laboratory has identified an interaction between Hsp20 and the 
catalytic unit of PDE4 (Sin et al 2011), and PDE4D isoforms were shown to be present in cardiac 
AKAP-Lbc immune complexes.  




PKA phosphorylation events are integral to cardiac processes such as excitation-
contraction coupling and cardioprotection, and therefore the precise regulation of PKA 
activity is vital to cardiac function (Bers & Despa 2006, Fan et al 2005a). cAMP-dependent 
PKA activation is regulated by the creation of localised cAMP gradients secondary to the 
actions of tethered phosphodiesterase enzymes (Houslay 2010), and by the physical 
compartmentation of discrete pools of PKA by AKAPs (Scott & Santana 2010). It is now 
appreciated that the functions of AKAPs are infinitely more complicated than simply 
scaffolding PKA; indeed, they have been shown to simultaneously associate with multiple 
binding partners to facilitate the integration of a number of diverse signaling networks 
(Smith et al 2010, Welch et al 2010). A major focus of current cyclic nucleotide research is 
on the characterisation of these macromolecular signaling complexes, or signalosomes. 
AKAP-nucleated complexes may contain various combinations of cAMP effectors (PKA, 
Epac and ion channels), signal terminating enzymes (protein phosphatases and PDEs) and 
other scaffold proteins, which can link cAMP signal transduction to Ca
2+ and growth factor 
signals (Dodge-Kafka & Kapiloff 2006, Terrenoire et al 2009). Physical 
compartmentalisation of signaling enzymes within these macromolecular complexes 
confers spatial regulation of cAMP signal transduction, whilst bringing multiple cAMP 
effectors into close proximity allows for rapid and efficient signal transmission, facilitating 
temporal regulation of cAMP signaling (Scott & Santana 2010). 
 
One of the major mediators of cardioprotection is the small heat shock protein Hsp20. 
Hsp20 is phosphorylated by PKA at Ser16 on its N terminus, and this modification is vital 
for its cardioprotective actions (Section 1.7.3.2.). As with the myofilament protein TnI, 
levels of phosphorylated Hsp20 have been shown to be reduced in failing human hearts, 
underlining the importance of this protein in normal cardiac functioning (Qian et al 2009). 
Phosphorylated Hsp20 has been demonstrated to protect against ischaemia-reperfusion 
injury (Fan et al 2005b), apoptosis and necrosis (Qian et al 2009), and cardiac hypertrophy 
(Fan et al 2006). Selective targeting of signaling elements that can enhance this 
modification therefore represents a new therapeutic avenue for the prevention and 
treatment of pathological cardiac remodelling and ischaemic injury. Previously, no AKAP     Chapter 5  Results       
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had been identified for the pool of PKA that phosphorylates Hsp20. The data presented in 
this chapter identifies the cytosolic AKAP, AKAP-Lbc, as this scaffold protein in cardiac 
myocytes. Co-immunoprecipitation and colocalisation studies demonstrated a specific 
association between AKAP-Lbc and Hsp20 (Figure 5-3 and 5-4). Hsp20 Ser16 
phosphorylation was attenuated in cells where AKAP-Lbc was either specifically knocked 
down by siRNA-mediated gene silencing (Figure 5-5), or competed out by a PKA 
anchoring-defective AKAP-Lbc mutant (Figure 5-6).   
 
AKAP-Lbc is expressed at high levels in the heart, and has been implicated in the 
development of cardiac hypertrophy (Carnegie et al 2008), therefore its association with 
Hsp20, a cardioprotective protein with known anti-hypertrophic effects, is immediately 
intriguing. AKAP-Lbc is a large, multi-domain protein which contains tandem Dbl 
homology (DH) and pleckstrin homology (PH) domains. The DH domain is associated with 
guanine nucleotide exchange activity for small GTPases such as Rho, and so AKAP-Lbc 
functions as a guanine nucleotide exchange factor (GEF) for the small GTPase Rho 
(Appert-Collin et al 2007). RhoA is a well known mediator of cardiac hypertrophy, though 
the downstream signaling pathways involved are incompletely understood (Brown et al 
2006). The Rho-GEF activity of AKAP-Lbc is stimulated by Gα12, but is inhibited by PKA 
phosphorylation of AKAP-Lbc on Ser1565 (Diviani et al 2004). Anchored PKA was shown to 
phosphorylate AKAP-Lbc on Ser1565 in response to forskolin stimulus, and it can be 
postulated that factors promoting PKA phosphorylation of AKAP-Lbc might also promote 
phosphorylation of Hsp20 and lead to the induction of its anti-hypertrophic effects.  
 
AKAP-Lbc contains binding sites for PKA (Diviani et al 2001), PKC and PKD isoforms 
(Carnegie et al 2004), and has recently been shown to scaffold B-Raf and the signaling 
scaffold protein KSR-1 to organise a growth factor- and cAMP-dependent signaling 
network critical to cell growth and proliferation (Smith et al 2010). The ability of AKAP-Lbc 
to scaffold both PKA and PKD isoforms is intriguing, as unpublished data from our 
laboratory has recently indicated that Hsp20 can be phosphorylated by PKD, and that this 
phosphorylation may be linked to the development of cardiac hypertrophy. Thus, the 
interaction of Hsp20 with AKAP-Lbc could facilitate its phosphorylation by both of these 
kinases to modulate hypertrophic signaling. AKAP-Lbc has been shown to assemble an     Chapter 5  Results       
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activation complex for PKD by synchronising PKCη phosphorylation and activation of the 
catalytic domain of PKD with PKA phosphorylation of the C terminus of PKD, which 
facilitates its release from the AKAP (Carnegie et al 2004). PKD has been proposed to act 
downstream of RhoA to mediate hypertrophic signals. Carnegie and co-workers found 
that activated PKD translocates to the nucleus, where it phosphorylates class II histone 
deacetylases (HDACs). This promoted nuclear export of HDACs, and resulted in 
derepression of the transcription factor myocyte enhancer factor 2 (MEF2), and the 
transcription of hypertrophic genes (Carnegie et al 2008) (Section 1.6.6.1.). Expression of 
AKAP-Lbc is known to be upregulated in hypertrophic NRVM, and this has been proposed 
to augment activation of PKD and promote development of a hypertrophic phenotype 
(Carnegie et al 2008). Hsp20 phosphorylation by PKA in response to β-adrenergic stimulus 
is known to have anti-hypertrophic effects (Sin et al 2011). Thus, the induction of cardiac 
hypertrophy may involve a complex signaling network centring on AKAP-Lbc, where 
activation of RhoA and PKD favours a hypertrophic phenotype, and PKA activation, with 
subsequent phosphorylation of Hsp20 and AKAP-Lbc, opposes these effects. Future 
studies must determine the relative contributions of PKA and PKD phosphorylation of 
AKAP-Lbc-anchored Hsp20 to the hypertrophic response.  
 
As well as enhancing its anti-hypertrophic actions, PKA phosphorylation of Hsp20 has 
been shown to protect against β-agonist-induced apoptosis in the heart. Adult cardiac 
myocytes infected with adenoviral Hsp20 constructs where Ser16 is mutated to Asp to 
mimic constitutive phosphorylation (S16D mutants) display a significant reduction in 
cellular markers of apoptosis, including caspase-3 activity (Fan et al 2004a). The anti-
apoptotic effects of Hsp20 are thought to be mediated by its association with the pro-
apoptotic protein Bax, which physically prevents translocation of Bax to the mitochondria, 
where it could damage mitochondrial integrity by releasing cytochrome c, with 
subsequent activation of caspase-3 (Fan et al 2005b). Transfection of NRVM with a PKA 
anchoring mutant of AKAP-Lbc to attenuate Hsp20 Ser16 phosphorylation was associated 
with increased caspase-3 activity. This phenotype could be partially rescued by co-
transfection of an Hsp20-S16D mutant, but was not rescued by co-transfection of a 
phospho-null mutant of Hsp20 (Figure 5-7). This effect should be confirmed by monitoring 
other markers of apoptosis, such as pyknotic nuclei or DNA laddering, or by TUNEL     Chapter 5  Results       
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(terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling) assay, which 
detects DNA fragmentation. The importance of AKAP-Lbc-mediated phosphorylation of 
Hsp20 should also be determined for Hsp20’s other cardioprotective effects, such as 
ischaemia-reperfusion injury.  
 
Though AKAP-Lbc itself has not been directly implicated as a mediator of apoptosis, PKC 
signaling and RhoA activation have both been linked with phorbol ester-mediated 
apoptosis (Chang & Lee 2006). Thus, it appears that signal transduction pathways co-
ordinated by this AKAP are involved in the induction of apoptosis. AKAP-Lbc scaffolding of 
PKA and Hsp20 may counter these pro-apoptotic effects. It would be interesting to 
determine whether Bax can also interact directly with AKAP-Lbc, as another pro-apoptotic 
protein, BAD, has previously been shown to reside in a complex together with the AKAP 
WAVE-1, PKA and PP1, to regulate glycolysis and apoptosis in the liver (Danial et al 2003).  
 
The effects observed on apoptosis in cells expressing the AKAP-Lbc anchoring mutant may 
not have been specific to Hsp20. The pool of PKA scaffolded by AKAP-Lbc is likely to have 
more far-reaching effects than just directing the phosphorylation of a single heat shock 
protein. In order to selectively inhibit AKAP-Lbc-mediated PKA phosphorylation of Hsp20, 
the disrupter peptide strategy employed in Chapter 4 could be used to displace Hsp20 
from its binding site on the AKAP. Mapping studies described above have narrowed this 
site to the central portion of AKAP-Lbc, between residues 1388 and 1922 (Figure 5-8 and 
5-9). This spans a 60kDa region, so further studies will be required to determine the exact 
binding site of Hsp20. Truncation analysis and mutagenesis studies could be employed 
but are often very time consuming. The peptide array approach adopted in Chapter 4 can 
provide a rapid way of identifying interaction sites between two proteins. An Hsp20 
peptide array could be overlayed with the GST-AKAP-Lbc fragment containing the Hsp20 
binding site, and this information used to design a specific cell permeable peptide 
disruptor of the Hsp20-AKAP-Lbc interaction. This would then provide an ideal strategy to 
specifically monitor the effect of AKAP-Lbc-mediated PKA phosphorylation on the 
cardioprotective effects of Hsp20.  
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Macromolecular complexes regulating β-adrenergic signaling pathways in the heart often 
contain signal terminating enzymes, such as protein phosphatases and 
phosphodiesterases, as a way of regulating their activities. For example, in the 
macromolecular complex co-ordinated by mAKAP and the ryanodine receptor, PKA and 
PDE4D3 constitute a negative feedback loop, whereby activation of PKA in response to 
increased local cAMP levels also leads to the phosphorylation and activation of PDE4D3. 
which then hydrolyses local cAMP (Dodge et al 2001). It has also been shown that PP2A 
scaffolded by mAKAP contributes to this regulation by promoting the dephosphorylation 
and deactivation of PDE4D3 (Dodge-Kafka et al 2010). Hsp20 has recently been found to 
associate with the protein phosphatase PP1 in the heart, to modulate Ca
2+ handling at the 
SR (Qian et al 2011). PP1 has been identified in complexes nucleated by Yotiao (Westphal 
et al 1999), WAVE-1 (as described above) (Danial et al 2003) and AKAP220 (Schillace & 
Scott 1999), and it would be interesting to determine whether it is present in the Hsp20-
AKAP-Lbc complex, in association with either Hsp20 or the AKAP, as inhibition or 
displacement of this enzyme could provide a means of modulating Ser16 phosphorylation 
of Hsp20 to enhance cardioprotection. Though many AKAP complexes include a protein 
phosphatase, none have yet been specifically linked with complexes nucleated by AKAP-
Lbc, so such a finding might have implications for other pathways co-ordinated by this 
multi-purpose AKAP.  
 
Prior to the work detailed in this chapter, no specific PDE activity had been associated 
with AKAP-Lbc. PDE4 activity was found to co-purify with AKAP-Lbc in heart cell lysates, 
together with a smaller amount of PDE3 activity (Figure 5-13B) and PDE4D isoforms were 
demonstrated in an AKAP-Lbc immune complex together with Hsp20 and PKA (Figure 5-
13A). Recent work from our laboratory, some of which is detailed above (Figure 5-12), has 
demonstrated a specific interaction between Hsp20 and PDE4 isoforms, which is 
mediated by a binding domain within the conserved catalytic unit of the PDE (Sin et al 
2011). Biochemical studies are currently underway to determine whether PDE3 and PDE4 
isoforms also associate directly with AKAP-Lbc, or whether, in the case of PDE4, this 
interaction is mediated indirectly via Hsp20.  
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In summary, the data presented in this chapter identify a new macromolecular complex in 
the heart which is nucleated by AKAP-Lbc, and includes the cardioprotective heat shock 
protein Hsp20 along with PKA and signal terminating phosphodiesterase 4D isoforms. 
Selective modulation of the signaling elements within this complex affects the 
cardioprotective functions of Hsp20. It has previously been shown that disruption of the 
Hsp20-PDE4D interaction enhances phosphorylation at Ser16 to protect against cardiac 
hypertrophy (Sin et al 2011), and I now show that disruption of the AKAP-Lbc-Hsp20 
interaction promotes cardiac myocyte apoptosis. Elucidating the structural components 
of the macromolecular complex formed by AKAP-Lbc, Hsp20 and other signaling enzymes 
in the heart will enable the development of novel peptides or small molecule inhibitors 
that can selectively enhance phosphorylation of Hsp20 at Ser16 to promote 
cardioprotection.    
 
 
6.                                                                            
 
Final Discussion 
The discovery of the second messenger 3’5’-cyclic adenosine monophosphate in 1958 
revolutionised our understanding of cellular signal transduction pathways (Sutherland & 
Rall 1958). The realisation that cAMP helped mediate the actions of the hormone 
adrenaline on glycogenolysis in liver cells was followed by the identification of the cAMP-
dependent protein kinase (PKA) as a major effector of cAMP signals (Walsh et al 1968). 
Since then, hundreds of PKA substrates have been identified, and modification of protein 
function by PKA phosphorylation has been shown to produce cellular outcomes as diverse 
as cardiac myocyte contraction (Solaro et al 1976) and gene transcription (Delghandi et al 
2005).  
 
cAMP is a freely diffusible molecule, and could potentially flood the interior of the cell, 
leading to the indiscriminate activation of multiple downstream effectors (Houslay et al 
2007). It is now accepted that this situation is avoided by the compartmentalisation of 
cAMP signals. Discrete microdomains of cAMP, created by the actions of 
phosphodiesterase enzymes, have been directly visualised in live cells using genetically 
encoded cAMP sensors (Zaccolo & Pozzan 2002).  PKA is anchored to specific subcellular 
targets by its interaction with AKAPs, therefore only particular pools of PKA are exposed 
to activating concentrations of cAMP at any one time (Baillie 2009). Thus, signals from 
one second messenger can result in the activation of distinct signal transduction 
pathways, and diverse physiological responses (Buxton & Brunton 1983). 
 
More than 50 years on from the discovery of cAMP, the field of cyclic nucleotide research 
is still expanding, and some of the accepted paradigms of compartmentalised cAMP 
signaling are being challenged. For example, it has recently been shown that under 
certain circumstances cAMP signaling may persist once initiating GPCRs have been     Chapter 6  Final Discussion       
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internalised (Calebiro et al 2010a, Calebiro et al 2010b). Emerging evidence also indicates 
that Epac can also be compartmentalised within cells, and compartmentalised Epac 
signaling has been linked with the cAMP-dependent regulation of vascular endothelial cell 
permeability (Rampersad et al 2010) and cellular proliferation (Hochbaum et al 2010).  
 
Much of current cyclic nucleotide research is focused on the characterisation of 
macromolecular signaling complexes, or signalosomes. These complexes are nucleated by 
AKAPs, and consist of various combinations of cAMP effectors (PKA, Epac and ion 
channels), signal terminating enzymes (protein phosphatases and PDEs) and other 
scaffold proteins which link cAMP signal transduction to Ca
2+ and growth factor signaling 
pathways (Welch et al 2010). A number of important signalosomes have been identified 
in the heart, which are critical to the regulation of excitation-contraction coupling. cAMP-
dependent PKA phosphorylation of proteins involved in ECC plays an integral part of the 
body’s fight or flight response, and has been shown to directly influence Ca
2+ transport 
(Marx et al 2000), myofilament Ca
2+ sensitivity (Stelzer et al 2007), and cardiac 
contractility (Takimoto et al 2004) in order to increase cardiac output (Mudd & Kass 
2008). New associations and participants are continually being identified within these 
macromolecular complexes, for example, PDE4B has recently been shown to associate 
with the LTCC to influence Ca
2+ transients (Leroy et al 2011).  
 
cAMP dynamics are particularly important at the cardiac myofilament. During times of 
physiological stress, cardiac output increases in response to β-adrenergic stimulation, 
which leads to PKA phosphorylation of the myofilament proteins troponin I and myosin-
binding protein-C. These phosphorylation events contribute to enhanced force 
development during systole and an accelerated rate of relaxation during diastole (Stelzer 
et al 2007). PKA phosphorylation of myofilament proteins is known to be reduced in 
cardiac failure (Zakhary et al 1999); however, the precise signaling elements regulating 
PKA activation at the myofilament, and the subsequent phosphorylation of myofilament 
proteins, are poorly understood. In the first part of this thesis, I investigated the signaling 
elements modulating cAMP-dependent phosphorylation of TnI at the myofilament. cAMP 
levels in the vicinity of TnI were shown to be regulated by members of the 
phosphodiesterase 4 family using a genetically encoded FRET-based cAMP sensor     Chapter 6  Final Discussion       
165 
 
targeted to TnI. A specific interaction was then demonstrated between TnI and the PDE4 
isoform PDE4D9. This study represents the first demonstration of an interaction between 
a myofilament protein and a phosphodiesterase enzyme, and could provide the basis for 
a novel therapeutic strategy for heart failure, as modulation of this interaction could 
promote TnI phosphorylation and an increase in cardiac output.  
 
In the second part of the thesis, I focused on identifying factors which regulate PKA 
phosphorylation of the small heat shock protein Hsp20. Hsp20 is known to protect against 
ischaemic injury and hypertrophy in the heart, and these cardioprotective actions are 
enhanced by its PKA phosphorylation on Ser16. A combination of biochemical techniques 
and FRET-based studies identified a novel macromolecular complex comprising PKA, 
Hsp20 and the scaffolding protein AKAP-Lbc, which facilitated Ser16 phosphorylation of 
Hsp20. AKAP-Lbc scaffolding of PKA was demonstrated to be vital for the anti-apoptotic 
actions of Hsp20 in the heart. This novel complex also includes members of the 
phosphodiesterase 4D subfamily. The AKAP-Lbc/PKA/Hsp20/PDE4D complex appears to 
play a key role in cardioprotection via the modulation of Hsp20 Ser16 phosphorylation, 
and selective targeting of these signaling elements in order to enhance this modification 
and promote cardioprotection could be of benefit in the treatment of pathological cardiac 
remodelling and ischaemic injury. 
 
In this thesis, members of the PDE4 family were found to regulate the PKA 
phosphorylation of both Hsp20 and TnI. The development of PDE4 inhibitors would 
therefore seem to be an attractive option in the treatment of diseases where these 
phosphorylation events are known to be downregulated, such as heart failure. The PDE4 
family has generated significant interest from pharmaceutical companies due to its 
involvement in a number of chronic disease states, particularly inflammatory diseases 
such as asthma and chronic obstructive pulmonary disease (COPD) (Houslay et al 2007). 
PDE4 provides the primary cAMP hydrolytic activity in inflammatory cells such as 
macrophages, eosinophils and neutrophils (Bielekova et al 2000, Spina 2008), and PDE4B 
has been shown to regulate the release of inflammatory cytokines from immune cells (Jin 
et al 2005). Increased intracellular cAMP levels suppress the production of pro-
inflammatory cytokines, and induce anti-inflammatory cytokines in macrophages (Wall et     Chapter 6  Final Discussion       
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al 2009). Thus, there is considerable interest in inhibition of PDE4 as an anti-inflammatory 
strategy. PDE4B and PDE4D have also been linked with depression (Millar et al 2007, 
Zhang et al 2002), therefore PDE4 inhibitors would appear to have huge therapeutic 
potential. However, the development of these inhibitors has been plagued with 
difficulties, and there are few real success stories. The non-selective PDE inhibitor 
theophylline has been used for many years as a second line treatment for asthma, but has 
relatively low efficacy and causes a number of side-effects, including nausea, vomiting, 
diarrhoea and headaches. Theophylline has also been linked with the development of 
cardiac arrhythmias, and so patients also require careful plasma monitoring of drug 
levels, which is both expensive and time consuming (Spina 2008). PDE4 inhibitors such as 
rolipram have also undergone clinical trials for depression, but their licensing was 
prevented by the presence of similar side-effects, particularly emesis (Hebenstreit et al 
1989). Second generation PDE4 inhibitors have now been developed which exhibit lesser 
side-effects, and one such inhibitor, Roflumilast (DAXAS®) was recently licensed in the UK 
for the treatment of severe exacerbations of COPD (Rabe 2010). It is clear that inhibition 
of PDE4 as a therapeutic strategy is problematic due to the number of cellular processes 
which involve this large enzyme family, and therefore a more specific strategy must be 
considered.  
 
In Chapter 4, I made use of a peptide disruptor of the TnI-PDE4D9 complex to increase 
PKA phosphorylation of TnI in cells. Cell permeable peptides have previously been shown 
by us to disrupt the interaction between Hsp20 and PDE4 and protect against cardiac 
hypertrophy in cultured cardiac myocytes (Sin et al 2011). These peptides therefore have 
great therapeutic potential. Unlike other methods of inhibiting PDE4 in cells, such as gene 
silencing, which knocks down expression of a whole isoform, peptide disruptors displace 
one specific pool of a single PDE isoform within the cell, and allow more precise 
identification of protein function. From a pharmacological point of view, this targeted 
approach should also result in significantly fewer side-effects. It will be interesting to 
determine the effects of the TnI-PDE4D9 disruptor peptide in physiological assays of 
myocyte shortening, as it would be predicted to enhance cardiac contraction. It should 
also be noted that the studies detailed in this thesis were largely performed in rat tissue. 
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similar expression levels and functions; however, human hearts exhibit higher non-PDE4 
activity (Richter et al 2010), and therefore the effects of these peptides, and indeed the 
significance of the TnI-PDE4D9 interaction, may differ across species. 
 
A major finding of the work detailed in this thesis is the association between Hsp20 and 
AKAP-Lbc. AKAP-Lbc is an intriguing protein which scaffolds PKA, PKC and PKD isoforms, 
and possesses intrinsic Rho-GEF activity. AKAP-Lbc is upregulated in hypertrophic cardiac 
myocytes, and it is thought that this enhances its activation of anchored PKD, and that 
augmented PKD signaling contributes to a fetal gene response and a hypertrophic cellular 
phenotype (Carnegie et al 2008). The Rho-GEF activity of AKAP-Lbc may also contribue to 
hypertrophy, as activated RhoA is a well known mediator of hypertrophic signaling(Diviani 
et al 2004). The finding that Hsp20, a cardioprotective protein with known anti-
hypertrophic effects, directly interacts with AKAP-Lbc, could be highly significant. PKA 
phosphorylation of Hsp20 on Ser16 enhances its cardioprotective actions, and would 
protect against hypertrophy. It has previously been shown that the Rho-GEF activity of 
AKAP-Lbc is inhibited by phosphorylation of AKAP-Lbc by the same pool of PKA. Thus, 
factors which promote Hsp20 phosphorylation would also promote phosphorylation of 
AKAP-Lbc, resulting in dual actions against hypertrophy.  
 
6.1 Final conclusion 
The work presented in this thesis advances our understanding of how cAMP/PKA signals 
are regulated in the heart, both at the myofilament and in the cytosol. Novel interacting 
partners have been identified for the key cardiac proteins TnI and Hsp20. These 
interacting partners function to regulate PKA phosphorylation of TnI and Hsp20, and 
therefore have the potential to modulate cardiac contraction and cardioprotection. 
Selective disruption of interactions within macromolecular signaling complexes in the 
heart (and other organs) using cell permeable peptides or small molecule disruptors could 
provide a novel, targeted therapeutic strategy for the treatment of many diseases where 
cAMP signaling is dysregulated. Future studies should concentrate on defining the roles of 
such peptides within physiological systems, and identifying other interacting partners 
within these complexes, such as protein phosphatases.   
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